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Abstract 
 
 
Cerebellar symptoms are associated with poor prognosis in MS. A small number of 
studies have reported a specific cognitive profile associated with cerebellar damage, 
including reduced information processing speed, impairments in visuospatial functions 
and verbal fluency deficits. The cerebellum is thought to encode models of sensory 
information, providing mental representations of the world used to plan motor actions. 
Motor planning may be a key factor in the disability that cerebellar involvement 
imposes. This study explores how the cognitive profile of those with MS with cerebellar 
symptoms (RR-MSc) relates to motor planning and motor function, and how this differs 
from those with MS without cerebellar symptoms (RR-MSnc) and healthy controls 
(HC). 
 
Participants were assigned to three groups: HC (n = 21), RR-MSnc (n = 21) and RR-
MSc (n = 14) using a validated self-report cerebellar symptom questionnaire 
(NARCOMS-TACS). Participants completed a cognitive test battery: BICAMS 
(CVLT-II, SDMT, BVMT-R), WLG, PASAT3 and TOPF. For assessment of motor 
functioning and motor planning, participants completed the 9-hole peg test (9HPT) as 
a sensorimotor control, and grooved pegboard test (GPT) which has greater motor 
planning demands. Subtraction of 9HPT from GPT was used to compute a motor 
planning index (MPI).   
  
One-way ANCOVAs demonstrated significant differences between groups on all 
cognitive tests other than WLG. Post-hoc tests showed significant differences between 
RR-MSc and HC on all tests except WLG, and RR-MSc and RR-MSnc on SDMT, 
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CVLT-II and PASAT3. On 9HPT, GPT and MPI, HC performed significantly better 
than both MS groups, and the RR-MSnc performed significantly better than RR-MSc. 
There were significant correlations between neuropsychological variables (other than 
WLG) and MPI. 
 
RR-MSc showed greater impairment than RR-MSnc on cognitive tests and tasks 
requiring motor functioning and motor planning. RR-MSc demonstrated a specific 
cognitive profile associated with more significant and widespread impairments. 
Clinical implications are discussed.  
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1. Introduction 
 
A significant proportion of those with multiple sclerosis (MS) experience cognitive 
impairment (Benedict & Zivadinov, 2011; Langdon, 2011). Cognitive impairment is 
associated with worse prognosis and functional difficulties (Amato et al., 1995; 2010; 
Bruce, Hancock, Arnett, & Lynch, 2010; Bobholz & Rao, 2003; Langdon, 2010). Early 
research has demonstrated greater cognitive and motor impairment in those with MS 
with cerebellar involvement (Weier et al., 2015a). Individuals with cerebellar 
involvement have been shown to have a worse prognosis and appear to benefit less 
from neurorehabilitation (de Groot et al., 2009; Langdon & Thompson, 1999; Thorpe 
et al., 2015; Vasconcelos et al., 2016). It is possible that cerebellar involvement in MS 
could eventually be designated as a differential disease subtype. 
  
1.1. Multiple Sclerosis 
 
MS is a chronic and progressive immune-mediated inflammatory disease of the central 
nervous system (CNS). It is a demyelinating disease of undetermined aetiology, 
however many risk factors are identified (Ramagopalan, Dobson, Meier & Giovannoni, 
2010).  The reported incidence is 203.4/100,000 in the UK (Mackenzie, Morant, 
Bloomsfield, MacDonald & O’Riordan, 2014). The mean age of onset is approximately 
30-years with increased incidence in females (Rejdak, Jackson & Giovannoni, 2010). 
In Europe and the USA, MS is the foremost cause of non-traumatic neurological 
disability (Hauser & Okenberg, 2006). It is often considered degenerative, as with time 
cognitive and behavioural dysfunction accumulates causing more impairment.  
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1.1.1. MS Pathophysiology 
 
The formation of lesions (sclerotic plaques) that accompanies disease progression in 
MS is believed to be the culmination of two pathological processes - inflammation and 
neurodegeneration (Compston & Coles, 2008). The exact order and procedure of 
pathogenesis in MS is controversial.  
 
(i) Inflammation 
 
MS is considered an autoimmune disorder, as lymphocytes do not effectively 
distinguish healthy cells from antigens, resulting in inflammation and myelin 
breakdown. Inflammation is caused by autoreactive lymphocytes (T-cells) moving 
across the blood-brain barrier (Compston & Coles, 2008). This mediates damage to the 
myelin sheath of neurons. The myelin sheath is a plasma membrane around the axon of 
a neuron, which is formed by Schwann cells and oligodendroglial cells (Siegel, 
Agranoff, Albers, Fisher & Uhler, 1999), which speeds up neural transmission through 
saltatory conduction. Without this, the communicative function of the neuron is 
impaired causing expressed symptoms.  
 
During the initial stages of disease progression inflammation is transient, and Schwann 
cells and oligodendroglial cells cause remyelination, resulting in temporary 
symptomatic relief (Compston & Coles, 2008). Remyelination is effective at 
temporarily repairing cells, however this myelin is less durable and endogenous 
remyelination eventually fails (Chari, 2007; Czepiel, Boddeke & Copray, 2015).  
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(ii) Neurodegeneration 
 
Repeated inflammation and resultant damage results in the build-up of scar tissue 
known as plaques or lesions (Compston & Coles, 2008). Plaques can occur in any areas 
of white matter, however there are several predilection sites including the 
periventricular regions, brainstem, cerebellum, optic nerves, prefrontal cortices, medial 
temporal cortices and spinal cord (Donadieu et al., 2016; Wingerchuk, Lucchinetti & 
Noseworthy, 2001). Cumulative axon loss can result in progression to a higher level of 
functional disability. Demyelination and axonal loss in MS is known as brain atrophy. 
 
1.1.2. MS Aetiology  
 
The contribution of genetics is compelling, with concordance rates in monozygotic 
twins of approximately 25-30% (Sadovnick et al., 1993; Willer et al., 2003). 
Specifically, the human leukocyte antigen (HLA) is implicated (Hillert, 1994). 
Aetiological hypotheses combine genetics, and environmental factors including: major 
compatibility complex haplotypes (Dyment et al., 2005; Ramagopalan, Knight & 
Ebers, 2009), sun exposure and vitamin D (Munger et al., 2006), and the Epstein-Barr 
virus (Sundqvist et al., 2012). Transcultural studies have also demonstrated relations to 
geographical latitude with higher incidence in temperate zones (Kurtzke, 2000), as well 
as countries with predominantly White populations (UK and Norway) (Albor et al., 
2017), and in those who have migrated to such countries compared with their ancestral 
groups (Torjesen, 2016) The aetiology of MS is therefore complex and multifactorial.  
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1.1.3. Diagnosis and subtypes 
 
A revision of the McDonald (2001) criteria (Polman, 2011) is typically utilised for 
diagnosis of MS. This requires demonstration of lesions in time and space, as well as 
ruling out differential diagnosis. MRI is utilised to detect lesions, and neurological 
dysfunction must occur on at least two occasions (lasting more than 24 hours) of more 
than 30 days apart.  
 
The onset of MS can occur before the age of 18, known as paediatric MS. However, 
the present study will focus on adult onset MS, as more widespread cognitive deficits 
are recognised within paediatric MS possibly due to the impact of the disease on a 
developing central nervous system (Amato, Krupp, Charvet, Penner, & Till, 2016). 
 
(i) Clinically Isolated Syndrome (CIS)  
 
The first episode of neurological disturbance, associated with a single white matter 
lesion is known as a CIS. Thirty to 70% of patients subsequently develop MS (Miller, 
Barkhof, Montalban, Thompson & Filippi, 2005).  
 
(ii) Relapsing and remitting MS (RR-MS) 
 
Approximately 85% of individuals diagnosed with some form of MS present with RR-
MS (Leary, Porter & Thompson, 2005). Individuals with RR-MS have distinct attacks 
of acute or sub-acute neurological symptoms (varying in frequency and severity) 
followed by partial or complete remission (Leary, Porter & Thompson, 2005). When 
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symptoms do not fully alleviate, individuals with RR-MS are left with residual 
symptoms, which accumulate into physical disability (Leary, Porter & Thompson, 
2005). Lublin, Baier and Cutter (2003) demonstrated these residual deficits in 42% of 
patients with expanded disability status scale (EDSS; a measure of disability in MS) of 
>0.5. 
 
Benign MS is a subdivision of RR-MS that is diagnosed retrospectively, following a 
significant time without symptoms (Lublin et al., 2014).   
 
(iii) Secondary progressive MS (SP-MS) 
 
SP-MS is diagnosed retrospectively through recognition of progressive worsening over 
time following an initial relapsing course (Lublin et al., 2014). This is diagnosed 
following deterioration independent of relapses for more than six months (Katz Sand, 
Krieger, Farrel & Miller, 2014).  There is a possibility for individuals with SP-MS to 
have ‘superimposed relapses’ (Leary, Porter & Thompson, 2005). Confavreux and 
Vukusic (2006) report that the progressive stages of MS typical age of onset is 38. 
 
(iv) Primary progressive MS (PP-MS) 
 
PP-MS accounts for 15% of the MS population and is a gradual accumulation of 
neurological disability with recognised progressive myelopathy with no periods of 
remission (Leary, Porter & Thompson, 2005; Lublin et al., 2014). This has a later age 
of onset than other forms of MS and affects more males than other subcategories 
(Leary, Porter & Thompson, 2005).  
 16 
(v) Progressive relapsing MS (PR-MS) 
 
This is a progressive disease from onset with intercalated relapses. This accounts for 
approximately 10% of the PP-MS population (Leary, Porter & Thompson, 2005). 
 
1.1.4. MS Symptoms 
 
MS is a heterogeneous disorder. Compston and Coles (2008) report common 
symptoms, including cognitive impairment, affective disorders (mainly depression), 
tremor, poor balance, dysarthria, weakness and spasm, bladder dysfunction and erectile 
dysfunction (in men), pain, temperature sensitivity and fatigue. These are not disease 
specific, hence the involvement of imaging in diagnosis. These symptoms impair 
quality of life (QoL), and accumulation of neurological disability is associated with 
reduced QoL (Janardhan & Bakshi, 2000).  
 
1.1.5. Treatment and course 
 
There is no cure for MS. Pharmaceutical treatments are available for specific 
symptoms, as well as acute relapse (typically steroid based treatments including 
methylprednisolone) (Anlar, 2009). Disease-modifying treatments (DMTs) focusing on 
the inflammatory process are used to reduce the frequency of relapse, including 
immunosuppressive and immune-modulating agents (Anlar, 2009). These reduce 
disability progression. DMTs are split into first generation drugs (beta interferons and 
glatiramer acetate - released in 1990s) which have moderate efficacy, and second 
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generation drugs (Tysabri, Fingolimod and Mitoxantrone – the latter rarely used due to 
cardio-toxicity) which have greater efficacy but more significant risks.  
 
The course of MS is heterogeneous. Prognosis and course is associated with a multitude 
of factors including age of onset, treatment and relapse frequency. With the advent of 
DMTs, natural historical studies become irrelevant to those with treatments available 
(Hum, Lapierre, Scott, Duquette & Mayo, 2017). One study utilised an extensive 
medical registry to determine stability of MS based on three discrete onset periods (pre-
magnetic resonance imaging and pre-DMTs (pre-1995); MRI and first generation 
DMTs (1995-2004); MRI and second generation DMTs (2005-present) (Hum et al., 
2017). Stability (defined as EDSS of three or less with a change of one or less EDSS 
points over the study period) was demonstrated in most patients diagnosed in the past 
decade (54% males, 84% females). In the second group, 69% of females and 41% males 
were observed as stable (thus defined as benign MS). However, very little stability was 
demonstrated in those diagnosed pre-1995. Greater stability was recognised in females 
than males diagnosed since 1995. The authors reported that annualised relapse rate 
(ARR) was associated with a higher disability trajectory (Hum et al., 2017). This is 
corroborated by other studies demonstrating that high ARR early in disease course is 
associated with worse prognosis (Leray et al., 2010; Scalfari et al., 2010; Tremlett, 
Yousefi, Devonshire, Rieckmann, & Zhao, 2009), but later relapses were not so 
significantly associated (Scalfari et al., 2010; Tremlett et al., 2009). More recently 
individuals have been shown to reach disability milestones after longer disease 
durations (Hum et al., 2017; Tremlett, Zhao, Rieckmann, & Hutchinson, 2010). This is 
possibly associated with improved methods of detection and subsequent early use of 
DMTs. 
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1.1.6. Section Summary 
 
MS is a progressive immune-mediated inflammatory disease of the CNS associated 
with demyelination. It has an uncertain aetiology but this is likely to be a combination 
of environmental and genetic factors. It is characterised by the formation of sclerotic 
plaques through inflammation and neurodegeneration. 85% of people with MS are 
diagnosed with RR-MS, with periods of symptom flare-up with subsequent complete 
or partial remission. Symptoms of RR-MS include cognitive impairment, physical 
disability and affective changes and all contribute to reduced QoL. With time, the 
majority progress to SP-MS which represents a more significant level of accumulating 
disability.  
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1.2. MS Neuropsychological profile 
 
1.2.1. Prevalence of cognitive impairment in MS 
 
Cognitive impairment affects 50-60% of patients with MS (Benedict & Zivadinov, 
2011; Langdon, 2011). It can occur early within disease progression, and is 
occasionally the first symptomatic expression (Feuillet et al., 2007; Schulz, Kopp, 
Kunkel & Faiss, 2006). Neuropsychological profiles can be beneficial for provision of 
prognosis (Amato et al., 2010), with increased cognitive impairment being associated 
with worse prognosis. Cognitive impairment can be an independent predictor of 
conversion from CIS to MS (Zipoli et al., 2010).  Another study demonstrated a twofold 
increase in conversion to SP-MS and a threefold EDSS >4.0 in 10 years in those with 
cognitive impairment (Moccia et al., 2016).  
 
Cognitive profiles within sub-diagnoses of MS have not been thoroughly investigated, 
though could provide prognostic, diagnostic, and treatment planning information. This 
study will help to differentiate between cognitive profiles of those with RR-MS with 
cerebellar symptoms (RR-MSc), to those without cerebellar symptoms (RR-MSnc).  
 
1.2.2. Cognitive Impairment in MS 
 
In MS, cognitive impairment is related to functional difficulties with work and social 
activities, physical independence, sexual function, adherence to medication and driving 
(Amato et al., 1995; Bobholz & Rao, 2003; Bruce, Hancock, Arnett, & Lynch, 2010; 
Langdon, 2010). Higher premorbid functioning (cognitive reserve) reduces the rate of 
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cognitive decline associated with brain atrophy (Nunnari et al., 2016; Sumowski et al., 
2009). Lengthy periods of formal educational are associated with increased cognitive 
reserve, and cognitive reserve can be built up by reading, physical activity and 
cognitively challenging employment (Luerding, Gebel, Gebel, Schwab-Malek & 
Weissert, 2016).   
 
Reviews of controlled studies demonstrate a decline of cognition with the progression 
of the condition (Amato, Zipoli & Portaccio, 2006). Progressive decline is somewhat 
supported by MRI studies, which show a weak correlation between total lesion load 
and cognitive impairment in MS (Calabrese et al., 2009). Individuals with a progressive 
phenotype are twice as likely to demonstrate cognitive impairment after controlling for 
disease and demographic variables (Planche, Gibelin, Cregut, Pereira & Clavelou, 
2016). 
 
In some cases, demyelination within specific brain regions can predict which cognitive 
domains may be affected (Rovaris et al., 2000; Swirsky-Sacchetti et al., 1992; Wishart 
& Sharpe, 1997). Lesions affecting functional connectivity are strongly associated with 
cognitive sequelae (Hawellek, Hipp, Lewis, Corbetta, Engel, 2011) as cognitive tests 
and functions involve networks of neuroanatomical areas. This is of interest in the 
current study due to the consideration of diffuse projections between the cerebellum 
and the frontal lobes. One aspect of the present study will consider those with 
neurological symptoms of cerebellar dysfunction in comparison to the wider 
heterogeneous group of RR-MS.  
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1.2.3. Considerations for neuropsychological testing in MS 
 
Visual deficits are common in MS, typically caused by optic nerve inflammation (optic 
neuritis) resulting in blurred vision. This affects 38-50% of individuals with MS 
(Arnold, 2005). Other visual deficits, such as loss of colour perception, contrast 
sensitivity and visual processing difficulties (Vleugels et al., 2000) can occur secondary 
to brain lesions. Nystagmus (involuntary eye movement) is a common visual symptom 
associated with lesions to the brain stem and cerebellum (Iyer et al., 2015; Kutzelnigg 
et al., 2007; Weier et al., 2015b). 
 
Motor dysfunction can confound neuropsychological tests in MS, therefore tasks 
requiring fine motor control should be avoided (Langdon et al., 2012). Individuals with 
cerebellar symptoms are likely to have motor symptoms which may impact on 
neuropsychological tests (Middleton & Strick, 2000). Motor decline appears to be more 
rapid in older populations, though older age has not been linked to more rapid cognitive 
decline in MS (Roy et al., 2016).  
 
1.2.4. Cognitive domains affected 
 
1.2.4.1. Attention and Information Processing Speed 
 
IPS is the underlying efficiency of cognition, associated with the time taken to perform 
a mental task. Tasks that measure IPS require the processing of information as opposed 
to a reflex response, however are often simple. Attention is the cognitive process that 
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facilitates selection, focus and sustained processing of information (Costa, Genova, 
DeLuca, & Chiaravalloti, 2016).  
 
Deficits in IPS and attention are the most common cognitive deficits in MS (Benedict 
et al., 2017; Costa, Genova, DeLuca, & Chiaravalloti, 2016). Deficits in IPS can be 
recognised early in the disease progression, including within the CIS (Hynčicová et al., 
2017), and are typically the first cognitive deficit to emerge (Van Schependom et al., 
2015). A longitudinal study demonstrated worsened performance on the Paced 
Auditory Serial Addition Test (PASAT) and Symbol Digit Modalities Test (SDMT) 
one-year post diagnosis demonstrating reduction in IPS and attentional processes with 
disease progression (López-Góngora, Querol & Escartín, 2015). Compared to healthy 
controls, individuals performed worse on the SDMT (Drake et al., 2010; Hughes, 
Denney & Lynch, 2011; O’Connell, Langdon, Tubridy, Hutchinson & McGuigan, 
2015), and the PASAT (Drake et al., 2010; Forn, Belenguer, Parcet-Ibars & Ávila, 
2008). Extricating the difference between IPS, attention and working memory is 
challenging, however subsequent analyses of these tasks implicated IPS as the reasons 
for deficits (Forn et al., 2008; Lengenfelder et al., 2006). Similarly, Lengenfelder et al. 
(2006) demonstrated that individuals with MS could achieve the same working memory 
span if greater processing time was allowed, concluding that working memory deficits 
may be attributable to IPS deficits.  
 
IPS deficits have been associated with reduced QoL in MS (Barker-Collo, 2006; 
Langdon, 2010). Strober, Chiaravalloti, Moore and DeLuca (2014) showed that the 
SDMT was the sole predictor of unemployment in a logistic regression analysis 
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including tests of executive functions, memory, attention, working memory, 
visuospatial perception as well as on measures of physical functioning. 
 
Demyelination of white matter which impairs communication between cortical areas 
are neuroanatomical correlates of reduced IPS. In a meta-analysis, Rao et al. (2014) 
report a moderate to strong correlation between the SDMT and PASAT scores and T2 
lesion volume in patients with mixed-MS subtypes. Similarly, in a meta-analysis, brain 
volume loss was associated with worse scores on PASAT (Vollmer et al., 2016). The 
corpus callosum, nerve fibres connecting both hemispheres of the brain and a 
predilection site for atrophy in MS, has been linked to reduction of IPS and attentional 
processes (Bergendal et al., 2013; Morrow, Menon, Rosehart, & Sharma, 2017; Ozturk 
et al., 2010). Moroso et al. (2017) showed an association between grey matter volume 
decrease in the posterior lobules and reduced IPS. Atrophy of the anterior and superior 
left thalamus surface has been related to reduced IPS in MS patients (Bergsland, 
Zivadinov, Dwyer, Weinstock-Guttman and Benedict, 2016; Debernard et al., 2015).  
 
The current evidence base suggests that IPS deficits are often observed early in disease 
course, and can be recognised utilising the PASAT and SDMT. IPS deficits possibly 
act as fundamental deficit that creates inefficiencies in other cognitive domains. 
Degeneration of white matter, lesions to areas associated with neuroanatomical 
networking, as well as atrophy of predilection sites for MS appear to be correlates.  
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1.2.4.2. Executive Functions 
 
Executive functions are higher-order processes, which involve planning, problem 
solving, mental flexibility, abstract reasoning, initiation, inhibition and judgement.  
There is no typical profile of executive functions within MS (Chiaravalloti & DeLuca, 
2008). Though mild executive deficits are commonplace in MS, extensive deficits only 
present in a small proportion (Drew, Tippett, Starkey & Isler., 2008). Individuals with 
MS typically perform poorly on tests of problem solving – especially when mental 
flexibility is required (Cerezo Garcia, Plasencia & Benito, 2015; Langdon, 2010; 
Roman & Arnett 2016) as well as tasks requiring set-shifting, fluency, working 
memory, inhibition (Cerezo Garcia, Plasencia & Benito, 2015; Drew et al., 2008; Henry 
& Beatty, 2006; Parmenter et al., 2007), planning and sequencing (Arnett et al., 1997; 
Voelbel et al., 2011), categorizing, temporal ordering, and conceptualising (Cerezo 
Garcia, Plasencia, Benito, Gomez, & Maros, 2009; Roca et al., 2008; Roman & Arnett, 
2016). Cerezo García, Plasencia and Benito (2015) conclude that flexibility, 
abstraction, and inhibition were the three components of executive function that were 
most deficient. However, most studies used timed tasks, thus IPS might be responsible 
for purported executive deficits (Genova, DeLuca, Chiaravalloli & Wylie, 2013; 
Leavitt et al., 2014; Owens, Denney & Lynch, 2013). Therefore, tests of executive 
functions may be less specific with this population.  
 
Executive dysfunction has been linked to higher EDSS scores and a progressive 
phenotype (Cerezo Garcia, Plasencia & Benito, 2015; Hanssen, Beiske, Landrø & 
Hessen, 2014). However, dysexecutive symptoms can be recognised early in disease 
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course (particularly verbal fluency deficits), including CIS (Hynčicová et al., 2017; 
Viterbo Iaffaldano & Trojano, 2013).  
 
These deficits impact day-to-day activities, including financial decision-making 
(Tracy, Basso, Marson, Combs & Whiteside, 2017) bill-paying and cooking (Voelbel 
et al., 2011), however these may be associated with planning time (implicating IPS), 
not performance (Denney, Hughes, Owens & Lynch, 2012; Drew, Trippett, Starkey & 
Isler, 2008). There are equivocal findings regarding executive functions and QoL. 
Executive dysfunction has been associated with maladaptive coping and poor 
emotional regulation strategies (Grech et al., 2016; Phillips et al., 2014), however some 
studies report no relation to QoL (Grech et al., 2015). 
 
Frontoparietal networks, deep grey matter nuclei, and atrophy of the thalamus and 
insula have been implicated in executive functioning in MS in fMRI paradigms (Kern 
et al., 2015; Koini et al., 2016; Llufriu et al., 2016; Muhlert et al., 2013). Perseverative 
errors have been related to frontal white matter lesions (Arnett et al., 1994), and verbal 
fluency to the anterior and posterior corpus callosum (Bodini et al., 2013; Morrow, 
Menon, Rosehart, & Sharma, 2017) as well as higher cortical lesion loads particularly 
in the anterior cingulate cortex (Calabrese et al., 2009; Geisseler et al., 2016; Lazeron 
et al., 2005). 
 
There is no typical executive function profile due to the heterogeneity of MS and 
neuroanatomical correlates are likely associated with networks of cortical and 
subcortical areas. Consideration of subgroups of RR-MS may help provide clarity. 
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Verbal fluency will be considered within the present study due to its recognised 
presentation early in disease course.  
 
1.2.4.3. Memory  
 
Within neuropsychological research, memory is theoretically divided into different 
systems. Working memory has a limited capacity and maintains and manipulates 
multimodal information for a short period (Kreutzer, DeLuca & Caplan, 2011). There 
are many differing long-term memory subsystems. Episodic memory refers to events 
that have been personally experienced, whereas semantic memory refers to knowledge 
gained about the world without a specific timestamp. Differing systems are also 
identified for verbal or visual memory systems. Neuropsychological evaluation and 
research often considers free recall and cued recognition differentially.  In a meta-
analysis including 3891 participants with MS, memory deficits of at least moderate 
effect sizes were recognised in all memory domains (Prakash, Snook, Lewis, Motl, & 
Kramer, 2008). 
 
Working memory deficits are common in MS. They can present in CIS, and deficits 
worsen with disease progression (Panou et al., 2012). According to a review the central 
executive of Baddeley’s model (Baddeley, 2000) is most impaired in MS, with 
significant impacts of reduced IPS (Brissart et al., 2012; Lengenfelder et al., 2006). The 
involvement of IPS was corroborated by individuals showing improvement in working 
memory performance when additional time was given (Leavitt, Lengfelder, Moore, 
Chiaravolloti & DeLuca, 2011). Working memory deficits can cause cognitive-motor 
interference in MS. For instance, carrying out working memory tasks whilst walking 
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was shown to interfere more with the cognitive tasks in CIS than within healthy controls 
(Jakob, Remšak, Jazbec, Ledinek & Rot, 2017). Cognitive reserve and intellectual 
enrichment is positively associated with greater working memory spans (Sandry & 
Sumowski, 2014). 
 
Long-term memory function deficits are recognised in 40-60% of people with MS (Rao 
et al., 1993) and are typically due to registration of information (DeLuca et al., 1998; 
DeLuca, Leavitt, Chiaravalloti & Wylie, 2013; Gmeindl & Courtney, 2012; Langdon, 
2010). This is known as the acquisition hypothesis (Lafosse, Mitchell, Corboy & Filley, 
2013), which implicates IPS or attentional systems (Chiaravalloti, Stojanovic-Radic & 
DeLuca, 2013). Empirical support comes from studies using the selective reminding 
task, whereby initial acquisition of memories is supported by a lengthy learning phase. 
Individuals with MS take longer to acquire information (DeLuca et al. 1994; Demaree 
et al., 2000; Lafosse et al., 2013), but recall is equitable to healthy controls (DeLuca et 
al., 1994; 1998). However, some studies suggest difficulties with registration are 
associated with earlier stages of MS, instead implicating retrieval in those with higher 
EDSS scores (Brissart, Morele, Baumann & Debouverie, 2012), or progressive 
phenotypes (Drake, Carra, Allegri & Luetic, 2006). Difficulties with memory tasks can 
be noted as early as the CIS (Hynčicová et al., 2017). 
  
Some MS patients demonstrate deficits in autobiographical memory (Ernst et al., 2015; 
Paul, Blanco, Hames & Beatty, 1997), which has been negatively correlated with QoL, 
perhaps caused by dissonance between pre-morbid coping and coping following 
disease progression (Kenealy, Beaumont, Lintern & Murrell, 2000; Langdon 2010). In 
a study of MS participants with working memory and long-term memory functions, 
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prospective memory (memory for planned actions) was shown to be impaired compared 
to controls in a virtual week paradigm (Rendell, Jensen & Henry, 2007).  
 
Demyelinating lesions and atrophy of the limbic system (Sahin, Selouan, Markowitz, 
Melhelm, & Bilello, 2016) or reduced activation of the hippocampus (González Torre 
et al., 2017; Hulst et al., 2015; Planche et al., 2016; Sumowski et al., 2016) have been 
associated with memory dysfunction. Left hippocampal atrophy has been associated 
with verbal memory impairments (Pardini et al., 2014; Sacco et al., 2015), and right 
hippocampal lesions have been associated with spatial memory dysfunction (Pardini et 
al., 2014).  
 
The current evidence base suggests that individuals with MS often have impaired 
memory functions, which typically increase with disease progression. The prevailing 
opinion is that these are initially more associated with registration of memories 
(implicating IPS and attention) and later in disease progression, associated with 
retrieval. The limbic system and hippocampus have been implicated.  
 
1.2.4.4. Language  
 
A historical cohort study demonstrated that language functions are typically intact in 
MS (Rao et al. 1991). Specific language deficits such as aphasias are rare aside from 
large cortical lesions (Jónsdóttir, Magnússon & Kjartansson, 1998), and such 
dysfunction has been reported predominantly in single case investigations (Barwood & 
Murdoch, 2013). Examinations of the verbal comprehension index on the Weschler 
Adult Intelligence Scale (WAIS-III; Wechsler, 1997; WAIS-IV; Wechsler, 2014) 
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demonstrate relatively preserved verbal comprehension index (VCI) compared to 
premorbid estimates (Clemmons et al., 2004; Drew, Tippett, Starkey & Isler., 2008). 
Connick, Chadran and Bak (2013) showed some impaired language functions in 
progressive MS, however these are likely associated with frontal executive dysfunction 
such as verbal fluency as opposed to posterior-parieto-temporal-occipital areas.  
 
The current evidence base predominantly suggests that linguistic functions remain 
largely intact in MS. Thus, this domain will not be considered within the current study.  
 
1.2.4.5. Visuospatial and visuoconstructive functions 
 
Approximately 25% of patients with MS demonstrate deficits with visuospatial and 
visuoconstructive functions, which often correlate with parietal-temporal-occipital 
lesions (Marasescu, Cerezo Garcia & Benito, 2016). Lesions to these areas are 
common, however the small prevalence of such impairment may be associated with 
low activation of brain volume or a replacement of connections following atrophy 
(Marasescu et al., 2016). They reported an association between higher EDSS and worse 
performances on picture completion tasks and block design tasks within the WAIS-III 
(Wechsler, 1997), the Rey-Osterrieth complex figure task (ROCFT; Osterrieth, 1944) 
and other tasks of visuomotor and visuoconstructive tasks. However, the ROCFT is 
confounded by MS sensorimotor impairment. Conversely, deficits have also been 
recognised in individuals with CIS, associated with lower white matter volumes 
(Hynčicová, et al., 2017).  
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Aside from visuospatial memory, there is little research into visuospatial functions in 
MS, nor the impact of impairment on QoL. Visuospatial learning is a significant 
predictor of cognitive impairment in MS (Langdon et al., 2012). Therefore, visuospatial 
learning tasks should be incorporated into assessments of cognitive dysfunction for 
those with MS. 
 
1.2.5. The effect of common mental illness on cognition in MS 
 
Common mental illness rates are raised in MS. Boeschoten et al. (2017) report a 31% 
prevalence of depression in MS populations in a large meta-analysis, and Murphy et al. 
(2017) report 50% will experience a post-diagnosis depressive episode within their 
lifetime. This population pose a higher risk of suicide and parasuicide (Brenner et al., 
2016).  Clinically significant anxiety is also common within MS with a reported 
prevalence of 22% (Boeschoten et al., 2017). Anxiety disproportionately influences 
females to males with MS (Théaudin, Romero, & Feinstein, 2016), and often reduces 
six-months post-diagnosis (Giordano et al., 2011), perhaps associated with the ‘theory 
of resilience’ where an individual develops psychological resilience to overcome 
adversity (Chwastiak & Ehde, 2007; Murphy et al., 2017). 
 
Morrow, Rosehart and Pantazopoulos (2015) showed a worsened IPS, visual-spatial 
memory and executive function in individuals with depressive symptoms. Also, 
depression has been linked to reduced performances on the selective reminding test, the 
SDMT and the PASAT (Niino et al., 2014).  In a review by Arnett et al. (2008), a 
negative association was found between depression and cognitive functioning in studies 
that were adequately powered. Bruce, Hancock, Arnett and Lynch (2010) suggested 
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that self-reported cognitive impairments (specifically, memory functions) were 
associated with self-report of depression, anxiety and neuroticism. However, these did 
not typically corroborate objective cognitive assessments. Golan et al. (2017) 
demonstrated a significant yet small correlation between depression and cognitive 
function when controlling for EDSS, fatigue, comorbidities and psychotropic 
medications, as well as a small correlation with motor function.  
 
Depressive symptoms are commonly associated with reduction of IPS in the general 
population, however depression in RR-MS reduces IPS further than in healthy 
counterparts (Lubrini et al., 2016). Individuals with depression in the context of MS are 
more likely to perform worse in executive tasks (Arnett, Higginson & Randolph, 2001; 
Chiaravolloti & Deluca 2008; Hanssen, Beiske, Landrø & Hessen, 2014; Raimo et al., 
2016). Causality is hard to determine as depression may exacerbate cognitive 
impairment, or perhaps depression is a secondary symptom of dysexecutive syndrome 
(Portaccio, 2016). However, most neuropsychological studies exclude those with 
mental health diagnoses and these still report executive dysfunction. In a study 
excluding those with depression but measuring depressive symptomology, scores on 
the PASAT and delayed recall on selective reminding test were associated with Beck’s 
Depression Inventory (BDI; Beck, Steer & Brown, 1996) score and the 
neuropsychiatric inventory (NPI; Cummings et al., 1994) (Figved et al., 2008), showing 
subthreshold psychiatric impacts on cognitive performance.  
 
Morrow, Rosehart and Pantazopoulos (2015) report worsened IPS, visual-spatial 
memory and working memory in RR-MS in those with significant anxiety compared 
with those without. Goretti et al. (2014) showed an association between state anxiety 
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reduced performance on SDMT and PASAT, which remained when depression and 
fatigue were statistically removed. However, causality cannot be demonstrated, as 
significant impairment may cause state anxiety during testing. Anxiety appears to 
impact working memory (Arnett et al., 1999; Arnett, Higgonson & Voss, 1999; Niino 
et al., 2014; Thornton & Raz, 1997) IPS and attentional deficits, as well as possible 
long-term memory dysfunction (Niino et al., 2014).  
 
The impact of common mental illness on cognition in MS provides implications for 
treatment. Individuals with diagnosed common mental illnesses are often excluded 
from research trials due to the confounds that inclusion may carry. Thus, within the 
present study those with a diagnosed psychiatric illness were excluded. However, 
greater incidence of symptoms of common mental illness are considered part of the 
overall syndrome. 
 
1.2.6. Fatigue and cognition in MS 
 
Fatigue refers to a subjective recognition of exhaustion, or an overpowering lack of 
mental or physical energy, whereas cognitive fatigue refers to subjective difficulties 
concentrating or thinking clearly (Golan et al., 2017; Kluger, Krupp, & Enoka, 2013). 
 
Sixty-five to 80% of individuals with MS report experiencing clinically significant 
fatigue (Minden et al., 2006; Weiland et al., 2015), and many consider this as one of 
the most disabling symptoms (Amato et al., 2001; Bakshi, 2003) which is significantly 
independently associated with lower QoL (Janardhan & Bakshi, 2002). There are mixed 
reports of the effect of fatigue on neuropsychological test performance in MS. Some 
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have demonstrated deficits in executive functioning, IPS, verbal fluency, sustained 
attention and working memory tasks due to subjective fatigue (Diamond, Johnson, 
Kaufman & Graves, 2008; Krupp & Elkins, 2000; Rotstein, O’Connor, Lee, & Murray, 
2012; Weinges-Evers et al., 2010). However, several studies found no association 
between fatigue and cognitive performance when fatigue is based on self-report (Beatty 
et al., 2003; Bol, Duits, Hupperts, Verlinden, & Verhey, 2010; Hanken, Eling & 
Hildebrandt, 2015; Johnson, Lange, DeLuca, Korn & Natelson, 1997; Morrow, 
Weinstock-Guttman, Munschauer, Hojnacki, & Benedict, 2009; Niino et al., 2014; 
Parmenter, Denney, & Lynch, 2003; Paul et al., 1998). A comprehensive review 
reported the cognitive signature of MS related fatigue to be solely associated with 
reduced alertness and vigilance (Hanken, Eling & Hildebrandt, 2015).  
 
In an ecologically valid examination, Beatty et al. (2003) noted increased self-report of 
fatigue during employment, but this did not translate to performance reduction. Bol, 
Duits, Hupperts, Verlinden and Verhey (2010) demonstrated that mental fatigue 
contributed to 39% of the total variance for cognitive complaints (using the 
multidimensional fatigue inventory), and physical fatigue was non-significant. 
However, these were not reflected on objective cognitive tests. The findings that 
subjective fatigue impacts cognitive complaint, but not cognitive test performance, was 
replicated by Jougleux-Vie et al. (2014) for verbal episodic memory.  
 
Reported reduced alertness and vigilance (Hanken, Eling & Hildebrandt, 2015) could 
potentially be explained by symptomatic overlap of depression and fatigue (Golan et 
al., 2017). Thus, Golan et al. (2017) examined the independent associations between 
depression and subjective cognitive fatigue on objective cognitive test performance 
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whilst controlling for disability, comorbidities and psychotropic medications. They 
reported no independent correlation of fatigue and cognitive test performance, but a 
small effect for depression (depression and fatigue combined only accounted for 1-6% 
of the variance in cognitive scores). Of importance to the current study was the 
significant impact of fatigue on motor function independent of EDSS, depression, and 
other confounds (Golan et al., 2017). 
 
Krupp (1997) report that the pathogenesis of fatigue is an amalgamation of 
neurobiological factors (nerve conduction and degeneration), psychological factors 
(depression and anxiety) and cognitive decline. Hanken, Eling and Hildebrandt (2015) 
suggested atrophy in the fronto-parietal networks, and subcortical structures including 
hypothalamus and thalamus were implicated in those with fatigue on alertness and 
vigilance tasks. Wilting et al. (2016) also implicated the thalamic region with fatigue. 
Reduced cerebellar volumes have not been found to contribute to development of 
fatigue (Weier et al., 2014).  
 
Fatigue affects a large proportion of individuals with MS and this has significant 
impacts on their self-reported functioning and QoL. However, overall subjective 
cognitive fatigue appears not to be linked to objective cognitive performance. 
 
1.2.7. Medication and cognition in MS   
 
The effectiveness of disease-modifying treatments on cognition is unclear (Amato, 
Portaccio & Zipoli, 2006; Langdon, 2010). One RCT of interferon-beta 1a 
demonstrated a slight improvement in verbal learning and recall, as well as auditory 
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working memory (Fischer et al., 2000), however it is hard to draw conclusions as the 
study was terminated early. A study of interferon beta 1-b (IFN β-1b) demonstrated 
improved performance in delayed visual memory recall when comparing those on a 
lower dose of IFN β-1b than those receiving a higher dose (Paty & Li, 1993), however 
this study was greatly underpowered. Another IFN β-1b study demonstrated improved 
attention and visual learning/recall in RR-MS matched for EDSS (Barak & Achiron, 
2002), however again this was underpowered. In a larger prospective study of IFN β-
1a, a comprehensive cognitive assessment was conducted at baseline and two-year 
follow up, which revealed significant changes in cognition compared to placebo in the 
domains of IPS, learning and memory (Fischer et al., 2000). This also suggested that 
IFN β-1a prevented decline in PASAT performance (Fischer et al., 2000). Cohen et al. 
(2002) reported that in a large study of SPMS, two years of IFN β-1a treatment did not 
significantly improve PASAT performance. IFN β-1a was associated with stability of 
cognitive impairment in a large three-year longitudinal study, and five-year follow-up 
in individuals with mild RR-MS – particularly in females (Patti et al., 2010; 2013). In 
a review of DMTs on cognition, criticisms of studies were associated with being 
underpowered, only considering subgroups of participants, or focusing on cognition as 
a minor aspect of the study (instead focusing on clinical outcome such as relapse rates) 
(Patti, 2012). Now that DMTs are standard care in MS, it is difficult to conduct RCTs 
evaluating their efficacy (Patti, 2012). There appear to be some benefits of DMTs on 
cognitive performance, however these may be secondary to reduced relapse frequency 
or other neurologic phenomena.   
 
Effectiveness of symptomatic treatments on cognition are also unclear. RCTs of 
donepezil and rivastigmine on memory impairment in MS demonstrated no significant 
 36 
differences between the intervention and control groups (Krupp et al., 2011; 
Shaygannejad, Janghorbani, Ashtari, Zanjani, & Zakizade, 2008). A Cochrane review 
of pharmacological interventions for memory disorder in MS concluded that there are 
no effective pharmacological treatments of memory impairments in MS (He, Zhou, 
Gou, Hao & Wu, 2011).  Jensen, Ravnborg, Mamoei, Dalgas and Stenager (2014) 
report significant improvements on the SDMT for individuals taking slow-release 
Fampridine-SR treatments. A small medication trial of 60 participants over four weeks 
demonstrated greater improvements in PASAT performance in the placebo arm 
compared to the Fampridine-SR trial. Morrow & Rosehart (2015) demonstrated a 
medium effect size improvement on the SDMT (though no significant difference on 
PASAT) for use of mixed amphetamine salts extended release. However, this used a 
very small sample size and involved only a single dose on the morning of testing. Early 
trials have indicated positive effects of L-amphetamine sulphate on learning and 
memory (Morrow et al., 2009) and has showed promise for slowed IPS (Benedict et al., 
2008). A review paper indicated that, except for L-amphetamine, symptomatic drug 
treatments do not have an impact on cognitive performance (Patti, 2012). 
 
Polypharmacy (the use of four or more medications simultaneously) is common in MS, 
due to the constellations of symptoms and requirement to reduce disease progression. 
Polypharmacy has been demonstrated to worsen prospective memory and increase self-
reported fatigue (Thelen, Lynch, Bruce, Hancock & Bruce, 2014).  
 
Research on pharmacological-based impacts on cognition is limited, and this is an area 
which warrants further investigation. It is possible that differential medication use could 
add confounds to research in MS.   
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1.2.8. Summary 
                                 
Cognitive impairment affects a significant proportion of people with MS. The profile 
of impairment varies and typically worsens with disease progression. This has 
significant impacts on QoL and daily functioning. High cognitive reserve appears to be 
somewhat protective of cognitive decline. The most common and severe impairments 
are of attention and IPS. Memory difficulties and executive dysfunction are common 
within MS, however it is likely that attention and IPS have a significant impact on timed 
tasks of executive functions, and the registration of memories. Psychiatric 
symptomology appears to have a significant negative impact on individual performance 
on cognitive tests, and therefore individuals with psychiatric diagnoses are typically 
excluded from studies examining cognitive profiles. However increased symptoms of 
depression and anxiety are typically recognised when comparing the MS group to 
controls. The clinical population demonstrates variability, and thus subcategories of 
individuals with RR-MS should be considered. Considerations of sub-diagnostic 
categories, may facilitate understanding of more specific cognitive profiles. The present 
study aims to find differences between individuals who have cerebellar involvement in 
MS compared to those who do not. 
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1.3. Role of Cerebellum in Cognition 
 
1.3.1 Cerebellar structure and anatomy 
 
The cerebellum (translated literally from Greek as ‘little brain’) is caudal to the cerebral 
cortex. It is divided into two hemispheres, separated by the vermis. It occupies 10% of 
the intercranial space, and has five times more neurons than the entire cerebral cortex 
(Herculano-Houzel, 2009; Miall, 2013). It has three lobes (anterior, posterior and 
flocculonodular). The cerebellum connects with the brainstem via the brachium 
conjunctivum, brachium pontis and restiform body, and afferent projections stem from 
deep nuclei, of which the cerebellum is wrapped around (Maill, 2013).  These serve as 
the only output fibres from the cerebellum.  
 
1.3.2. Cerebellar Function 
 
Historically, the cerebellum was considered a group of subcortical nuclei solely 
responsible for motor control. This is one aspect of cerebellar function, and damage can 
result in motor symptoms such as stiffness, rigidity, tremor and akinesia (Middleton & 
Strick, 2000) as well as ataxia, dysmetria, dysarthria and dysphagia (Schmahmann, 
2004), loss of coordination, hypotonia, nystagmus, ocular dysmetria, and 
dysdiadochokinesia (Weier et al., 2015a; 2015b). Postural and intention tremors are 
two of the most common cerebellar symptoms in MS (Weier et al., 2015a). A survey 
revealed that these postural and intention tremors are reported in 58%, though 
asymptomatic in 20% of these (Alusi et al., 1999). 
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It is now acknowledged that the cerebellum has a much wider role. This is shown 
clinically in the ‘cerebellar cognitive affective syndrome’ (CCAS) (Schmahmann & 
Sherman, 1998; Schmahmann, 2004) recognised in patients with focal lesions to the 
cerebellum. Symptoms include executive dysfunction (deficits in shifting, abstract 
reasoning, working memory, verbal fluency, inhibition and planning) and other 
cognitive deficits (spatial cognition and visual-spatial memory) (Schmahmann & 
Sherman, 1998; Schmahmann, 2004) as well as affective and personality changes, 
dysmetria, dysarthria and ataxia (Manto et al., 2012). CCAS is suggestive of wide 
ranging neural connections from the cerebellum to cortical areas.  
 
Schmahmann et al. (1998) reported those with CCAS without executive dysfunction 
showed anterior cerebellar damage and no posterior cerebellar damage (thus leading to 
motor, as opposed to cognitive changes). This reflects a functional topographical 
organisation of the cerebellum, with anterior areas associated with motor control 
(projecting to the sensorimotor cortex) and posterior lobes being involved in higher-
order processes (projecting to frontal areas). Evidence of this functional topographical 
architecture is found in a meta-analysis utilising fMRI activation likelihood estimates 
(ALE) (Stoodley & Schuhmann, 2009). This implicated lobule V, VI and VIII in 
sensorimotor tasks, lobules VIIIA/B in motor activation, and VIIIB in somatosensory 
activation (Stoodley & Schuhmann, 2009). Higher-order processes are associated with 
the posterior lobule. Lobule-VI and Crus-I are associated with language and working 
memory, Crus-I and lobule-IV for emotional processing and language and executive 
functions on Crus-I and lobule-VII (Stoodley & Schmahmann, 2009).  
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1.3.3. Corticocerebellar loops 
 
Neuronal tracing has confirmed the existence of cerebellar loops which facilitate 
communication between the cerebellum and cortical areas (Kelly & Strick, 2003; 
Middleton & Strick, 2000), including premotor, prefrontal, oculomotor and 
inferotemporal areas, with each loop associated with specific cognitive or behavioural 
functions (Kelly & Strick, 2003; Middleton & Strick, 2000).  
 
These ‘loops’ involve neocortical projections from different lobules of the cerebellum, 
via the pontine nuclei, and back to the cerebellum through the thalamus (Balsters & 
Ramnani, 2011). Afferents from the primary motor cortex project to lobules IV, V, VI, 
and parts of HVIIB and HVIII, whereas afferents from the pre-frontal cortex project to 
Crus-I and Crus-II (Kelly & Strick, 2003; Koziol et al., 2014). Habas et al. (2009) 
demonstrated structural and functional connectivity of the cerebellum to areas of the 
cortex utilising resting state functional connectivity MRI.  
 
1.3.4 Cerebellar lesions in MS 
 
Within MS focal white matter lesions can occur in any area of the CNS, however there 
are predilection sites in the cerebellar peduncles and hilar regions of dentate and olivary 
nuclei due to their proximity to the ventricular system (Weier et al., 2015a). Calabrese 
et al. (2010) recognised cerebellar lesions and atrophy in all MS phenotypes. Primary 
cerebellar symptomology in MS appears in 11-33% of patients (Rot, Ledinek & Jazbec, 
2008; Weinshenker, Issa & Bakerville 1996).  
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Specific impairments in cognition, motor skills and locomotion have been linked to 
cerebellar damage (Weier et al., 2015a). Cerebellar grey matter pathology contributes 
to cognitive and motor dysfunction in MS independent of cortical pathology 
(Damasceno, Damasceno, & Cendes, 2014). In one study, cerebellar lesion load was 
demonstrated to be the sole significant predictor of EDSS (including the cerebellar 
functional system score), and arm and leg function (Damasceno, Damasceno, & 
Cendes, 2014). Motor function (measured by the nine-hole peg test; 9HPT) can be 
indicative of cerebellar atrophy (Ruet et al., 2014; van de Pavert et al., 2016). 
 
1.3.5. Prognosis and rehabilitation outcome in those with cerebellar symptoms 
 
Cerebellar lesions in MS have been linked to poor prognosis and poor rehabilitation 
outcomes (de Groot et al., 2009; Langdon & Thompson, 1999; Thorpe et al., 2015; 
Vasconcelos et al., 2016).  
 
Regarding prognosis, Thorpe et al. (2015) report that higher baseline scores in the 
cerebellar functional system (FS) (as well as bowel/bladder, brainstem, and cerebral 
functional systems) are predictive of later institutionalisation and thus a worsened 
prognostic outcome. Functional systems are not discrete systems and thus the 
cerebral/mental functional system could also be impacted by cerebellar lesions. A 
longitudinal cohort study of individuals recently diagnosed with MS considered 
predictors for cognitive and physical functioning three years post-diagnosis (de Groot 
et al., 2009). Impairment of the cerebellar tract was associated with an inability to walk 
more than 500 meters as well as impaired dexterity (de Groot et al., 2009). Similarly, 
Vasconcelos et al. (2016) demonstrated that cerebellar (and pyramidal) dysfunction 
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according to functional systems, was associated with a worse prognosis in a Brazilian 
mixed-race cohort. Stewart et al. (2017) reported that relapse phenotype differentially 
promoted disability accumulation with the most pronounced being pyramidal, 
cerebellar and bowel/bladder functional systems.  
 
Regarding rehabilitation outcome, Langdon and Thompson (1999) report that 
cerebellar dysfunction (measured on the cerebellar functional system) is an independent 
predictor of poor rehabilitation outcome in a sample of individuals predominantly 
within the progressive phase of MS. This has been associated with poor prognosis for 
transfers and balance when sitting. Cerebellar function combined with vocabulary skills 
accounted for 57% variance in functional independence measure (FIM) change scores 
from admission to discharge. 
 
1.3.6. The cerebellum and automation of motor functions 
 
Cerebellar involvement in motor learning is longstanding and widely suggested 
(Balsters & Ramnani, 2011; Ito, 2000). The cerebellum develops the capacity to 
programme motor actions by creating subcortical representations of cerebral 
commands, requiring minor inputs to carry out the action (Marr & Thatch, 1991). This 
disencumbers frontal regions for higher-order tasks, known as automation. Automation 
is an ability to perform one task simultaneously with a cognitively demanding task, 
with little or no interference in performance (Poldrack et al., 2005). Automated actions 
are more stereotyped, less influenced by feedback and increasingly efficient requiring 
reduced attention (Shiffrin & Schneider, 1984). 
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fMRI have demonstrated increased excitation of the cerebellar region following 
practice resulting in automation of an action (Putteman et al., 2005; Ramnani, Toni, 
Josephs, Ashburner, & Passingham, 2000). One study demonstrated that cerebellar 
damage can prevent automation of movements, requiring individuals to recruit 
increased attention (Lang & Bastian, 2002). This used a duel-task paradigm, where 
participants performed a novel arm movement, whilst carrying out an auditory vigilance 
task (counting frequencies of a given letter in a string of letters). Individuals with 
cerebellar damage only mildly improved their performance with practice, and practice 
effects ameliorated when an attentional task was added (Lang & Bastian, 2002).  Two  
studies utilised positron emission tomography (PET) to examine healthy participants 
learning of sequential finger movements (Jueptner et al.,1997; Jueptner, Frith, Brooks, 
Frackowiak & Passingham, 1997). Increased medial cerebellar activation (as well as 
activation of deep dorsal areas of the cerebellar nuclei) occurred when carrying out 
previously learned actions compared to new actions which were associated with 
prefrontal areas (Jueptner et al., 1997; Jueptner, Frith, Brooks, Frackowiak & 
Passingham, 1997). This suggests that monitoring and execution of new actions utilises 
executive functions within prefrontal areas, with subsequent automation being 
conducted by the cerebellum. None of these studies utilised populations with MS. 
 
This process involves cerebellar encoding of internal models providing mental 
representations of the world for motor-planning (Ito, 1969; 2008). Internal models are 
neural representations of strategies that mimic sensory and/or output data of motor and 
cognitive processes (Kawato, 1999), known as embodied representations. During an 
experience, all perceptual systems capture a representation within their modality of the 
experience (e.g. with proprioception and visuospatial representations), which 
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amalgamate into a multimodal representation, or model, of the experience. Within 
motor function, afferents from the premotor cortex, anterior cingulate gyrus or 
supplementary cortex instructs the motor cortex to move muscles. Sensory feedback is 
received by the cerebellum, which creates an internal model (Ito, 2008).  This provides 
a template for reactivation and simulation, which contributes to an individual's 
predictive abilities (Pezzulo, 2008). These mental representations are not pure 
reproductions, but instead can be manipulated mentally and internally re-enacted 
(Barsalou, 1999; Pezzulo, 2011). Ito (2008) describes forward and inverse models for 
controlling movement. Forward models include reference to the internal feedback, 
whereas inverse models replace the feedback control entirely (Ito, 2008). This includes 
motor planning, as the primary motor cortex interacts with specific cerebellar lobules 
(Kelly & Strick, 2003). 
 
In motor control, the human body requires the ability to anticipate an array of musculo-
skeletal inputs, CNS latency, and response dynamics (Herreros, Arsiwalla & 
Verschure, 2016). This relies on anticipatory control loops with the cerebellum, 
whereby the cerebellum learns to anticipate events based on experience (Herreros & 
Verschure, 2013).  The role of the cerebellum in anticipatory control loops is associated 
with adaptive filtering and creation of mental bodily representations based on 
predictions of sensory inaccuracies (Koziol et al., 2014; Shadmehr & Krakauer, 2008). 
This includes using implicit memory to create sensory predictions (D’Angelo, 2011; 
Spencer & Ivry, 2009). This is required as action potential of neurons travel too slowly 
and are too ‘noisy’ to gain accurate feedback (Shadmehr, Smith & Krakauer, 2010). An 
example of this process is in compensatory eye movements, whereby humans maintain 
images centrally on the retina during head and body movements. Frens and Donchin 
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(2009) implicated the cerebellar flocculus in forward model prediction – which is an 
estimation of state following the movement. Afferents from the flocculus interact with 
pontine areas and the medulla to integrate this prediction with current state estimates 
and consequential feedback movements. Therefore, the role of the cerebellum in 
voluntary motor control includes timing and co-ordination of each muscle working in 
tandem, the relationship between motor actions and sensory results, and to predict the 
sensory outcomes of performing an action (Moberget & Ivry, 2016).  
 
The ability to create mental simulations of eventualities and experiences allows humans 
to create goal-directed actions. This requires the integration of mental models and 
executive functions, to select, inhibit alternatives, and evaluate the simulation (Pezzulo 
& Castelfranchi, 2009). This is most easily conceptualised within the motor domain, 
but can be expanded to include cognitive internal models (Koziol et al., 2014).  
 
The implicated neuroanatomical structures involve olivary cells and purkinje cells. 
Individual olivary cells are associated with fundamental movements, by responding to 
messages from the cortex to produce a sequence of patterns of firing. This means that 
simple cerebral messages may be sufficient to implement more complex actions (Marr 
& Thach 1991). Therefore, the cerebellum can develop a representation of information 
developed in the motor cortex during motor acquisition, which can be automatically 
reproduced (Marr & Thach, 1991). This disencumbers frontal regions for higher-order 
tasks.   
 
Therefore, within the motor domain, the cerebellum is thought to play a role in encoding 
internal models of the world for motor planning. It does this by initially integrating 
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sensory feedback into models in the cerebellum which are augmented through continual 
feedback. Summoning mental models reduces reliance on comparatively noisy and 
latent CNS feedback, thus allowing for predictions of sensory inaccuracies, estimation 
of state, and the ability to plan motor actions. The present study aims to investigate this 
phenomenon in MS by comparing performance on a simple peg test of extremity 
function (9HPT) and a peg test requiring greater levels of motor planning (grooved 
pegboard test; GPT; Matthews & Klove, 1964), comparing healthy controls with RR-
MS and RR-MSc. It is hypothesised that the latter group would have more difficulties 
with the GPT, due to the greater involvement of motor planning and thus the 
cerebellum.  
 
1.3.7. Cognitive profile in MS with cerebellar symptoms 
 
Of significance to the cognitive profile of individuals with RR-MS with cerebellar 
symptoms (RR-MSc) are the connections between the corticocerebellar loops, which 
support higher-level cognitive functions (Cerasa et al., 2013). There is an increased risk 
of cognitive impairment in RR-MSc than RR-MS individuals without cerebellar 
symptoms (RR-MSnc) and RR-MSc demonstrate a different cognitive profile 
(Valentino et al., 2009; Weier et al., 2014). However, the current evidence base 
examining the influence of cerebellar involvement on the cognitive profile of RR-MS 
is limited.  
 
It is thought that motor and cognitive dysfunction occur simultaneously from onset in 
RR-MSc (Weier et al., 2014). The RR-MSc profile is characterised by more severe 
deficits in IPS, language, verbal fluency and working memory compared to RR-MSnc, 
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recognised by impaired performance on the SDMT, PASAT and Controlled Oral Word 
Association Test (COWAT) (Bozzali et al., 2013; Cerasa et al., 2012; Damasceno, 
Damasceno & Cendes, 2014; Ruet et al., 2014; Valentino et al., 2009; van de Pavert et 
al., 2016; Weier et al., 2014). Ceresa et al. (2013) also demonstrated further deficits 
with immediate and delayed spatial memory with the ROCFT.  
 
Weier et al. (2014) utilised the cerebellar FS score to differentiate 172 individuals with 
a range of MS phenotypes into non-cerebellar (cerebellar FS = 0) or cerebellar 
(cerebellar FS > 0). This neurologic differentiation was corroborated by significantly 
reduced normalised cerebellar volume within the cerebellar group. The cerebellar group 
had a significantly higher EDSS, older age and longer disease durations. This group 
also had significantly worse performances on the 9HPT and measures of IPS 
(SDMT/PASAT). Hierarchical multiple linear regression analyses revealed that 
cerebellar signs and age predicted 26% of the total variance on the SDMT and these 
variables with T2 lesion volume predicted 23% of the PASAT. They reasoned that 
cerebellar symptoms appear to contribute to disability however, not independently of 
normalised brain volume and T2 lesion volume.  
 
Damasceno, Damasceno and Cendes (2014) compared healthy controls with 
individuals with RR-MS. A higher burden of cerebellar intracortical lesions were 
associated with worse SDMT scores, and higher burden of cerebellar leukocortical 
lesions were associated with lower PASAT scores (Damasceno, Damasceno & Cendes, 
2014). Similarly, Bozzali et al. (2013) associated PASAT scores with reduced 
anatomical connectivity with the corpus callosum right hippocampus and cerebellum 
in a study comparing healthy controls to RR-MS. Cerasa et al. (2012) showed reduced 
 48 
scores on the paced visual serial addition task (PVSAT) in RR-MSc with reduced 
connectivity (demonstrated on fMRI) between left cerebellum crus-1/Lobule-IV 
(posterior areas) and right superior parietal lobe. IPS reduction has been associated with 
reduced Crus-II (Lesage et al., 2010) and inferior middle cerebellum (Bozzali et al., 
2013) connectivity to prefrontal circuits. 
 
IPS reductions may be due to overwhelmed compensatory strategies following cortical 
reorganisation due to corticocerebellar loop damage (Rocca et al., 2012; Ruet et al., 
2014). These include overuse of compensatory ‘higher’ cortical areas for basic tasks 
due to inefficiencies in the cerebellum, and a saturation effect of cognitive load results 
in cognitive deficits. This is demonstrated by an imaging study by Ceresa et al. (2012) 
where MS patients with damage to corticocerebellar loops demonstrated increased 
activity in parietal areas and worse neuropsychological performance. 
 
Reduced functional connectivity between the cerebellum and cortical areas has also 
been shown to impact executive functions in RR-MSc (Ceresa et al., 2012). Increased 
response times were associated with reduced bilateral cerebellar activations during the 
incongruent condition of the Stroop task (Rocca et al., 2012; Trennery, 1989). 
Similarly, grey matter cerebellar lesion load and reduced cerebellar volume have been 
linked to executive dysfunction in Hayling Sentence Completion Task (Burgess & 
Shallice, 1997). 
 
van de Pavert et al. (2016) found an association with cerebellar lesion load and volume 
and reduction of memory performance on the Adult Memory and Information 
Processing battery (AMIPB; Coughlan & Hollows, 1985) (specifically on story recall 
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immediate and delayed; figure recall immediate and delayed), and word and face 
recognition on the Recognition Memory Test (Warrington, 1984). However, in one 
study of MS patients with a minimum disease duration of ten years, when all cognitive 
domains are examined simultaneously, there was no relationship between cerebellar 
lesions (assessed with a multimodal MRI) and cognitive impairment (Daams et al., 
2016). Similarly, Valentino et al. (2009) reported no significant relationship between 
total lesion load in the cerebellum (and cortex) and cognitive impairment. 
 
Findings from the above research imply correlations between cerebellar atrophy, 
neuroanatomical connections and performance on neuropsychological test 
performance. However, more research is needed in the area to gain a fuller 
understanding of the cognitive profile of those with RR-MSc. One aspect of the present 
study will further consider the cognitive profile in RR-MSc. 
 
1.3.8. The interrelation of cerebellar cognitive impairment and motor 
function/planning 
 
The action-based view of cognition posits that higher-order cognitive phenomena have 
evolved out of the structures available from the motor domain (Pezzulo, 2011). These 
structures create models involved within several social and cognitive abilities such as 
perspective taking, imitation, understanding others’ actions (Pezzulo, 2011), creativity 
and innovation (Vandervert, Schimpf & Liu, 2007). Similarly, Gallese et al. (2003) 
suggested that this was required for effective empathy and through generations of 
mental representations of affective states. Use of the same neural structures have been 
demonstrated for language comprehension (Scorolli, Borghi and Glenberg, 2009), 
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verbal working memory tasks (Küper et al., 2016; Marvel & Desmond, 2010; Sweet, 
Rao, Mayer & Cohen, 2004) and whilst perceiving others carry out actions (Rizzolatti 
& Craighero, 2004).  
 
Schmahmann (2004) recognised the anatomical uniformity of the cerebellum and thus 
hypothesised a uniform functionality for interactions with other areas of the cortex – 
the ‘universal cerebellar transform’. This is “an oscillation dampener maintaining 
function automatically around a homeostatic baseline and smoothing out performance 
in all domains” (Schmahmann, 2004, p374-375), implying that external stimuli interact 
with internal representations, which produces automated self-generated responses 
(Koziol et al., 2014). The universal cerebellar impairment is suggested to be dysmetria 
(dysfunction in performance of sharp alternating movements) involving the motor 
domain, but broadening to cognitive dysmetria. This is witnessed in the symptomology 
of CCAS (Schmahmann & Sherman, 1998).  
 
In accordance with the universal cerebellar transform, lesions to the cerebellum would 
result in universal cognitive impairment, whereby comparable dysfunction would be 
evident across the domains – a disruption around a homeostatic mechanism (Koziol et 
al., 2014; Schmahmann, 2004). This is likely to result in disrupted behaviours that are 
inconsistent with the external environment. Several fMRI studies have demonstrated 
that increased cerebellar activation results in more rapid cognitive performances in 
healthy controls, but the same is not true for those with MS (Bonnet et al., 2010; Genova 
et al., 2009; Moroso et al., 2017; Rocca et al., 2012). Moroso et al. (2017) found that 
SDMT was associated with atrophy of the posterior cerebellum, though was not 
associated with total cerebellar atrophy. They suggested that failures of the posterior 
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cerebellum prevent rapid cognitive performances, due to lack of optimisation and 
automation of cognitive function (Moroso et al., 2017). This conclusion is associated 
with the recognition that the cerebellum is involved in typically ‘frontal’ cognitive 
functions, via the recognised diffuse projections from posterior regions to the prefrontal 
cortex.  
 
One suggested cognitive mechanism is the role of the cerebellum in automisation of 
attentional demands (through cerebellar modulation), by creating an internal 
representation of the cognitive task, which disencumber cortical regions. This is a 
stereotyping of cognitive processes by integrating internal representations, and 
consequently amalgamating these models with external visual stimuli (Moroso et al., 
2017). This results in a more efficient processing thus greater IPS, due to the 
disengagement of the cerebral cortex and automatic responses from the cerebellum. 
Moroso et al. (2017) suggest that failings of cerebellar-frontal projections result in 
employment of the medial prefrontal cortex as a compensatory mechanism. Bonnet et 
al. (2010) termed this ‘cognitive compensation failure’. They recognised that medial 
prefrontal regions were activated in those with RR-MS compared to healthy controls 
who would activate cerebellar regions (during a go/no go paradigm). This results in 
cognitive impairment due to utility of higher-level decision making areas of the brain 
to carry out the tasks that would be automated in healthy controls. The cognitive 
compensation failure theory, posits that the limited cognitive load available to carry out 
tasks results in reduction of speed of response. 
 
Similar neuroanatomical processes are implicated in higher-order domains as in the 
motor domains for automation. Koziol et al. (2014) implicates synaptic strengthening 
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between Purkinje cells, and suggests that the process involves the receipt of information 
from the prefrontal cortex which strengthens the internal representation that most 
similarly matches the external stimuli (Koziol et al. 2014; Moroso et al. 2017). This 
disengages the cortex and incorporates the cerebellar generated automatic response, 
thus increasing competency within tasks (Koziol et al., 2014; Moroso et al., 2017).  
 
Binétray et al. (2016) demonstrated an experimental separation of cognitive processes 
and motor speed. This compared two crossing-off tests (COTs) with RR-MS and 
healthy controls (HC). One COT replicated visual exploration (sweeping visuomotor 
movements) and one COT replicated writing habits (left/right visuomotor movements). 
The former develops at an earlier age and thus is more naturalistic, whereas the latter 
is a more composite task requiring greater processing of information due to inhibition 
and switching by returning to the left side of the page. Within the visual exploration 
COT, there were no differences between HC and RR-MS. In the writing habit COT, 
significant differences were reported, and this was associated with reduced IPS. It is 
possible that this difference was associated with decreased cerebellar activation and 
thus reduced ability to generate automatic processes. Therefore, RR-MS were slower 
at this task due to reduced IPS, potentially from inefficiencies of automated cerebellar 
models. This study had a small sample of MS patients who had very low levels of 
disability (EDSS 0-1) and there were no measures of cerebellar dysfunction. Similarly, 
cognitive status was minimally assessed. The present study will utilise a reasonably 
exhaustive cognitive battery, a larger sample, considering motor planning (not just 
function) and includes a measure of cerebellar function. A broader range of disability 
will also be included, which will increase generalisability of findings to the clinical 
population.  
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Being able to understand and measure the interrelation of cerebellar cognitive 
impairment, motor function impairment and motor planning impairment may help to 
identify a subtype of MS. The current research aims to gain clarity on the interplay of 
these neurological variables whilst differentiating RR-MSc, RR-MSnc and HC. This, 
in turn would allow for different treatment and rehabilitation strategies. 
 
One aspect of the present study was to examine the notion that RR-MSc may lack the 
ability to efficiently optimise and automate cognitive functions resulting in 
impairments in motor function. They may lack efficient integration of executive 
functions with cerebellar models required in motor planning, causing impairment in 
motor planning. Since the same structures involved in motor planning are utilised in 
cognitive automation, it is possible that there may be a link between motor planning 
deficits and IPS reductions due to increased recruitment of higher cortical areas of 
limited information processing capacity (as opposed to summoning cognitive 
‘subroutines’ form cerebellar models). Alternatively, it may be all cognitive domains 
are equally effected due to simultaneous reductions in motor function and cognition 
associated with a universal cerebellar transform.   
 
The present study aims to understand how cerebellar damage underpins motor planning, 
and whether this relates to cognitive function. To the author’s knowledge, this is the 
first study to look at this association in MS.   
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1.3.9. Summary 
 
The cerebellum is a predilection site for atrophy and lesions in MS. Corticocerebellar 
loops which connect the cerebellum to cortical areas are likely to be involved in the 
increased cognitive and motor impairment in RR-MSc. A link between the cerebellum 
and automatic tasks has been demonstrated. The cerebellum is thought to develop 
subcortical models of sensory experiences for motor planning. Atrophy and lesions to 
the cerebellum are thus likely to impair motor planning and function, which will be 
investigated within the present study. The cognitive profile of RR-MSc is thought to be 
associated with further reduced IPS, and more executive dysfunction, however more 
research is required within this area. One theoretical explanation of increased cognitive 
impairment within RR-MSc is that it is due to inefficiencies of the capacity of the 
cerebellum to create subcortical representations, or models, based on information from 
all perceptual and cognitive systems. These models interact with external stimuli to 
coordinate performance in all cognitive domains (universal cerebellar transform), 
implying that damage will create universal cerebellar impairment. Another, perhaps 
complementary, theoretical explanation is that the cerebellum automates cognitive 
processes which results in reduced attentional input for aspects of cognition. 
Consequently, the process becomes more efficient by disencumbering the cortex to 
focus on higher-order tasks. This inefficiency of creation of subcortical models for 
automation has been thought to create both cognitive and motor symptoms 
simultaneously. Thus it is likely that inefficiencies of motor planning will be associated 
with cognitive decline, particularly IPS. Such impairment has not yet been 
demonstrated in the MS population.  
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1.4. Outline of the research: Objectives and Rationale  
 
The first aspect of the study is to ascertain the differences in cognitive profile between 
the groups: RR-MSnc, RR-MSc and HC. To the author’s knowledge, this is the first 
study with the chosen test battery with RR-MSc individuals. This has clinical and 
theoretical implications, including differential diagnosis, prognosis markers, and 
increased theoretical understandings of MS phenotypes.  
 
The second aim is to experimentally test for motor functioning and planning deficits 
comparing RR-MSc, RR-MSnc and HC. This may provide insight into understanding 
motor difficulties experienced by this clinical population. This has clinical implications 
regarding the management, understanding, and treatment of individuals with MS and 
to the author’s knowledge has not yet been studied. 
 
The final aim is to provide clarity on whether differences in motor functioning and 
planning will be related to cognitive function, particularly IPS. The hypothesised 
association with IPS is due to the notion that cerebellum disencumbers ‘higher’ cortical 
areas for higher-order tasks through automation. Thus, reduced cerebellar function may 
lead to inefficient processing of information due to the cognitive compensation failure, 
thus reduce IPS. However, the theory that the cerebellum acts as a universal transform 
would also suggest that other cognitive deficits will relate to motor functioning 
impairment. This study helps to consider these two, perhaps complimentary theories. 
To the authors knowledge, this is the first time this has been considered in MS.   
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This research has significant clinical implications of beginning to identify a cognitive 
subtype of MS, which may provide prognostic information that will have implications 
for treatment and rehabilitation. It will also further theoretical understanding of the 
cerebellar contribution to motor functioning, motor planning and cognitive function. 
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1.4.1. Hypotheses 
  
1. RR-MSc will have a different cognitive profile to RR-MSnc and HC, 
demonstrated by worse performances on tests examining IPS, verbal memory, 
visual memory and verbal fluency. 
2. Individuals with RR-MSc will perform worse than RR-MSnc and HC on tasks 
of motor planning  
3. Differences in motor functioning will be related to cognitive function, most 
significantly IPS. 
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2. Methodology 
 
2.1. Research Approval 
 
Confirmation of a favourable ethical opinion was received from the NHS Health 
Research Authority, following Proportionate Review (See Appendix 1).  Subsequently, 
the Research and Development (R&D) department in a Middlesex NHS Foundation 
Trust gave permission for recruitment of MS participants (See Appendix 2 and 
Appendix 3). Ethical approval was then obtained from the research ethics committee at 
Royal Holloway, University of London. Insufficient numbers of participants were 
identified at the initial research site, and consequently an application to add participant 
identification centres (PICs) to the project was granted from the NHS Health Research 
Authority. Finally, R&D was granted from an additional Greater London NHS 
Foundation Trust as a PIC for recruitment of MS participants (See Appendix 4).  
 
2.2. Design 
 
The study took an independent-groups design comparing three groups: individuals with 
relapsing-remitting multiple sclerosis with cerebellar symptoms (RR-MSc), those with 
relapsing-remitting multiple sclerosis without cerebellar symptoms (RR-MSnc), and 
healthy controls (HC).  A neuropsychological test battery, questionnaire battery and 
two peg tests were administered to participants in each group. The cognitive tests in the 
study have published norms, however, these have been published at different times and 
from different locations. Similarly, considerations of cognitive tests outside of specific 
batteries involves confounds such as order effects and fatigue effects. Therefore, 
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inclusion of a control group for the basis of comparison serves to reduce these 
confounds.   
 
2.3. Participants 
 
A total of 56 participants were recruited. Twenty-one were allocated to the healthy 
control group, with ten males, a mean age of 37.05 and a mean premorbid IQ of 115.34. 
Twenty-one were allocated to the RR-MSnc group with six males, a mean age of 39.81 
and a mean premorbid IQ of 109.22. Fourteen individuals were allocated to the RR-
MSc group with seven males, and mean age of 40.57 and a mean premorbid IQ of 
99.83. 
 
2.3.1. Inclusion / Exclusion Criteria  
 
Participants were included in the study if they met all the below inclusion criteria, and 
did not meet any of the exclusion criteria. 
 
• Inclusion 
o All participants were fluent English speakers, whose first language is 
English. 
o All participants were aged 18-60 years of age. 
o MS participants only:  
§ All MS participants must have a diagnosis of RR-MS by a 
Consultant Neurologist based on Polman et al. (2011) criteria or 
equivalent. 
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§ All MS participants had an EDSS 0-5.0 (able to walk 200 meters 
without aid or rest) as identified on Extended Disability Status 
Scale, telephone version (Lechner-Scott et al., 2003 – explained 
later, see section 2.8.2.1.). 
• Exclusion 
o Those affected by psychosis, substance misuse disorders, epilepsy, head 
injury or significant diagnosed pre-morbid depression or anxiety 
disorders. 
o Those who demonstrated significant visual, motor, or hearing 
impairments which would deny full engagement in cognitive tests. 
o Those who lacked capacity to consent to the study. 
Multiple sclerosis participants only:  
§ Those with MS who had a clinical relapse or steroid treatment in 
the previous two months. 
§ Following saturation of the RR-MSnc group, participants were 
excluded if they scored >4 on NARCOMS-TACS (North 
American Research Committee on MS Registry Tremor and 
Coordination Scale; NARCOMS-TACS; Marrie & Goldman, 
2011 – explained later see section 2.8.2.2). 
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2.4. Recruitment 
 
2.4.1. MS Participant Identification 
 
MS participants were recruited from NHS Foundation Trusts in Greater London and 
Surrey. Participants were approached by the clinical teams who provided participant 
information sheets (see Appendix 5) and gained permission for the researcher to make 
telephone contact. Alternatively, participants were provided with the option to contact 
the researcher via telephone or email. Upon contact, a home visit appointment was 
arranged to gain written informed consent (See Appendix 6) and for data collection. 
Participants with MS were well known to the treatment team, and had numerous home 
visits as part of their care, thus home visits were deemed safe and appropriate. An 
invitation letter was sent to individuals whom requested it (see Appendix 7). The 
researcher informed participants with MS that they are free to withdraw at any time, 
without giving a reason, and that this would not affect the standard of care they receive 
or their legal rights. This was provided both verbally and on the participant information 
sheets.  
 
Participants were assigned to RR-MSnc or RR-MSc based on the NARCOMS-TACS 
(Marrie & Goldman, 2011 – explained later see section 2.8.2.2.), as tremor and loss of 
co-ordination in MS is indicative of cerebellar involvement. In MS populations of mild-
moderate disability, this scale has demonstrated adequate construct validity (for 
detection of cerebellar symptoms), as well adequate criterion validity (Marrie & 
Goldman, 2011).  Individuals were allocated to the RR-MSc group if they scored four 
or five out of a possible five on the NARCOMS-TACS indicating at least ‘severe tremor 
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or loss of co-ordination’. Specifically, they endorsed the statement that every day 
“tremor or loss of coordination problems [force me to modify/prevent me from doing] 
my daily activities”.  
 
A substantial amendment was submitted following saturation of the RR-MSnc group 
to use the NARCOMS-TACS prior to gaining consent for data collection. It was 
deemed less intrusive to participants to ask this question outside of informed consent 
than to unnecessarily inconvenience participants who would not be suitable for 
allocation to RR-MSc. 
 
2.4.2. Healthy Control Participant Identification 
 
An opportunistic sampling method was used to identify HCs. This included 
approaching local businesses and through friends and acquaintances of the researcher. 
HCs were recruited from Cambridgeshire, Greater London and Berkshire. Following 
identification of potential participants an invitation letter (see Appendix 8) was sent and 
the HC participant information sheet (see Appendix 9). All participants contacted the 
researcher if they wished to be involved, and then an appointment was arranged to gain 
written informed consent (see Appendix 10). Individuals known to the researcher were 
given the opportunity to complete the assessment at home or in the researcher’s home. 
If participants were not known to the researcher, company buildings, or offices at Royal 
Holloway, University of London were used. Controls were informed that they were 
entitled to withdraw at any time without giving a reason, both verbally and on 
participant information sheets. 
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All groups were demographically matched for age and gender. Efforts were taken to 
match pre-morbid intelligence, however the matching process was not successful, and 
this was statically controlled for. Participants were not matched for employment, as MS 
patients are much less likely to be employed than those without MS, even at low levels 
of disability (Schiavolin et al., 2013). According to Weier et al. (2014) patients with 
cerebellar signs also tend to be older and more physically disabled. Data for healthy 
controls were collected following saturation of the RR-MSnc group, since there is a 
larger cohort to select from for the matching process.  
 
2.4.3. Excluded participants 
 
Following identification by the clinical team, ten participants were excluded. Three 
participants were excluded due to restricted ambulation resulting in an EDSS greater 
than five. Three participants were excluded due to being over 60 years of age.  Two 
participants were excluded as English was not their first language. Two participants 
were excluded at telephone screening since they did not score four or more on the 
NARCOMS-TACS and RR-MSnc group had met saturation. Only one participant not 
included within the study completed the full battery – which was associated with further 
information being provided regarding ambulation in a post data-collection discussion. 
 
2.5. Lone Working  
 
Although only participants known to the research team or clinical team were offered 
home visits, potential risks associated with visiting homes of participants were 
identified. Thus, the Camden and Islington NHS Foundation Trust Lone Working 
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Policy (September, 2015) was adhered to. Participants not known to the clinical or 
research team were seen in public buildings (offices or Royal Holloway, University of 
London).  
 
2.6. Data storage 
 
Participants were allocated an anonymised participant identification number. 
Participant name and identification number pairings were kept in a separate encrypted 
and password-protected spreadsheet. Data were also stored in an encrypted and 
password-protected spreadsheet. 
 
2.7. Power Analysis 
 
Statistical power analysis was carried out to determine the number of participants 
required to ascertain whether there was an interaction between group membership (RR-
MSnc, RR-MSc, HC) and measured variables. The anticipated analyses were to utilise 
3x1 one-way ANOVAs for the main dependent variables (pegboard and cognitive test 
scores) with the independent variable as group membership.  
 
A power analysis was conducted utilising data from Valentino et al. (2009) due to a 
similarity of design. This study involves a similar clinical population, with the 
comparison of individuals with RR-MSnc and RR-MSc. Similar inclusion and 
exclusion criteria were utilised compared to the proposed study. Participants in 
Valentino et al. (2009) also carried out a cognitive test battery with some similarities 
(SDMT and semantic fluency tasks). 
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 Within this study, the smallest significant effect-size was !2 = 0.82 (for SDMT one-
way ANOVA). Therefore, a large effect size of !2 = 0.8 (as reported in Cohen, 1992) 
was utilised for the power calculation.  
 
G*Power (Faul, Erdfelder, Lang & Buchner, 2007) was used for power analysis 
computations. Input parameters were set as follows: α = .05, power = .8, effect size (!2) 
= 0.8, group number = 3, for one-way ANOVA. This demonstrated that 21 individuals 
would be required per group, a total requirement of 63 participants for an actual power 
of !2 = 0.86. 
 
2.8. Materials  
 
2.8.1. Cognitive Tests 
 
Since motor dysfunction in the MS population is common, especially in those with 
cerebellar symptoms (Middleton & Strick, 2000), cognitive tests were selected that did 
not require fine motor control. Short tests were also selected, due to cognitive fatigue 
within this clinical population. Schwid et al. (2003) demonstrated a reduction in 
performance of MS participants at the end of testing compared to the beginning, 
highlighting the requirement for short testing batteries.  
 
Three tests (SDMT, BVMT-R learning trials and CVLT-II learning trials – defined 
below) in the current battery make up the the Brief International Cognitive Assessment 
for Multiple Sclerosis (BICAMS; Langdon et al., 2012). This was developed by an MS 
expert consensus group and is considered the gold standard for cognitive screening in 
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MS. This shows excellent psychometric properties with a sensitivity of 58%, specificity 
of 86% and accuracy of 75% when compared to the full Brief repeatable battery of 
neuropsychological tests (BRB-N; Rao & the Cognitive Function Study Group of the 
National Multiple Sclerosis Society, 1990).  The final two tests (WLG and PASAT3 – 
defined below) form part of the BRB-N, considered a sensitive measure of cognitive 
impairment in MS (Boringa et al., 2001). 
  
2.8.1.1. Symbol digit modalities test (SDMT; Smith, 1982): The SDMT (see Appendix 
11) is a test of IPS. In this test, symbols are paired with numbers in a nine-item key at 
the top of the record sheet. The record sheet also contains rows of symbols with their 
number pairings missing. Individuals are required to vocalise the numbers that 
correspond to symbols presented within the record sheet as fast as possible. There is an 
initial practice phase of 10 items to ensure understanding. The total score is the number 
of correct responses within a 90-second time limit. The oral nature of this test ensures 
that fine motor skills do not act as a confound. A systematic review demonstrated 
excellent psychometric properties for the SDMT-oral (Jaywant, Barredo, Ahern, & 
Resnik, 2016). Parmenter, Weinstock-Guttman, Garg, Munschauer and Benedict 
(2007) reported good psychometric properties with MS with a sensitivity of 82% and 
specificity of 60% to cognitive impairment in MS. López-Góngora, Querol, and 
Escartín (2015) also report good psychometric properties with sensitivity of 78% and 
specificity of 69% to cognitive impairment in MS. The SDMT demonstrates good test-
retest reliability (r = .80) (Smith, 1991), moderate to high concurrent validity, 
(correlations with WAIS Digit Symbol Coding subtest of r = .62 to r = .91) (Bowler et 
al., 1992; Hinton-Bayre et al., 1997; Lewandowski; 1984; Morgan & Wheelock, 1992) 
and good construct validity in MS as it is strongly associated with neuroimaging disease 
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markers (Christodoulou et al., 2003). It has been demonstrated to be effective at 
determining cognitive impairment within MS and competently distinguishes between 
people with MS and healthy controls (Drake et al., 2010; Hughes, Denney & Lynch, 
2011; Langdon, 2012; O’Connell, Langdon, Tubridy, Hutchinson & McGuigan, 2015).  
 
2.8.1.2. Word List Generation Task (WLG): Version A. The word list generation task 
(See Appendix 12) is a 90-second semantic fluency task. It assesses spontaneous word 
generation under a specific category. Within the present study, Version A was utilised 
which uses ‘fruits and vegetables’ as the category. Viterbo, Iaffaldano and Trojano 
(2013) demonstrated on a semantic fluency test that a cut-off of <28 words has a 
sensitivity of 82% and specificity 66% in discriminating participants with and without 
cognitive impairment in CIS indicative of MS. Tests of verbal fluency have been 
associated with neuroimaging markers, particularly associated with atrophy to the 
anterior and posterior corpus callosum (Bodini et al., 2013; Morrow, Menon, Rosehart, 
& Sharma, 2017).  
 
2.8.1.3. Paced Auditory Serial Addition Test (PASAT; Gronwall & Sampson, 1974):  
The PASAT (see Appendix 13) is a test of IPS and sustained and divided attention as 
well as working memory and calculating speed. The researcher provides participants 
with an audio recording which presents numbers at a rate of one every three seconds. 
The participant must add this number to the previous number presented. The PASAT 
has been reported to be aversive (Bosnes, Dahl & Almkvist, 2015; Roman, 1991; 
Walker et al., 2012) due to pressurised presentation tempos. The PASAT has a three 
second presentation interval (PASAT3) and a two second presentation interval 
(PASAT2). Due to the aversive nature, only the PASAT3 was utilised, as this was 
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deemed sensitive enough within the MS population. Within the MSFC (Multiple 
Sclerosis Functional Composite) (Fischer, Rudick, Cutter, & Reingold, 1999), only the 
PASAT3 is used as standard, with an optional two second trial. This has demonstrated 
good inter-rater reliability (r = .90 to .97) (Solari et al., 2005). Thompson (2000) also 
reported excellent internal consistency (with split half reliability of r = .96), and good 
test-retest reliability (r = .92) (Solari et al., 2005). When compared with an extensive 
working memory test battery, the PASAT was reported to have a 49% sensitivity and 
85% specificity for cognitive impairment (Hansen et al., 2015). López-Góngora, 
Querol, and Escartín (2015) report a sensitivity of 73% and specificity of 59% for the 
PASAT3 for cognitive impairment. On MRI markers, the PASAT has been associated 
with lesion volume (Rao et al., 2014) and brain volume loss in MS (Vollmer et al., 
2016). 
 
2.8.1.4. California Verbal Learning Task (CVLT-II; Delis, Kramer, Kaplan & Ober, 
2000). The CVLT-II (see Appendix 14) is a measure of episodic verbal learning and 
memory. The CVLT-II involves a list of 16 words, within four categories. The 
experimenter reads aloud the list five times (at a rate of one word per second), and the 
participant responds with as many words as they can remember. This is conducted over 
five trials with a maximum score of 16 on each trial. From this, a total score is calculated 
(maximum 80). This has demonstrated good internal consistency with split-half and α 
coefficients from α = .83 to .96 for clinical samples (Delis et al., 2000). It also has good 
predictive validity with regards to employment, good support for construct validity in 
MS (Stegen et al., 2010). CVLT-II correlates strongly with the CVLT (r = .76) (Delis 
et al., 2000). It demonstrates good sensitivity to cognitive impairment in MS (Strober 
et al., 2009) and one paper reported a sensitivity of 61% (Niccolai et al., 2015). Good 
 69 
test-retest reliability has been demonstrated in general population, (Woods, Delis, 
Scott, Kramer & Holdnack, 2006), as well as in MS populations (Benedict, 2005; Delis 
et al., 2000). In accordance with the BICAMS, only the first five trials (learning trials) 
of the CVLT-II were conducted (Langdon et al., 2012). This reduces the number of 
cognitive processes involved (Stegan et al., 2010), however aforementioned 
psychometric properties are inferential since these utilise the other trials (including 
delayed recall, recognition, and category cued trials) (Langdon, 2012). The CVLT-II 
has demonstrated good construct validity within the MS population, linked to lesion 
area, number, and volume on MRI measures (Benedict et al., 2002; Houtchens et al., 
2007; Langdon et al., 2012; Mike et al., 2011). 
 
2.8.1.5. Brief Visual Memory Test Revised (BVMT-R; Benedict, 1997): The BVMT-
R (see Appendix 15) is a test of visual memory. Participants are presented with a set of 
2x3 geometric figures for 10 seconds. Following removal of the stimulus sheet, 
participants are required to draw these shapes accurately in the same position as they 
appear on the stimulus sheet. This is conducted over three trials. The BVMT-R is scored 
by allocating one point for accurate drawing and one point for positioning within the 
matrix (a total of two points for each geometric figure). Each trial has a potential 
maximum score of 12, and this is conducted over three trials providing an overall score 
(maximum 36). This test shows good inter-rater reliability (r > .90), and good test-retest 
reliability (r = .80) (Benedict, 1997). It demonstrates a 60% sensitivity to cognitive 
impairment in MS (Niccolai et al., 2015). It has good concurrent validity correlating 
strongly with measures of explicit memory – e.g. Hopkins Verbal Learning Test (r = 
.65 to .80) (Benedict, Schretien, Groniger, Dobraski & Shpritz 1996). It has been 
demonstrated to be sensitive to impairment with MS Samples (Benedict et al., 2001; 
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Langdon et al., 2012). In accordance with the BICAMS administration (Langdon et al., 
2012) only the learning trials were carried out. Again, this makes discussed 
psychometric properties inferential, however it provides a ‘purer’ representation of the 
cognitive domain of immediate recall visual memory, than if a delayed recall trial was 
incorporated. Construct validity has been demonstrated as the BVMT-R is significantly 
associated with neuroanatomical markers and lesion load in MRI scans (Benedict et al., 
2002; 2009; Houtchens et al., 2007; Langdon et al., 2012). 
 
2.8.1.6. Test of Premorbid Functioning (TOPF; Wechsler, 2011): The TOPF is a brief 
test to predict premorbid IQ and memory performance (see Appendix 16). It consists of 
70 words with abnormal grapheme/phoneme translations. Participants read the list, and 
the number of phonetically correct words provides a raw score. Raw scores, gender, 
age and years of education are entered into the TOPF premorbid IQ calculator 
(Wechsler, 2011), which provides an overall premorbid full-scale IQ. O’Carroll (1995) 
reported that intelligence is correlated with almost all cognitive measures and thus 
comparison of this to current cognitive tests may be demonstrative of deterioration in a 
domain from premorbid estimates. Similarly, within the present study utilising the 
TOPF is important to ensure that groups are matched for premorbid function (thus not 
over/under emphasising differences). The TOPF shows good test re-test reliability (r = 
.89 to .95) and high split-half reliability (r = .92 to r = .99) (Wechsler, 2011). It 
demonstrates concurrent validity with the WAIS-IV verbal comprehension index (r = 
.75), processing speed index (r = .37) (Wechsler, 2011).  
 
An overview of domains tested by cognitive tests is provided in Table 1. 
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Table 1: Domains assessed by cognitive tests 
Cognitive Test  Domain 
Oral Symbol digit modalities test 
(SDMT; Smith, 1982) 
Information processing speed 
Word List Generation Task  Verbal fluency 
Paced Auditory Serial Addition Test  - 
three second intervals (PASAT3; 
Gronwall & Sampson, 1974) 
Information processing speed and 
working memory 
California Verbal Learning Task 
(CVLT-II; Delis, Kramer, Kaplan & 
Ober, 2000) – learning trials 
Immediate verbal recall memory 
Brief Visual Memory Test (BVMT-R; 
Benedict, 1997) – learning trials 
Immediate visual recall memory 
Test of Premorbid Functioning (TOPF; 
Wechsler, 2011) 
Premorbid intellectual functioning 
estimate 
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2.8.2. Questionnaires  
 
2.8.2.1. Expanded Disability Status Scale (EDSS Telephone Version; Lechner-Scott 
et al., 2003): The EDSS (see Appendix 20) is a quantitative measure of disability used 
in MS. Scores on the EDSS range from zero (no disability) to 10 (death due to MS). 
Typically, a physician ascertains an expanded disability status scale (EDSS; Kurtzke, 
1983) score through examination, however Lechner-Scott et al. (2003) validated a 
telephone-administered standardised interview. Lechner-Scott et al. (2003) showed a 
strong correlation between telephone and physical examination (r = .95). Individuals 
are only included in the present study with EDSS five or below. If an individual can 
walk less than 200 meters, then they are excluded as this provides an EDSS greater than 
five. Scores below this are initially based on the distance an individual can walk without 
aid or rest. If an individual is defined as unrestricted in ambulation or could walk more 
than 500 meters without aid, functional system scores are calculated to work out EDSS. 
To determine functional system (FS) scores, questions were asked regarding symptoms 
under the following subsections: vision, brainstem, pyramidal, cerebellar, sensory, 
bowel and bladder, and cerebral functional systems (see Appendix 20). For subsections 
with more than one question, the worst single score was used to determine the FS score.  
 
Frequency of FS scores were used with an FS frequencies table (see Appendix 21) to 
determine EDSS score below 4.5. Permission was granted from Professor Ludwig 
Kappos (senior author of Lechner-Scott et al., 2003) to utilise the English version of 
this within the present study. The EDSS has good concurrent validity in RR-MS when 
using MRI as a disease marker (Kalkers et al., 2001). It has good internal consistency 
(α ≤ .96) and test-retest reliability (r = .87) (Schäffler et al., 2013). The EDSS has 
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acknowledged weaknesses in sensitivity to change and aspects of reliability, however, 
this is the primary measure utilised for disability within MS. Variable inter-rater 
reliability has been demonstrated (r = .32 to .76), however this was greater for lower 
EDSS scores (<3.5) – relevant to the present study (Meyer-Moock, et al., 2014). 
Psychometric properties are given for the physician administered EDSS. However, due 
to the significant relationship of this with the telephone administered EDSS (Lechner-
Scott, 2003) similar psychometrics can be inferred.  
 
2.8.2.2. NARCOMS-Tremor and Coordination Scale (North American Research 
Committee on MS Registry, NARCOMS-TACS; Marrie & Goldman, 2011): This scale 
is a single response questionnaire-based measure, comparing current condition to 
experiences before developing MS. This defines tremor as “the rhythmic shaking of the 
head, hands or legs” and loss of coordination as “clumsiness or imbalance (e.g. 
staggering gait or unsteady gait like being drunk)” (Marrie & Goldman, 2011, p119). 
Responses include ‘normal’ (0), ‘minimal tremor or loss of coordination’ (1), ‘mild 
tremor or loss of coordination’ (2), ‘moderate tremor or loss of coordination’ (3), 
‘severe tremor or loss of coordination’ (4), ‘total disabling tremor or loss of 
coordination’ (5). Each provides a subsequent descriptor of frequency of tremor or loss 
of coordination, as well as the impact on changing daily activities. The scale has shown 
adequate criterion validity (correlation with an external criterion or gold standard 
measure) for those with an EDSS of 0-6.5. The NARCOMS-TACS correlated with 
cerebellar functional system score (r = .51) and the 9HPT (r = -.51) as well as hand and 
mobility domains of the Performance Scales (Marrie & Goldman, 2011). Performance 
Scales are a validated patient report measure of eight physical and mental domains 
(Schwartz, Vollmer, Lee & NARCOMS, 1999). Construct validity was adequate, as the 
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NARCOMS-TACS was moderately to strongly correlated with Performance Scales, 
EDSS, 9HPT and cerebellar FSS. 
 
2.8.2.3. The Fatigue Severity Scale (FSS; Krupp, LaRocca, Muir-Nash, & Steinberg, 
1989): The FSS is a nine-item questionnaire assessing subjective impacts of fatigue on 
functioning (e.g. motivation, physical functioning, employment) over the past week 
(see Appendix 18). Responses are marked on a seven category Likert scale (1 = strongly 
disagree; 7 = strongly agree), and a mean response is calculated. Krupp et al. (1989) 
reported the FSS demonstrated excellent internal consistency (α = .81 for people with 
MS and α = .88 within the healthy population) and good test-retest reliability. A 
difference between people with MS and the general population was found after 
controlling for depression (P < .001) (Armutlu et al., 2007).  
 
2.8.2.4. The Hospital Anxiety and Depression scale (HADS; Zigmond and Snaith, 
1983): the HADS is a 14-item scale with seven statements measuring anxiety (HADS-
A) and seven measuring depression (HADS-D) (see Appendix 17). The scale reduces 
the focus on aspects of anxiety and depression that are common somatic symptoms of 
illness (sleep disturbance, fatigue, appetite changes). Therefore, it is more specific 
when assessing anxiety and depression with individuals with long-term conditions such 
as MS. The HADS has been demonstrated to be more effective than the Beck 
Depression Inventory-Fast Screen (BDI-FS) at predicting functional outcomes in those 
with depression in the context of MS (Hanna et al., 2016). Each item is rated 0-3, with 
higher ratings pertaining to higher symptom severity. The range of the HADS-A and 
HADS-D is 0-21. HADS-A and HADS-D demonstrate good internal consistency (α = 
.82 and .83 respectively) (Honarmand & Feinstein, 2009). One systematic review 
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reported that caseness for anxiety and depression was 8/21 with a specificity of 78% 
and sensitivity of 90% for anxiety, and a specificity of 79% and sensitivity of 83% for 
depression (Bjelland, et al., 2002). It has also been demonstrated to be sensitive to 
depression and anxiety in MS (Watson, Ford, Worthington, & Lincoln, 2014). Zigmond 
and Snaith (1983) provide cut-off scores of 0-7 (normal range), 8-10 (mild range), 11-
14 (moderate range), 15-21 (severe range). 
 
2.8.3. Peg Tests  
 
2.8.3.1 Nine-hole peg test (9HPT; Mathiowetz, Weber, Kashman & Volland, 1985): 
The 9HPT (see Appendix 22) This provides a quantification of extremity function and 
physical disability. It is used as part of the multiple sclerosis functional composite 
measure (MSFC; Fischer, Rudick, Cutter, & Reingold, 1999) for research and clinical 
purposes. Participants are required to pick up pegs from the container with one hand 
and place them in the holes in any order until all holes are filled, subsequently, without 
pausing removing them one at a time and returning them to the container. This is 
completed twice for each hand (beginning with the dominant hand). Scores are derived 
from time taken to complete the task. Solari et al. (2005) report a high inter-rater (r = 
.84 - .96) and intra-rater (r = .91 - .99) reliability. This measure has very good internal 
consistency (α = .93) Rasova, Martinkova, Vyskotova and Sedova (2012), and high 
test-retest reliability (r = .88). Concurrent validity between the EDSS score and 1-year 
change (r = .27) (Cutter et al., 1999). Poor performances have been demonstrated to be 
indicative of cerebellar atrophy (Ruet et al., 2014; van de Pavert et al., 2016). This has 
been widely utilised as a measure of upper extremity tremor (Alusi, Worthington, 
Glickman, Findley & Bain, 2000; Fox, Bain, Glickman, Carroll & Zajicek, 2000).  
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2.8.3.2. The Grooved Pegboard Test (GPT; Matthews & Klove, 1964): The test 
consists of a pegboard with 25 holes (see Appendix 23).  Canoe-shaped pegs must be 
precisely oriented and inserted into differentially oriented canoe-shaped holes. This has 
a high motor planning demand compared to the 9HPT, due to the precise orientation 
required. First the researcher demonstrates placing five pegs in the top five holes, 
leaving 20 for the participant to complete. The participant then completes the remaining 
holes, ensuring that they fill holes sequentially from the opposite side of the board to 
the hand that they are using, completing a line and then returning to the opposite side 
from the hand that they are using, until all lines are completed. This is completed once 
for each hand (beginning with the dominant hand) and a mean score is taken. This tests 
manipulative dexterity, and requires more motor planning and co-ordination than the 
9HPT. It demonstrates marginal/high test-retest reliability within healthy controls (r = 
.67 to .86) (Dikmen et al., 1999; Levine et al., 2004; Ruff & Parker, 1993). It has modest 
concurrent validity with relation to tapping speed (Schear & Sato, 1989). Kessler et al. 
(1991) have demonstrated a weak/modest association with activities of daily living and 
GPT scores in MS.  
 
2.8.3.3. Motor Planning Index (MPI) The MPI was calculated to provide a measure 
of motor planning. This was calculated by subtracting the 9HPT time from the GPT 
time. This procedure is based on subtraction logic (Shoeben, 1982) which suggests that 
one can subtract time taken to complete a task from time taken to complete a similar 
task (aside from one critical component) to measure the critical component. Early 
experimental designs for IPS and attention in MS utilised this construct for calculation 
of motor programming, and controlled processing speed, amongst other constructs 
(Kujala, Portin, Revonsuo, & Ruutiainen, 1994; 1995). Difference scores (subtraction 
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logic) are still commonplace in more recent MS literature (Roth, Denney, & Lynch, 
2015). This MPI assumes that the GPT and 9HPT have the same sensorimotor 
component, and GPT has a greater motor planning element. Assuming this, subtracting 
9HPT from GPT will provide an indication of the time of the motor planning 
component. Criticisms of this index are discussed in section 4.2.1.    
 
2.9. Counterbalancing 
 
To experimentally control for order effects on the pegboard tests, counterbalancing 
procedures were performed, where half of participants for each group performed the 
9HPT first and half performed the GPT first. This was to avoid non-specific practice 
effects, as well as effects of fatigue on performance. Random number sheets were 
created using SPSS Statistics 21.0 (IBM, 2012). Participants were allocated a random 
number following group allocation to ensure that counterbalancing was successful for 
each group.   
 
2.10. Participant information material development 
 
 
Participant information sheets for MS participants (see Appendix 5), were reviewed by 
a specialist occupational therapist and specialist physiotherapist. Amendments in 
accordance to their feedback were made. 
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2.11. Procedure 
 
Participants were informed of the structure of the assessment and the estimated time of 
60-90 minutes, and given an opportunity to ask questions. Participants were informed 
that they would not receive individualised feedback at the end of the session. 
Participants were informed that they could opt in to receive a summary of the research, 
by indicating a preference on the consent form (see Appendix 6 and Appendix 10). 
Written informed consent was gained and participants were informed of their ethical 
and legal rights.  
 
Demographic information (gender, age, and educational level) was gathered through 
self-report. Individuals with MS also provided their time since diagnosis through self-
report. Closed questions around inclusion/exclusion criteria were also presented before 
beginning data collection. Questionnaires were administered first. Following 
administration of questionnaires, MS participants were allocated to RR-MSnc or RR-
MSc and were assigned their randomised number 0/1 for counterbalancing purposes. 
The questionnaires, pegboard tests and cognitive tests were administered in the order 
demonstrated in Table 2.  
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2.12. Measure administration order 
 
Table 2: Questionnaire, cognitive test and pegboard administration order 
Procedure Tests administered 
Questionnaires 1. EDSS Telephone Version 
2. NARCOMS-TACS 
3. FSS 
4. HADS  
Pegboard Test 1 5. 9HPT/GPT*  
Cognitive Tests 6. TOPF 
7. SDMT 
8. CVLT-II Learning Trials 
9. BVMT-R Learning Trials 
Pegboard Test 2 10. 9HPT/GPT*  
Cognitive Tests 11. WLG 
12. PASAT3 
 * order determined by counterbalancing procedure 
 
2.13. Neuropsychological testing  
 
Standardised procedures were adhered to as per individual test guidelines. This allows 
for replication of the study, comparison of the study findings with other research and a 
standardised procedure within the present study. This also allowed for comparisons to 
published norms to determine cognitive impairment within the samples and compare 
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the samples for generalisability to the population. Testing was completed in one session 
for all participants, however participants were aware they could request breaks.  
 
Every effort was made to reduce potential distractors within the physical environment, 
including requesting participants to turn of audio and visual equipment. Where possible 
participants were requested to sit opposite the researcher at a table. This allowed for 
standardised presentation of stimulus materials, and standardisation for peg tests 
(regarding ease of manipulation of materials). A stopwatch was used for timed tasks. 
 
Testing was carried out by the researcher (a trainee clinical psychologist), following 
demonstration of competence to a Professor of Neuropsychology.  
 
2.14. Analysis 
 
Data were analysed utilising a software package for statistical analysis Statistical 
Package for the Social Sciences 21.0 (SPSS; IBM Corporation, 2012). All variables 
were analysed for normality of distribution. Positively skewed data were transformed 
utilising square root, log10 and inverse transformations successively until normality 
was sufficient for parametric analyses. Negatively skewed data were transformed 
utilising reflections of the above, and power transformations (2-4) until normality was 
sufficient for parametric analyses.  
 
Data were examined to ascertain whether the groups were comparable with regards to 
gender, pre-morbid intelligence, EDSS and age. A chi-square test was carried out to 
determine whether groups were matched for gender (as self-defined gender was binary 
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within the present study). A one-way ANOVA was utilised to ascertain whether the 
groups differed significantly for pre-morbid intelligence estimates, depression, anxiety 
and fatigue.  
 
Differences in pre-morbid intelligence estimates resulted in entering them as co-
variates within an ANCOVA to statistically control for influence on other variables. A 
between-groups one-way ANCOVA was utilised to compute differences between 
cognitive/peg test variables (9HPT; SDMT; CVLT-II learning trials; BVMT-R learning 
trials; GPT; WLG; PASAT3). Planned contrasts were conducted to look for differences 
between group means. If data were normally distributed, these would have been 
conducted utilising post-hoc least significant difference (LSD) tests. However, if data 
were not normally distributed Games-Howell tests would be utilised in accordance with 
Field (2013). All statistical analyses used an alpha of (α <.05) for determining 
significance.  The alpha values were not adjusted for multiple corrections for reasons 
discussed in later sections (see section 3.2.). Fisher transformations were utilised to 
compare strength of correlation coefficients between MPI and cognitive test variables. 
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3. Results 
 
3.1. Exploratory Data Analysis 
 
All data analysis was carried out using IBM SPSS Statistics 21.0 (2012). The dataset 
was checked for completeness and there were no missing data.  Data was checked for 
accuracy of scoring by a professor of neuropsychology. Visual inspection and 
considerations of descriptive statistics demonstrated accurate data entry. 
 
The data were examined to determine whether the assumption of normality was met, 
required for parametric testing. A cut-off of ±2.58 (p < .01) was considered for kurtosis 
and skew as suggested by Tabachnick and Fidell (2013). Control data were skewed for 
SDMT and negatively skewed for TOPF. RR-MSnc data were positively skewed for 
9HPT and MPI. GPT and MPI were positively skewed for the RR-MSc group (see 
Appendix 24). 
 
Tabachnick and Fidell (2013) suggest using square-root transformations for moderately 
positively skewed data. The 9HPT was significantly positively skewed for RR-MSnc 
(z = 2.73, p <.01). A square-root transformation was carried out on 9HPT scores. For 
substantially positively skewed data, Tabachnick and Fidell (2013) recommend a 
logarithmic transformation (Log10). GPT was significantly positively skewed within 
the RR-MSc group (z = 3.34, p < .01) and MPI was significantly positively skewed for 
the RR-MSnc group (z = 2.79, p < .01) and RR-MSc group (z = 3.38, p < .01). Data 
were transformed with a log10 transformation. Skew and kurtosis fell below ±2.58 for 
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all groups following transformations and thus these met normality assumptions for 
parametric statistical procedures (p < .01) (see Appendix 24). 
 
SDMT was significantly positively skewed within the healthy controls (HC) (z = 3.09, 
p < .01). These were transformed using a square-root transformation. Following these 
transformations, data were still minorly skewed (z = 2.64 p < .01). However, this was 
deemed normal enough for parametric assumptions (p < .001). Premorbid intelligence 
estimates (pFSIQ) were significantly negatively skewed within HC (z = -3.81, p < .01). 
These were transformed using an x4 transformation, which resulted in minor skew 
following transformation (z = -2.62, p < .01). However, these were deemed normal 
enough for parametric assumptions (p < .001). SDMT and pFSIQ transformations were 
very close to the ±2.58 value for (p < .01) and thus normality was assumed (see 
Appendix 24). 
 
3.2. Statistical Analyses 
 
When repeat analyses are required, post-hoc adjustments of the p-value are often 
implemented. These are designed to reduce the chance of making a type-I error due to 
familywise error. A criticism of these adjustments is that they are overly conservative 
(Coolican, 2014; Perneger, 1998) and thus result in type-II error. Within the current 
study, repeated analyses were required due to the number of cognitive tests and 
pegboard tests within the battery. Correcting p-values would result in a very stringent 
p-value. Thus, following recommendations by Perneger (1998), post-hoc adjustments 
were not implemented, however results should be considered in the context of a raised 
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propensity for type-I error. Therefore, outputs were presented as least statistical 
difference (LSD) values. 
 
3.3. Demographic Variables 
 
An overview of descriptive statistics for demographic variables is presented in Table 3. 
 
3.3.1. Age 
 
Participants were aged between 23 and 59 (M = 38.96, SD = 10.02). In the HC group 
ages ranged from 23 to 59 (M = 37.05, SD = 12.39), in the RR-MSnc group ages ranged 
from 25 – 52 (M = 39.81, SD = 8.05), and in the RR-MSc group ages ranged from 27 
– 53 (M = 40.57, SD = 8.88). A one-way independent ANOVA was used to compare 
mean group ages, which revealed no significant difference between groups (F(2,53) = 
.63, p = .536). Age was therefore not considered in subsequent analyses.  
 
3.3.2. Gender 
 
The sample was comprised of 23 males and 33 females, a ratio of 1.43:1 for the full 
sample and a ratio of 1.69:1 for the MS sample alone. Within groups, the ratio (M:F) 
of the HC group was (10:11), RR-MSnc was (6:15), RR-MSc was (7:7). Pearson Chi-
Square revealed no significant difference in gender between groups (χ2(2) = 2.19, p = 
.335). Therefore, gender was not considered in subsequent analyses.  
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3.3.3. Estimated Premorbid IQ  
 
Estimated premorbid IQ (pFSIQ) was calculated with the TOPF scorer programme 
(Wechsler, 2011). This calculates pFSIQ based on age, gender, TOPF raw score, and 
years of education. pFSIQ ranged from 79.0 to 127.5 (M = 109.17, SD = 11.28). The 
HC group pFSIQ ranged from 91.8 to 123.1 (M = 115.34, SD = 7.49), the RR-MSnc 
group ranged from 79 to 127.5 (M = 109.22, SD = 12.33), and the RR-MSc group from 
86.9 to 118.5 (M = 99.83, SD = 7.88).  
 
An independent ANOVA compared the differences between groups in pFSIQ. The 
three groups differed significantly on pFSIQ scores F(2,53) = 10.64, p < .001). 
Levene’s test of homogeneity of variance provided a significant result (F(2,53) = 4.37 
p = .018) indicating variance assumptions were not met, and thus planed comparison 
Games-Howell tests were used. Games-Howell tests demonstrated that the HC group 
had a significantly higher pFSIQ than the RR-MSc group (p < .001). The RR-MSnc 
also had a higher pFSIQ than the RR-MS (p = .015). The RR-MSnc and HC group did 
not significantly differ (p = .203).  
  
Due to the significant difference identified, and the correlation of IQ with all cognitive 
domains (O’Carroll, 1995) pFSIQ scores will be added as a covariate within subsequent 
analyses.  
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3.4. Clinical Variables 
 
An overview of descriptive statistics for clinical variables is presented in Table 4. 
 
3.4.1. Symptoms of depression and anxiety 
 
Zigmond and Snaith (1983) report clinically significant cut-offs of HADS-A and 
HADS-D. Scores are categorised in the normal range (0-7), mild range (8-10) moderate 
range (11-14) and severe range (15-21). Caseness for anxiety or depression can be 
defined by scores of less than eight, i.e. those outside of the normal range (Bjelland, et 
al., 2002).  
 
Scores on the HADS-D ranged from 0 – 14. Within the HC group scores ranged from 
0 - 5 (M = 1.24, SD = 1.61) with all participants falling within the normal range 
(caseness: 0%). Within the RR-MSnc group scores ranged from 0 – 13 (M = 5.19, SD 
= 3.88), with 16 falling in the normal range, three in the mild range and two in the 
moderate range (caseness: 24%). Within the RR-MSc group scores ranged from 2 – 14 
(M = 7.29, SD = 3.58), with seven in the normal range, five in the mild range and two 
in the moderate range (caseness: 50%). An independent ANOVA was carried out to 
compare the differences between groups for HADS-D self-reported scores. This 
demonstrated a significant difference between groups (F(2,53) = 17.23, p < .001). 
Levine’s test of homogeneity of variance provided a significant result (F(2,53) = 6.57,  
p = .003), indicating variance assumptions were not met, and thus Games-Howell tests 
were used for planned comparisons. Games-Howell tests demonstrated that the HC 
group had significantly lower HADS-D scores than the RR-MSnc (p = .001) and RR-
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MSc group (p < .001). The RR-MSc and RR-MSnc group did not differ significantly 
(p = .246).  
 
Scores on the HADS-A ranged from 0 – 16. Within the HC group, scores ranged from 
0 – 12 (M = 4.29, SD = 2.88) with 20 falling in the normal range and one in the moderate 
range (caseness: 5%). Within the RR-MSnc group scores ranged from 1 – 12 (M = 6.29, 
SD = 3.61) with 13 in the normal range, five in the mild range and three in the moderate 
range (caseness: 38%). Within the RR-MSc group scores ranged from 2 – 16 (M = 7.43, 
SD = 3.80), with nine in the normal range, two in the mild range, two in the moderate 
range and one in the severe range (caseness: 36%). An independent ANOVA was 
carried out to compare the differences between groups for HADS-A self-reported 
scores. This demonstrated a significant difference between groups (F(2,53) = 3.89, p = 
.026). Planned comparisons demonstrated a significant difference between the HC 
group and RR-MSc (p = .01) but no significant difference between HC and RR-MSnc 
(p = .062) and RR-MSnc and RR-MSc (p = .335).  
 
The significant differences found between HC and both MS groups on HADS-D and 
the HC and RR-MSc on HADS-A are discussed in later sections (see section 4.1.1).  
 
3.4.2. Years since diagnosis 
 
Within the MS groups, years since diagnosis ranged from 0.09-22 years (M = 6.34, SD 
= 6.36). Within the RR-MSnc group, years since diagnosis ranged from 0.17 to 17 years 
(M = 4.79, SD = 4.80). In the RR-MSc group years since diagnosis ranged from 0.09 – 
22 years (M = 8.65, SD = 7.78). An independent t-test was used to compare the years 
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since diagnosis for the RR-MSnc and RR-MSc groups. Separate variance estimates 
were used since homogeneity of variance assumptions were not met (F = 9.24, p = 
.005).  There was no statistically significant difference between the two groups 
regarding years since diagnosis (T(20) = -1.66, P = .114). This will not be considered 
in subsequent analysis.  
 
3.4.3. EDSS Scores 
 
EDSS scores were computed from the verbally administered telephone EDSS 
(Lechner-Scott et al., 2003).  Within the MS groups, EDSS scores ranged from 0 to 5 
(M = 2.24, SD = 1.97). The RR-MSnc group ranged from 0 to 5 (M = 2.08, SD = 1.05), 
and the RR-MSc group ranged from 3.5 to 5.0 (M = 4.50, SD = .55). An independent 
t-test demonstrated a significantly higher EDSS in RR-MSc than RR-MSnc (t(33) = -
4.95, p < .001). The differences between groups will not be considered within the 
analysis, and reasons for this discrepancy is discussed in later sections (see section 
4.4.5.5.).  
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3.4.4. Fatigue 
 
Total score was calculated from the FSS responses and the mean response was 
calculated. Individuals who scored FSS < 4 were considered to have no fatigue, those 
scoring FSS 4-5 were within the borderline range, and those with FSS > 5 were 
considered to be fatigued. In the HC group FSS scores ranged from 1.11 to 4.56 (M = 
2.45, SD = 1.05), with three individuals meeting the borderline range for fatigue. In the 
RR-MSnc group FSS scores ranged from 1 to 6.56 (M= 4.19, SD = 1.55), with three 
individuals meeting the borderline range for fatigue, and 9 individuals meeting 
clinically significant fatigue. In the RR-MSc group FSS scores ranged from 2.67 to 6.67 
(M = 5.11, SD = 1.39), with two individuals meeting the borderline range for fatigue, 
and 8 individuals meeting the clinically significant range for fatigue. An independent 
ANOVA was carried out to compare the differences between groups for FSS mean self-
reported scores. This demonstrated a significant difference between the group (F(53,2) 
= 18.22, p < .001). Planned comparisons demonstrated significant differences between 
the HC group, RR-MSnc (p < . 001) and RR-MSc (p < .001). There was no significant 
difference between RR-MSnc and RR-MSc (p = .052).  The impact of the differences 
in fatigue between the HC group and MS participants will be discussed in section 4.1.  
 
3.4.5. NARCOMS-TACS Criterion Validity 
 
It is essential to consider the criterion validity of the NARCOMS-TACS, as this is the 
sole measure used for identification of cerebellar symptoms for group allocation. A 
similar procedure to Marrie and Goldman (2011) was used to ascertain the criterion 
validity of the NARCOMS-TACS for the current study. This used Spearman’s rank 
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correlations with casewise deletion. There were moderate to strong positive correlations 
between NARCOMS-TACS and 9HPT (r = .61, p < .001), GPT (r = .53, p < .001), MPI 
(r = .44, p < .001), and EDSS (r = .81, p < .001). This demonstrates adequate criterion 
validity of the NARCOMS-TACS to the peg tests and motor planning index. The 9HPT 
is widely utilised as a measure of upper limb tremor (Alusi et al., 2000; Fox et al., 
2000). This is of interest as the previous validation only had three percent of individuals 
reported severe tremor (Marrie & Goldman, 2011). Using Fishers transformation on the 
correlation coefficients, there is no significant difference between the strength of the 
correlations (9HPT vs GPT: z = .12, p = .90; 9HPT vs MPI: z = .36, p = .71; GPT vs 
MPI: z = .24, p = .81).  
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Table 3: Descriptive statistics for demographic variables 
 
 
*F: Full time; P: Part time, U: Unemployed, S: Extended sick leave 
 
 
  
    Gender Age Years Education Employment Premorbid IQ 
  N M:F x̅ (SD) Range x̅ (SD) Range F:P:U:S* x̅ (SD) Range 
HC 21 10:11 37.05 (12.39) 23 - 59 17.29 (2.45) 11 - 21 20:1:0:0 115.34 (7.49) 91.80 - 123.10 
RR-MSnc 21 6:15 39.81 (8.05) 25 - 52 16.57 (3.09) 11 - 22 12:7:2:0 109.22 (12.33) 79.00 - 127.50 
RR-MSc 14 7:7 40.57 (8.88) 27 - 53 13.86 (2.07) 12 -19 5:1:7:1 99.83 (7.88) 86.90 - 118.50 
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Table 4: Descriptive statistics for clinical variables 
 Years since 
diagnosis 
EDSS NARCOMS FSS HADS-D HADS-A 
 x̅ 
(SD) 
Range x̅ 
(SD) 
Range x̅ 
(SD) 
Range x̅ 
(SD) 
Range x̅ 
(SD) 
Range x̅ 
(SD) 
Range 
HC - - - - - - 2.45 
(1.05) 
1.11-4.56 1.24 
(1.61) 
0–5 4.29 
(2.88) 
0–12 
RR-MSnc 4.79  
(4.80) 
0.17- 
17.00 
2.98 
(1.05) 
0–5 0.81 
(0.75) 
0 - 2 4.19 
(1.55) 
1.00-6.56 5.19 
(3.88) 
0–13 6.29 
(3.61) 
1–12 
RR-MSc 8.65 
(7.78) 
0.09-
22.00 
4.50 
(0.55) 
0-5 4.14 
(0.36) 
4 - 5 5.11 
(1.39) 
2.67–6.67 7.29 
(3.58) 
2–14 7.43 
(3.80) 
2-16 
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3.5. Cognitive Tests  
 
ANCOVAs covarying pFSIQ were conducted for cognitive tests between the three 
groups. Descriptive statistics are provided for each cognitive test in Table 5. ANCOVA 
F values, as well as significance values (p = .05) are provided for ANCOVAs and 
planned comparisons in Table 6. The ANCOVAs revealed statistically significant 
differences for the CVLT-II (F(3,52) = 3.42, p = .002), the BVMT-R (F(3,52) = 2.93, 
p = .004), the PASAT3 (F(3,52) = 12.89, p <.001), and the SDMT (F(3,52) = 7.81, p 
<.001) whilst statistically controlling for pFSIQ. No significant differences were found 
in the WLG (F(3,52) = 2.55, p = .07). Planned comparisons for the CVLT-II revealed 
a significant difference between HC and RR-MSc (p = .01), and between RR-MSnc 
and RR-MSc (p = .008) but no significant difference between HC and RR-MSnc (p = 
.85). Planned comparisons for BVMT-R revealed a significant difference between HC 
and RR-MSc (p = .038) but no significant difference between HC and RR-MSnc (p = 
.40) or between RR-MSnc and RR-MSc (p = .11). Planned comparisons for PASAT3 
revealed significant differences between HC and RR-MSc (p = .0.13) and between RR-
MSnc and RR-MSc (p = .047) but not between HC and RR-MSnc (p = .37). Planned 
comparisons for SDMT demonstrated significant differences between HC and RR-
MSnc (p = .038), between HC and RR-MSc (p < .001) and between RR-MSnc and RR-
MSc (p = .025). 
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Table 5: Descriptive statistics for cognitive tests 
 
 
  
 HC RR-MSnc RR-MSc 
 M (SD) Range M (SD) Range M (SD) Range 
SDMT 59.52 (9.62) 48-88 51.57 (10.80) 23-73 42.07 (11.50) 21-62 
CVLT-II 50.14 (8.71) 35-64 49.91 (11.51) 32-72 40.14 (9.43) 22-58 
BVMT-R 26.14 (6.16) 11-34 23.62 (8.11) 8-33 18.21 (9.74) 6-30 
WLG 28.33 (5.70) 20-44 27.52 (5.47) 19-36 23.64 (5.06) 14-30 
PASAT3 50.33 (7.39) 34-60 45.67 (8.92) 24-56 35.43 (11.55) 17-54 
SDMT Sqrt 7.69 (0.60) 6.93-9.38 7.14 (0.79) 4.8-8.54 6.43 (0.92) 4.58-7.87 
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Table 6: ANCOVA and planned comparisons for cognitive tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ANCOVA Post Hoc Tests (Least Significant Difference) 
 ANCOVA F Significance HC vs RR-MSnc HC vs RR-MSc RR-MSnc vs RR-MSc 
CVLT-II 3.42 .024* .85 .01* .008* 
BVMT-R 2.93 .042* .40 .038* .11 
WLG 2.55 .070 .83 .12 .13 
PASAT3 12.89 < .001* .37 .013* .047* 
SDMT Sqrt 7.81 < .001* .038* < .001* .025* 
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3.6. Pegboard Tests  
 
ANCOVAs covarying pFSIQ were conducted for the pegboard tests between the three 
groups. Descriptive statistics  for pegboard tests are provided in Table 7. The motor 
planning index (MPI) was computed by subtracting the 9HPT from the GPT as 
described in the methodology. Figure 1 demonstrates a box plot of the MPI, 
demonstrating graphically the differences in means, as well as presenting the 
interquartile range. This was compared with ANCOVAs covarying pFSIQ between the 
groups. F values, as well as significance values (p = .05) are provided for ANCOVAs 
and planned comparisons in Table 8. The ANCOVAs revealed significantly significant 
differences between groups on the 9HPT (F(3,52) = 20.04, p < .001), GPT (F(3,52) = 
20.15, p < .001), and the MPI (F(3,52) = 16.75, p < .001). Planned comparisons revealed 
statistically significant differences on the 9HPT between HC and RR-MSnc (p = .01), 
between HC and RR-MSc (p < .001) and between RR-MSnc and RR-MSc (p < .001). 
Planned comparisons revealed statistically significant differences on the GPT between 
HC and RR-MSnc (p = .001), between HC and RR-MSc (p < .001) and RR-MSnc and 
RR-MSc (p < .001). Planned comparisons revealed statistically significant differences 
on the MPI between HC and RR-MSnc (p = .001), between HC and RR-MSc (p < .001) 
and between RR-MSnc and RR-MSc (p < .001). 
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Table 7: Descriptive Statistics for pegboard tests 
 
  
  HC RR-MSnc RR-MSc 
  M (SD) Range M (SD) Range M (SD) Range 
9HPT 19.12 (2.00) 15.83-22.77 22.29 (4.01) 17.63-33.75 28.95 (5.09) 21.71-37.18 
GPT 51.67 (5.34) 43.36-62.10 65.92 (16.75) 45.25-103.81 94.61 (32.98) 66.79-186.02 
MPI 32.55 (4.27) 25.13-40.42 43.63 (14.11) 27.30-82.09 65.66 (29.81) 39.32-148.84 
9HPT Sqrt 4.37 (0.23) 3.98-4.77 4.70 (0.41) 4.20-5.81 5.36 (0.47) 4.66-6.10 
GPT Log10 1.71 (0.04) 1.64-1.79 1.81 (0.10) 1.66-2.02 1.96 (0.13) 1.82-2.27 
MPI Log10 1.51 (0.06) 1.40-1.61 1.62 (0.13) 1.44-1.91 1.79 (0.16) 1.59-2.17 
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Table 8: ANCOVA and planned comparisons for pegboard tests 
 
 
  
 
 ANCOVA Post Hoc Tests (Least Significant Difference) 
 ANCOVA F Significance HC vs RR-MSnc HC vs RR-MSc RR-MSnc vs RR-MSc 
9HPT Sqrt 20.04 < .001* .01* < .001* < . 001* 
GPT Log10 20.15 < .001* < .01* < .001* < .001* 
MPI Log10 16.75 < .001* < .01* < .001* < .001* 
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3.6.1. Motor planning index 
 
Figure 1: Motor planning index boxplot 
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3.7. Defining cognitive impairment 
 
A cognitive impairment index was created for each participant. The index was 
computed utilising a similar procedure to previous published neuropsychological 
studies (e.g. Camp et al., 2005). Data were compared with published 
neuropsychological norms. SDMT, CVLT-II learning trials, BVMT-R learning trials, 
and PASAT3 utilised UK norms from Orchard, Giovannoni and Langdon (2013). WLG 
utilised Dutch norms from Boringa et al. (2001) as no UK norms are available. 
Participants were assigned a cognitive impairment grade for each cognitive test based 
on the number of standard deviations they fell below the published norm. Individuals 
were assigned grade zero if the score was greater than or equal to the published norm, 
a grade of one if the score was less than one standard deviation below the mean, a grade 
of two if the score was between one standard deviation and two standard deviations 
between the mean, and a grade of three if the score was more than two standard 
deviations below the mean. HC cognitive impairment index ranged from 0-9 (M = 4.19, 
SD = 2.44), RR-MSnc from 0-12 (M = 5.86, SD = 3.77) and RR-MSc from 2-15, RR-
MSnc and RR-MSc (M = 9.07, SD = 3.91). A one-way ANOVA demonstrated a 
significant difference between groups (F(53,2) = 8.85, p < .001). Planned comparisons 
revealed significant differences between HC and RR-MSc (p < .001) and RR-MSnc 
and RR-MSc (p = .008). No significant difference was found between HC and RR-
MSnc.  
 
‘Failure’ on a test was defined as 1.5 standard deviations below the published norm as 
fitting with BICAMS recommendations (Langdon et al., 2012). ‘Failing’ three tests was 
considered widespread cognitive impairment. Table 9 provides the frequency and 
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proportion of individuals ‘failing’ each cognitive task, and the frequency and proportion 
of individuals with widespread cognitive impairment.  
 
 
Table 9: Frequency of failed tests 
 HC (%) RR-MSnc (%) RR-MSc (%) 
SDMT 0 (0%) 5 (24%) 10 (71%) 
CVLT-II 8 (38%) 8 (38%) 9 (64%) 
BVMT-R 4 (19%) 6 (29%) 8 (57%) 
WLG 9 (43%) 10 (48%) 9 (64%) 
PASAT3 1 (5%) 3 (14%) 6 (43%) 
Widespread cognitive impairment 1 (5%) 6 (29%) 8 (57%) 
 
 
As data was compared with published norms for creation of cognitive impairment 
index, pFSIQ was not entered as a covariate within the analysis. Within the utilised 
published norms the estimated pFSIQ (derived from TOPF) was (M = 110.45, SD = 
8.48) for people with MS and (M = 111.03, SD = 8.75) for HCs. This is equivalent to 
the pFSIQ for HC and RR-MSnc within the current study (HC: M = 115.34, SD = 7.49; 
RR-MSnc M = 109.22, SD = 12.33), however RR-MSc (M = 99.83, SD = 7.88) 
appeared to have a lower premorbid IQ than the utilised data. Due to this, it could it 
could be argued that the RR-MSnc group would have less impairment than the RR-
MSc group because of a higher cognitive reserve associated with higher pFSIQ and 
thus less cognitive impairment. 
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3.8. Sample representativeness  
 
Table 10 compares published norms mean MS scores for SDMT, CVLT-II learning 
trials, BVMT-R learning trials, PASAT3 (Orchard, Giovannoni & Langdon, 2013) and 
WLG (Boringa et al., 2001) with mean MS scores from the present study (combining 
RR-MSnc and RR-MSc). No normative data was present for WLG. MS mean scores 
showed a high level of similarity to MS norms.  
 
Table 10: Descriptions of published norms and current study data 
 Mean (SD) 
HC norms1 
Mean (SD) 
HC2 
Mean (SD) 
MS norms1 
Mean (SD) 
RR-MS2 
SDMT 62.2 (9.8) 59.52 (9.62) 47.8 (14.0) 47.77 (11.89) 
CVLT-II Learning 
trials 
55.9 (12.4) 50.14 (8.71) 47.3 (12.4) 46.00 (11.64) 
BVMT-R Learning 
trials 
27.6 (5.0) 26.14 (6.16) 21.4 (6.9) 21.46 (9.07) 
PASAT 3 50.5 (8.7) 50.33 (7.39) 42.6 (13.8) 41.57 (11.13) 
WLG 26.3 (6.1) 28.33 (5.70) - 25.97 (5.58) 
1Boringa et al. (2001); Orchard, Giovannoni and Langdon, (2013)  
2Current Study: Combined RR-MSnc and RR-MSc scores 
 
Due to the relatively small MS sample size (n = 35) and control sample size (n = 21), 
it is of importance to consider whether the sample is typical of the population. By 
comparing the sample means with published norms (Table 10) we can infer that the 
current study has a relatively typical sample of the population.   
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3.9. Association between motor functioning and cognitive function 
 
To test the associations between motor planning and cognitive function, partial 
correlations (covarying pFSIQ) were carried out between MPI and all cognitive 
variables. Partial correlations were carried out between SDMT and MPI whilst 
controlling pFSIQ. Higher scores on the SDMT were significantly associated with 
reduced MPI whilst controlling for pFSIQ (r(53) = -.55, p < .001), demonstrating a 
strong negative correlation. r2 values were calculated to demonstrate the amount of 
variance shared by SDMT and MPI whilst controlling for pFSIQ, indicating 30% (r2 = 
.30) of MPI variance was shared with SDMT. Partial correlations were carried out 
between PASAT3 and MPI. Higher scores on the PASAT3 were significantly 
associated with reduced MPI whilst controlling for pFSIQ (r(53) = -.33, p = 013), 
demonstrating a moderate negative correlation. 11% of PASAT3 variance was shared 
with MPI (r2 = .11).  Partial correlations were carried out between BVMT-R and MPI 
(r(53) = -.44, p < .001) demonstrating a moderate negative correlation. 19% of BVMT-
R variance was shared with MPI (r2 = .19).   Partial correlations were carried out 
between CVLT-II and MPI (r(53) = -.35, p = .01), demonstrating a moderate negative 
correlation. 12% of CVLT-II variance was shared with MPI (r2 = .12). Partial 
correlations were carried out between WLG and MPI whilst controlling for pFSIQ 
(r(53) = -.18, p = .18) indicating no significant correlation. 3% of the variance of WLG 
variance was shared with the MPI (r2  = .03). 
 
For the hypothesis that motor planning is associated with IPS to be tested, one must 
compare the correlations between IPS and MPI as well as IPS and the pegboard tests, 
as a significantly stronger correlation should be noted between MPI/GPT than 9HPT. 
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Partial correlations were carried out between SDMT and PASAT3. Table 11 presents 
the correlation coefficients and statistical significance of these. 
 
Table 11: Correlations of IPS with motor function and planning 
 SDMT PASAT3 
 r p r p 
9HPT -.60 < .001* -.44 .001* 
GPT -.61 < .001* -.38 .004* 
MPI -.58 < .001* -.33 .013* 
 
Fisher transformations were computed to ascertain whether there was a statistically 
significant difference between correlation coefficients. For the SDMT, there was no 
significant difference between correlations coefficients for 9HPT v GPT (z = -.13, p = 
.90), GPT v MPI (z = -.26, p = .79) or 9HPT v MPI (z = -.13, p = .89). For the PASAT3, 
there was no significant difference between correlation coefficients for 9HPT v GPT (z 
= -.38, p = .70), GPT v MPI (z = -.26, p = .79), or 9HPT v MPI (z = -.64, p = .52). This 
suggests that information processing speed is not contributing more to the motor 
planning index than motor function. 
 
3.10. Summary  
 
The findings of the analysis demonstrated that all groups were successfully matched on 
age and gender. Groups were not matched for premorbid IQ and consequently this was 
entered as a covariate into subsequent analyses. Regarding clinical variables, MS 
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groups were matched for years since diagnosis. However, HC showed significantly 
fewer symptoms of depression than both MS groups and HC showed significantly fewer 
symptoms of anxiety than RR-MSnc. HC also demonstrated significantly fewer 
symptoms of fatigue than both MS groups. MS groups were not matched for EDSS 
scores. Regarding cognitive tests, HC significantly outperformed RR-MSc on all 
cognitive tests other than the WLG. HC significantly outperformed RR-MSnc only on 
SDMT. RR-MSnc significantly outperformed RR-MSc on SDMT, CVLT-II and 
PASAT3. The cognitive impairment index significantly differentiated RR-MSc from 
HC and RR-MSnc, but not HC from RR-MSnc. More than twice the frequency of 
widespread cognitive impairment was noted in the RR-MSc group than RR-MSnc 
group. On the tests of motor function and motor planning HC significantly 
outperformed RR-MSnc and RR-MSc, and RR-MSnc outperformed RR-MSc. There 
was a significant negative moderate-strong correlation between the SDMT, PASAT3, 
CVLT-II and BVMT-R and MPI. However, there were no significant differences 
between the strengths of the correlations for the MPI, GPT and 9HPT with measures of 
IPS.  
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4.0. Discussion 
 
Significant research has demonstrated that a substantial proportion individuals with MS 
have cognitive impairment, which impacts on quality of life and daily functioning. The 
most significant deficits are with IPS. Some research has begun to consider cognitive 
profiles of RR-MSc. Research has also demonstrated a link with the cerebellum and 
motor function and motor planning. The present study aimed to consider differences 
between the cognitive profiles of individuals with RR-MSnc and RR-MSc, and 
consider how these relate to motor planning and function.  
 
4.1. Hypothesis 1: RR-MSc will have a different cognitive profile to RR-MSnc 
and HC, demonstrated by worse performances on tests examining IPS, verbal 
memory, visual memory and verbal fluency 
 
Groups significantly differed on all neuropsychological variables other than the WLG. 
Significant differences were only found between HC and RR-MSnc on SDMT. RR-
MSnc significantly outperformed RR-MSc on CVLT-II, SDMT and PASAT3, but not 
the BVMT-R. HC significantly outperformed RR-MSc on all tests aside from WLG. 
This supports the notion that there is a difference in the cognitive profile between 
groups, and supports Hypothesis 1 aside from differences in verbal fluency.  
  
Age, gender and premorbid IQ are known to impact scores on cognitive tests. Within 
the current study, groups were matched for age and gender, and premorbid IQ was 
statistically controlled for. There was no significant difference between the two MS 
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groups in years since diagnosis. Therefore, these variables cannot account for the 
differences.  
 
The HC group significantly differed in self-reported symptoms of fatigue from the MS 
groups (which did not significantly differ from each other). The lack of a significant 
difference between the two MS groups furthers the notion that cerebellar dysfunction 
does not contribute to the development of fatigue (Weier et al., 2014). Within the RR-
MSnc group 43% met the clinically significant range for fatigue and 57% in the RR-
MSc group, whereas no HCs fell in this range. Within the general population, most 
individuals with MS report clinically significant fatigue (Minden et al., 2006; Weiland 
et al., 2015).  There have been mixed findings regarding the effects of self-reported 
fatigue on cognition, with some studies reporting significant impacts (Diamond, 
Johnson, Kaufman & Graves, 2008; Krupp & Elkins, 2000; Rotstein, O’Connor, Lee, 
& Murray, 2012; Weinges-Evers et al., 2010) and others reporting no significant 
difference (Beatty et al., 2003; Bol, Duits, Hupperts, Verlinden, & Verhey, 2010; 
Hanken, Eling & Hildebrandt, 2015; Johnson, Lange, DeLuca, Korn & Natelson, 1997; 
Morrow, Weinstock-Guttman, Munschauer, Hojnacki, & Benedict, 2009; Niino et al., 
2014; Parmenter, Denney, & Lynch, 2003; Paul et al., 1998). Overall, it appears that 
self-reported fatigue is not linked with objective cognitive performance. Thus, fatigue 
is unlikely to account for the difference in cognitive profile between the three groups.  
 
The HC group also significantly differed in self-reported symptoms of depression from 
the MS groups (whom did not significantly differ from each other). 0% of HC, 24% of 
RR-MSnc and 50% of RR-MSc met caseness for depression. The HC group 
significantly differed in self-reported symptoms of anxiety from the RR-MSc group, 
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but not the RR-MSnc group. However, the two MS groups did not significantly differ 
from each other. Five percent of HC, 38% of RR-MSnc and 36% of RR-MSc met 
caseness for anxiety. These raised rates of common mental illness are representative of 
the MS population (Boeschoten et al., 2017). Depression and anxiety have been 
demonstrated to affect cognition in MS (Arnett, Higgonson, & Voss, 1999; Arnett, 
Higginson, & Randolph, 2001; Arnett et al., 1999; 2008; Bruce, Hancock, Arnett & 
Lynch, 2010; Chiaravolloti & Deluca, 2008; Figved et al., 2008; Golan et al., 2017; 
Goretti et al., 2014; Hanssen, Beiske, Landrø & Hessen, 2014; Lubrini et al., 2016; 
Morrow, Rosehart & Pantazopoulos, 2015; Niino et al., 2014, Raimo et al., 2016; 
Thornton & Raz, 1997). However, it was not possible to statistically control for these 
variables using ANCOVA as this would significantly reduce the power of the analysis 
and increase the likelihood of type-II error. 
 
The prevalence of depression and anxiety is higher in the MS population than in the 
general population (Boeschoten et al., 2017) as is fatigue (Minden et al., 2006; Weiland 
et al., 2015). Therefore, it can be considered part of the clinical syndrome of MS, rather 
than just noise or error variance, and thus extricating these statistically as a covariate 
would reduce meaningful variance (Miller & Chapman, 2001). Overall therefore it 
appears that there are significant differences in cognitive tests likely associated with 
meaningful differences in cognitive function between HC, RR-MSnc and RR-MSc.  
 
When all variables were considered simultaneously, utilising a cognitive impairment 
index incorporating published norms, there was a significant difference found between 
RR-MSc and RR-MSnc (as well as HC). This is indicative of a different cognitive 
profile. However, it is possible that pFSIQ may have added a confound between RR-
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MSc and RR-MSnc, as the RR-MSnc had a greater pFSIQ and thus a greater cognitive 
reserve and this was not controlled for in the cognitive impairment index due to 
comparison with other data. However, differences in pFSIQ were only minimal 
(Orchard, Giovannoni & Langdon, 2013). When considering widespread cognitive 
impairment (‘failure’ on three or more cognitive tests) 57% of individuals met 
widespread cognitive impairment within the RR-MSc group, compared to 5% in the 
HC and 29% in RR-MSnc. This is indicative of a differing cognitive profile between 
the two MS groups characterised by greater widespread cognitive impairment within 
the RR-MSc group, and RR-MSnc being more associated with specific deficits.  
 
Overall, the present research indicates that HC, RR-MSnc and RR-MSc differ on 
cognitive test performance, and that RR-MSc and RR-MSnc have a different cognitive 
profile.  
 
4.1.1. Interpretation 
 
4.1.1.1. Information processing speed 
 
The highest significant difference between groups was found on the SDMT followed 
by the PASAT3, both established tools for measuring IPS in MS. An expert committee 
deemed the SDMT to be the most reliable, valid and sensitive screening test to cognitive 
impairment in MS for routine clinical use (Langdon et al., 2012). It is widely reported 
that SDMT performance is impaired in those with MS (Drake et al., 2010; Forn, 
Belenguer, Parcet-Ibars & Ávila, 2008; Hughes, Denney & Lynch, 2011; López-
Góngora, Querol & Escartín, 2015; O’Connell, Langdon, Tubridy, Hutchinson & 
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McGuigan, 2015), and in the present study SDMT was the only cognitive test that 
significantly differentiated RR-MSnc from HC. It demonstrated a high sensitivity with 
71% of RR-MSc ‘failing’ SDMT, and 24% of RR-MSnc ‘failing’ SDMT, and a high 
degree of specificity with 0% of control participants ‘failing’ SDMT.  Thus, it can be 
concluded that in the present study RR-MSnc had slower IPS than HC, and RR-MSc 
had slower IPS than RR-MSnc.  
 
However, the PASAT3 did not differentiate RR-MSnc from HC. Previous research has 
found PASAT to be moderately sensitive to cognitive impairment in MS (Hansen et al., 
2015; López-Góngora, Querol, & Escartín, 2015). This non-significant finding may be 
due to multiple factors. In MS studies, the SDMT has been shown to not be necessarily 
predictive of PASAT performance (Weier et al., 2014; Williams, O’Rourke, 
Hutchinson, & Tubridy, 2006). This is because SDMT and PASAT may represent 
somewhat different, albeit overlapping, cognitive domains (Costa, Genova, DeLuca, & 
Chiaravalloti, 2016; Weier et, 2014), for instance, the PASAT includes a significant 
working memory component, as well as IPS. This additional working memory 
component may impair RR-MSc due to the cerebellum’s role in the articulatory control 
system (see section 4.1.1.2.). Construct contamination is common in all tests designed 
to assess IPS (Chiaravalloti, Christodoulou, Demaree, & DeLuca, 2003). This is 
demonstrated by differing neuroanatomical correlates with cognitive tests on 
neuropsychological research involving neuroimaging. For instance, Yu et al. (2012) 
report that the SDMT was more sensitive to white matter tract damage in MS than the 
PASAT, and had stronger associations with markers of cerebral and cerebellar markers. 
Similarly, Damasceno, Damasceno and Cendes (2014) report that SDMT was 
associated with intracortical lesions, and the PASAT with cerebellar leukocortical 
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lesions. Similarly, Weier et al. (2014) suggests that PASAT performance is primarily 
linked to cerebellar and whole brain atrophy. The RR-MSnc group therefore are likely 
to have less impairment on PASAT than RR-MSc, and this pattern was recognised in 
the current study (with 43% of RR-MSc ‘failing’ the PASAT compared to 14% of RR-
MSnc). This might be associated with the fact that the SDMT is considered a purer 
indicator of IPS than PASAT, which represents IPS, attention and working memory 
domains.  
 
However, this may also be associated with the fact that three participants within the 
control group met the ceiling for PASAT3, thus reducing the difference between HC 
and MS groups. Future studies should consider utilising the PASAT2 to avoid this 
ceiling effect. The PASAT3 is easier than PASAT2, the latter being more irksome for 
participants, and thus PASAT2 was not included due to the distress this can cause to 
participants. However, this may have resulted in a loss of meaningful variance and 
sensitivity.  
 
Within the current study, RR-MSnc performed significantly better than RR-MSc on the 
PASAT3 and SDMT. This supports previous research demonstrating this difference 
(Bozzali et al., 2013; Cerasa et al., 2012; Damasceno, Damasceno & Cendes, 2014; 
Moroso et al., 2017; Ruet et al., 2014; Valentino et al., 2009; van de Pavert et al., 2016; 
Weier et al., 2014). Most of these studies utilised neuroimaging methods, aside from 
one who utilised the 9HPT as indicative of cerebellar dysfunction (Ruet et al., 2014).  
 
Overall, these findings are indicative of impairments in attention and IPS in individuals 
with RR-MSnc, and a further impairment in those with RR-MSc (including 
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impairments in attention and working memory). This fits with previous empirical 
evidence in this area. At a brain level, the cerebellum has five times more neurons than 
the entire cerebral cortex (Herculano-Houzel, 2009), which makes the its functions 
especially vulnerable to slowed information processing speed. Reductions are also 
likely associated with disruption to corticocerebellar networks which rely on the 
integrity of several subcortical structures including the cerebellum (Ceresa et al., 2013; 
Forn et al., 2008; Valentino et al., 2009). This results in recruitment of compensatory 
networks rather than from cerebellofrontal networks, the latter associated with fastest 
task responses (Ruet et al., 2014). Thus a plausible theoretical explanation may be 
associated with reduced IPS in RR-MSc from a lack of optimisation and automation of 
cognitive functions associated with the cerebellum (Bonnet et al., 2010), which has 
been linked to grey matter loss in Vermis II (Moroso et al., 2017). Thus, this is a 
possible demonstration of ‘cognitive compensation failure’ (Bonnet et al., 2010). This 
is further considered in later sections (see section 4.3).  
 
4.1.1.2. Memory 
 
The findings of the present study demonstrate significant differences between HC and 
RR-MSc, and RR-MSnc and RR-MSc on CVLT-II learning trials, a well-established 
verbal memory task. This indicates more significant impairment in verbal memory in 
RR-MSc compared to the other two groups.  
 
These findings are supported by neuroimaging findings by van de Pavert et al. (2016) 
who found associations with grey matter cerebellar lesion load in MS and reduction of 
visual and verbal immediate and delayed memory recall (shown on The Adult Memory 
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and Information Processing Battery; AMIPB; Coughlan & Hollows, 1985). Many 
previous studies did not find an association with cerebellar signs and the verbal memory 
domains using the Rey Auditory Verbal Learning Test (Ceresa et al., 2013; Valentino 
et al., 2009) or selective reminding task (Ceresa et al., 2012), and some did not assess 
verbal memory domains (Moroso et al., 2017). The findings from the present study 
suggest that use of CVLT-II, a highly sensitive measure to verbal memory decline in 
MS (Langdon et al., 2012) should be incorporated into neuropsychological batteries for 
clinical examination and research.  However, with the BICAMS cut-off (x̄ -1.5SD), 
38% of the HC group ‘failed’ the task, suggesting a reduced specificity of the measure. 
Thus, this should be utilised in conjunction with a broader battery, such as the BICAMS 
(Langdon et al., 2012).  
 
HCs performed significantly better on BVMT-R learning trials (visual memory) than 
RR-MSc. There was no significant difference between RR-MSc and RR-MSnc on 
BVMT-R. However, quite a substantial difference between means was recognised in 
RR-MSnc and RR-MSc, and more than twice as many RR-MSc ‘failed’ the BVMT-R 
compared to RR-MSnc. Thus, it is likely that the planned comparison between the two 
groups was underpowered (n = 35) for significance to be found.  
  
Cerebellar atrophy and lesions have been associated with reduction of immediate (and 
delayed) visual and verbal memory within MS demonstrated on the ROCFT and 
AMIPB (Ceresa et al., 2013; van de Pavert et al., 2016). However, no significance was 
demonstrated on the spatial recall test (SPART) (Ceresa et al., 2012). Some studies did 
not include visual memory within their battery (Moroso et al., 2017). Findings from the 
present study corroborate most studies within the area, that RR-MSc demonstrate a 
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reduction in visual memory compared to HC. The BVMT-R demonstrates a high level 
of sensitivity (Langdon et al., 2012) and is quicker to administer than the ROCFT and 
AMIPB – thus it is recommended that this is incorporated into clinical practice and 
research. However, it is possible that a lengthier examination such as the ROCFT and 
AMIPB may have demonstrated difference between RR-MSnc and RR-MSc. 
 
It is possible that these visual and verbal memory deficits could be associated with 
reduced registration of information (the acquisition hypothesis) (DeLuca et al., 1998; 
DeLuca, Leavitt, Chiaravalloti & Wylie, 2013; Gmeindl & Courtney, 2012; Langdon, 
2010), implicating IPS. Differences between RR-MSc and RR-MSnc in verbal memory 
may also be associated with damage to the cortico-subcortical circuitry involved in the 
articulatory control system, specifically associated with the posterior part of the 
cerebellum (Ceresa et al., 2013; Chen & Desmond, 2005; Desmond et al., 2003). The 
articulatory control system sub-vocally rehearses information from the phonological 
loop which maintains auditory working memory and supports long-term memory 
consolidation. Thus, damage to this process may impair verbal memory.  
  
No significant difference was found between HC and RR-MSnc for the CVLT-II or 
BVMT-R. This does not fit previous findings, and these are gold-standard screening 
tests for cognitive impairment within MS (Langdon et al., 2012). One of the most 
sensitive tests to cognitive decline in MS is SDMT (Langdon et al., 2012), and the 
power calculation was based on the effect size from SDMT (Valentino et al., 2009). 
Thus, it is possible that a larger sample would be required to detect differences in 
CVLT-II and BVMT-R between HC and RR-MSnc. For example, a moderate effect 
size was reported for all memory domains within a large meta-analysis (n = 3891) 
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(Prakash, Snook, Lewis, Motl & Kramer, 2008).  The lack of significance within the 
current study may also be associated with the high premorbid IQ (and thus cognitive 
reserve) of the RR-MSnc group discussed in later sections (see section 4.4.1.). It may 
also be associated with the removal of RR-MSc from the RR-MSnc group, which may 
make the RR-MSnc group atypical of the MS population due to reduced heterogeneity. 
 
4.1.1.3. Verbal Fluency 
 
There was no significant difference between groups in WLG. This does not replicate 
previous findings for verbal fluency tests in RR-MS (Bodini et al., 2013; Hynčicová et 
al., 2017; Morrow, Menon, Rosehart, & Sharma, 2017; Viterbo Iaffaldano & Trojano, 
2013). Similarly, this does it replicate findings for greater impairment in RR-MSc than 
RR-MSnc (Ceresa et al., 2012; Valentino et al., 2009), who demonstrated significant 
impairments in the COWAT (Valentino et al., 2009) and WLG (Ceresa et al., 2012). 
This may be associated with a lack of statistical power, discussed in later sections (see 
section 4.4.7.). However, within all groups many individuals ‘failed’ the WLG. This is 
potentially suggestive of the lack of specificity of the WLG to cognitive impairment in 
RR-MS.  
 
4.1.1.4. Widespread cognitive impairment 
 
The cognitive impairment index provides evidence against the notion that when 
cognitive domains are considered simultaneously there is no association with cerebellar 
symptomology and cognitive impairment (Daams et al., 2016). This demonstrated 
significantly greater global impairment in RR-MSc than RR-MSnc, but was unable to 
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differentiate RR-MSnc and HC. Widespread cognitive impairment (‘failure’ on three 
or more tests) was recognised in 5% of HC, 29% of RR-MSnc and 57% of RR-MSc. 
These findings taken together are suggestive of a cognitive subtype associated with 
cerebellar pathology, which supports most research within this area (Ceresa et al., 2012; 
Ceresa et al., 2013; Valentino et al., 2009). 
 
4.1.2. Summary 
 
The present findings support previous research demonstrating that cerebellar 
symptomology may indicate a distinct clinical subtype of RR-MS, involving more 
severe and widespread cognitive impairment (Ceresa et al., 2012; Ceresa et al., 2013; 
Valentino et al., 2009). Overall, there are significant differences between the cognitive 
profiles of RR-MSnc, RR-MSc, and HC. HC demonstrated less impairment than 
individuals with MS on measures of IPS, and RR-MSc showed greater impairment than 
RR-MSnc. HC also performed better on a verbal memory test than both MS groups, 
and on a measure of visual memory than RR-MSc. Cerebellar symptomology was 
associated with the most significant cognitive impairment in these domains. There was 
a much greater proportion of individuals with RR-MSc to have widespread cognitive 
impairment (57%) compared to RR-MSnc (29%) and HC (5%). These findings are 
possibly associated with the ‘universal cerebellar transform’, suggesting that cerebellar 
damage would result in impairment across the domains (Koziol et al., 2014; 
Schmahmann, 2004). However, domain specific involvement of the cerebellum has 
also been discussed. These findings support current research within RR-MSc, and 
provide clinical and research implications of utility of the BICAMS and PASAT3 as 
sensitive and timely measures of cognitive function within this population. Overall, the 
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null hypothesis that there are no significant differences between the cognitive profile 
of the three groups can be rejected.  
 
 
4.2. Hypothesis 2: Individuals with RR-MSc will perform worse than RR-MSnc 
and HC on tasks of motor planning  
 
The hypothesis that individuals with RR-MSc will perform worse than RR-MSnc and 
HC on tasks of motor planning was supported by the findings. Groups significantly 
differed on the test of motor function (9HPT), the test of motor function and planning 
(GPT) and the motor planning index (9HPT - GPT). HC performed these tasks 
significantly faster than RR-MSnc who performed significantly faster than RR-MSc. 
As with hypothesis 1 – age, gender and premorbid IQ cannot account for these 
differences.  
 
Low mood has been demonstrated to have an impact on motor function within MS 
(Maier et al., 2015). Maier et al. (2015) correlates BDI with 9HPT (as well as cognitive 
function), however causality cannot be determined. It could be that maladjustment to 
fine motor impairment has resulted in depression. Alternatively, it could be that 
psychomotor retardation, a common symptom of depression (F32, ICD-10; WHO, 
1992) could account for the difference. As with hypothesis 1, this variance is considered 
meaningful, and thus included within the analysis. The two MS groups did not differ 
significantly in depression scores. Self-reported fatigue has also been demonstrated to 
impact on motor function, independently of depression, EDSS and other clinical 
variables (Golan et al., 2017). This is part of the clinical picture of MS and there is no 
significant difference between the MS groups. However, it is possible that the impact 
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of mood and fatigue have accentuated differences between HC and MS groups within 
the present study. 
 
Previous research has supported the present findings of worsened performance on 
motor function within RR-MSc (Weier et al., 2014). However, to the authors 
knowledge, this is the first demonstration of reduced motor planning performance 
within RR-MSc. Overall, the null hypothesis that there is no difference between RR-
MSc and RR-MSnc and HC on tasks of motor planning can be rejected.  
 
4.2.1. Interpretation  
 
There are several criticisms of the MPI. MPI was calculated by subtracting the 9HPT 
from the GPT. This is based on subtraction logic (Shoeben, 1982). This assumes that 
task difficulty is additive – however it could be that the additional demands between 
the basic task and the more complex task could be mentally computed simultaneously 
(partly or wholly) with the basic task.  
 
Within the current study, both peg tests involve coordination of perceptive, visuospatial 
and motor functions. The 9HPT is a test of sensorimotor function requiring round pegs 
to be placed in round holes. The GPT has higher motor planning demands because each 
peg must be precisely oriented when it is placed in one of the canoe-shaped holes of 
differing orientations. Therefore, the difference between timed performance on the two 
tests gives an indication of how the increased motor planning demands affect GPT 
performance of the three different groups. For subtraction logic to create an accurate 
MPI, the GPT and 9HPT would have to have the same sensorimotor component.  
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However, there are some differences between the experimental conditions. The 9HPT 
and GPT may vary in difficulty because the former has nine holes and the latter 20 
holes (and five holes that the experimenter demonstrates with). Thus, the GPT has a 
larger field of operations, with more target holes to compute movement vectors for. 
Thus, it has additional motor planning complexity. This poses a rationale for the 
subtractive method for HC, as the difference between the 9HPT and GPT is the 
additional time required for healthy controls for extra motor planning demands. 
However, there is an additional sensorimotor loading on the GPT, as one is required to 
rotate the pegs which uses more dexterity and fine motor coordination than the 9HPT 
where one simply places cylindrical pegs within the holes (without considering 
orientation). This additional complexity may pose more difficulty in task completion 
for those with cerebellar symptoms due to expected motor/visual sequelae. Similarly, 
in the 9HPT, individuals are required to remove the pegs and return them to the 
container, once all the holes have been filled. This results in 18 manipulations of pegs 
(nearly equivalent to the GPT 20 manipulations) however, it requires less dexterity and 
fine motor control to remove pegs than place them. 
 
There are also subtle differences in task complexity. For instance, in the 9HPT, 
participants can place pegs in any order, whereas in the GPT individuals must fill the 
holes sequentially from the opposite side of the board to the hand they are using for 
each row. This adds an executive function differential. Binétray et al. (2016) considered 
these differences using a line crossing-off task. In one condition participants crossed 
out lines horizontally from left to right then right to left (an optimised form of visual 
exploration) (T2) and in the other condition from left to right, then starting from left 
and moving right on the next line (writing habit) (T1) (Binétray et al., 2016). T1 was 
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associated with more cognitive processes including executive compensatory processes 
of inhibiting crossing at the end of one line, and beginning again at the left side of the 
next line (Binétray et al., 2016). T1 speed was correlated with a composite test 
involving executive functions, flexibility and information processing speed, whereas 
T2 was not (Binétray et al., 2016). Within the current study, this suggests greater 
cognitive involvement when additional rules are set for order of filling holes for the 
GPT (such as in T1), compared to allowing intuitive and ecological completion in the 
9HPT. This is of specific importance as this may add further deficits to the RR-MSc 
group as they may have more difficulty generating automatic processes (such as those 
required for the GPT/T1/writing) (Bonnet et al., 2010), as well as having more cognitive 
impairment for the added cognitive demands on the GPT.  
 
For these considerations, it would be beneficial to manufacture a new pegboard with 
20-holes (with the same layout, peg weight, visual field, completion instructions) as the 
GPT but without the key-slots which require planning to orient. However, the value of 
utilising the standard 9HPT and GPT is that they are available and can be utilised by 
any research group. Consequently, if deemed clinically informative, the MPI could be 
calculated by most healthcare organisations. 
 
The findings demonstrate that RR-MS groups have poorer fine motor function and these 
difficulties are significantly worsened in those with cerebellar symptoms. This 
corroborates previous research showing a link with cerebellar lesions and atrophy and 
motor dysfunction, commonly on the 9HPT (Damasceno, Damasceno & Cendes, 2014; 
Ruet et al., 2014; van de Pavert et al., 2016; Weier et al., 2015a). Significant difference 
between RR-MSnc and HC may be associated with minor cerebellar dysfunction, or 
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reduced IPS which impacts the more demanding aspects of the GPT more than the 
9HPT. 
Despite the methodological considerations with MPI, the findings provide early support 
for a link between motor planning and RR-MSnc, which is exacerbated in RR-MSc. To 
the author’s knowledge, this is the first study in MS to demonstrate that RR-MSc 
perform worse with motor planning than RR-MSnc. More research with fewer 
methodological concerns is required within this area.  
 
For effective motor control, humans must be able to anticipate musculo-skeletal inputs, 
CNS latency and response dynamics, based on experience (Herreros, Arsiwalla & 
Verschure, 2016; Herreros & Verschure, 2013), which are stored as subcortical 
representations/models in the cerebellum. The cerebellum works to create mental 
bodily representations based on predictions of sensory inaccuracies (Koziol et al., 2014; 
Ramnani, Toni, Josephs, Ashburner, & Passingham, 2000; Shadmehr & Krakauer, 
2008;), which are incorporated with prospective memory for sensory predictions 
(D’Angelo, 2011; Spencer & Ivry, 2009). These representations can be mentally 
manipulated to suit the task of navigating vectors and attuning the peg to fit within the 
hole of the GPT (computing this by incorporating significant amounts of information 
of state estimation and movement predictions, amongst other information). Thus, 
inefficiencies of the cerebellum to create subcortical representations will result in 
impaired motor planning (Ito, 1969; 2008). It is likely that for this reason, individuals 
with cerebellar damage have reduced cognitive predictive abilities for motor actions 
and planning (Pezzulo, 2008). For HC completing the GPT and 9HPT, forward models 
(Ito, 2008) combining internal cerebellar information with CNS information will create 
a plan/model which results in efficient and accurate movements. It is likely that within 
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the present study, the inefficiencies in this process for individuals with RR-MSc 
resulted in significantly greater differences in motor function (9HPT) and motor 
planning (9HPT - GPT) than HC and RR-MSnc. 
 
4.3. Hypothesis 3: Differences in motor functioning will be related to cognitive 
function, most significantly IPS 
 
To test this hypothesis, MPI was used to operationalise motor functioning. When 
controlling for pFSIQ, a strong significant negative correlation was observed between 
SDMT and MPI and moderate significant negative correlation between PASAT3 and 
MPI. The r2 variances demonstrating 30% shared variance for SDMT and MPI, and the 
11% shared variance for PASAT3 and MPI demonstrating an association of IPS to MPI. 
Significant moderate negative correlations were also recognised on the CVLT-II and 
BVMT-R. 12% of CVLT-II variance, and in 19% of BVMT-R variance was shared 
with MPI. There was no significant correlation between WLG and MPI. These findings 
support the notion the differences in motor functioning are related to cognitive function, 
aside from WLG.  SDMT, the most utilised measure of IPS in MS, showed the strongest 
correlation with MPI. Thus the null hypothesis that there is no relation of motor 
functioning to cognitive function can be rejected.  
 
However, the existence of a specific link of motor planning to IPS was hypothesised. 
Table 11 demonstrates that there is a link between motor planning (GPT/MPI) and IPS 
(PASAT3/SDMT) but also demonstrates a significant association between 
sensorimotor function (9HPT) and IPS. There was no significant difference between 
the strengths of these correlations. This suggests that there may not be a specific link 
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between IPS and MPI but instead suggests cerebellar damage may be associated with 
simultaneous decline in motor function, planning and cognition.  
 
4.3.1. Interpretation  
 
The results from the present study demonstrate an association between motor 
functioning and planning and cognitive tests (aside from WLG). This association 
appears to indicate that cognitive dysfunction occurs simultaneously with motor 
dysfunction from the onset of RR-MSc, supporting previous research in the area (Ruet 
et al., 2014; Weier et al., 2014). This cognitive decline appears to be global in nature, 
(spanning IPS, working memory, and visual and verbal memory domains), however it 
should be noted that several cognitive domains were not fully considered, including 
language functions, visuospatial functions and executive functions. 
 
This global decline is likely associated with the ‘universal cerebellar transform’ which 
would hypothesise cross-domain impairment (Koziol et al., 2014; Schmahmann, 2004) 
as the cerebellum is acting as an ‘oscillation dampener’ to optimise performance 
(Koziol et al., 2014; Schmahmann, 2004). This suggests that the cerebellum acts to 
modulate arrays of cognitive and sensorimotor information to create congruous and 
efficient behaviours (Koziol et al., 2014; Schmahmann, 2004). Conversely damage to 
the cerebellum as in RR-MSc would result in dissonance and inefficient processing 
which would be universal in nature, resulting in global cognitive decline. 
 
It was hypothesised that the RR-MSc group would display further deficits in verbal 
fluency as individuals with cerebellar cognitive affective syndrome demonstrate verbal 
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fluency deficits (e.g. mutism or telegraphic speech) (Koziol et al., 2014). However, 
within the present study, this was not demonstrated. Further research into the role of 
executive functions and language functions in RR-MSc is required.  
 
It was hypothesised that the recognised deficits in IPS, which support previous research 
(Damasceno, Damasceno & Cendes, 2014; Weier et al., 2014) would be associated with 
motor planning (independently of function).  This was due to the consideration that 
reductions in IPS may be attributable to the same structures (at a brain level) and models 
(at a neuropsychological level) as motor planning. Thus, it was thought that disruption 
in these areas would result in a reduction in automation of cognitive functions and result 
in inefficiencies of information processing (Rocca et al., 2012; Ruet et al., 2014). This 
hypothesis was supported by fMRI studies demonstrating increased cerebellar 
activation in rapid cognitive processes in HC but not in those with MS (Bonnet et al., 
2010; Genova et al., 2009; Moroso et al., 2017; Rocca et al., 2012). 
 
However, within the present study a unique contribution of IPS to motor planning was 
not found, and instead equivalent correlations between motor planning and motor 
function were recognised with IPS (see Section 3.9). This indicates that IPS may simply 
be associated with motor function, as opposed to a specific relationship to motor 
planning. This discrepancy between the present findings and MRI data may be 
associated with insufficient statistical power as a relatively small sample was utilised 
within the present research (see section 4.4.7). Also, perhaps recruitment of 
compensatory cortical areas shown in RR-MSc (Bonnet et al., 2010; Ruet et al., 2014) 
is effective in completion of neuropsychological tests, but a saturation effect of 
cognitive load on the cerebral areas compensating for cerebellar damage may be 
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recognised in more ecologically valid examinations where domains are not considered 
in relative isolation of each other. More research is required in this area.  
 
4.4. Limitations  
 
4.4.1. Sample representativeness 
 
The overall female to male ratio for all participants was 1.43:1 and 1.69:1 for MS 
participants alone, marginally lower than the population prevalence. Prevalence data 
suggests that the incidence of MS in the general population is 2.35-2.40:1 (Ahlgren, 
Odén, & Lycke, 2011; Mackenzie, Morant, Bloomfield, MacDonald, & O’Riordan, 
2014). It is possible that this sample may have overemphasised male characteristics.  
 
The mean age of the sample groups ranged from 37.05-39.81. Within the general 
population, the mean age of onset is around 30 years of age (Rejdak, Jackson & 
Giovannoni, 2010). Progression and stability of disability in EDSS is heterogeneous 
(Cree et al., 2016; Hughes et al., 2012). However, in one large prospective study, only 
11% of patients reached EDSS 6 at a median time of 16.8 years (Cree et al., 2016). 
Thus, this sample may be more representative of a younger MS population. This may 
provide under estimates of motor impairment as motor decline is more rapid in older 
populations (Roy et al., 2016).  
 
Estimated premorbid IQ group means were 115.34 for HC, 109.22 for RR-MSnc and 
99.83 for the RR-MSc. Significant differences between the groups on this variable 
resulted in premorbid IQ being added as a covariate into analyses. In the general 
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population, 50% of individuals fall between IQ 90-109 (25-74th percentile) (Wechsler, 
2014). Thus, the sample has a higher average IQ than expected within the general 
population. This may have resulted in an underestimate of cognitive deficits as higher 
premorbid functioning (cognitive reserve) reduces the rate of cognitive decline 
associated with brain atrophy in MS (Nunnari et al., 2016; Sumowski et al., 2009).  
 
Visual inspection of mean scores for the present sample, and mean published norms 
(Orchard, Giovannoni & Langdon, 2013, Boringa et al., 2001) shown in Table 10, 
appear to demonstrate similarity between MS norms and MS observed scores, as well 
as HC norms and mean HC. This suggests that the current sample is representative of 
the wider population regarding cognitive strengths and weaknesses of healthy and MS 
populations. However, there are some differences between sampling methods and 
samples of these two studies discussed later (see section 4.4.4).  
 
Many of the control participants were known by the researcher. This may have 
impacted on test performance by affecting state anxiety or creating performance effects. 
 
4.4.2. Group Allocation 
 
One limitation of the present study was the use of the self-report NARCOMS-TACS 
questionnaire for group allocation. It is possible that this lacks specificity, as those in 
the RR-MSc group had higher EDSS scores and perhaps this group were not reporting 
primary cerebellar symptomology but instead this was associated with more global 
atrophy which resulted in cerebellar symptoms.  
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The NARCOMS-TACS demonstrated adequate criterion validity with the EDSS 
cerebellar functional system score (EDSS<6.5) (Marrie & Goldman, 2011). It 
demonstrated good criterion validity within the current study with strong correlations 
with 9HPT, an established measure of upper arm tremor (as well as GPT and MPI). 
However, it would be more valid to utilise imaging methods to recognize cerebellar 
atrophy or lesions. This would also avoid a binary grouping, instead being able to 
consider lesion load or T2-Weighted MRI based cranial volume measurements. This 
would allow for correlational analysis.  
 
Within the current study, there were moderate to strong correlations between 
NARCOMS-TACS and 9HPT, GPT, MPI and EDSS demonstrating a coherent data set 
despite small numbers and indicating good criterion validity of NARCOMS-TACS. 
 
4.4.3. Assessment Environment 
 
All MS participants were assessed within their own homes. Control participants were 
assessed within their own homes, their place of work, or within the home of the 
researcher. This may have resulted in differences in state anxiety during testing. 
 
Whilst all efforts were taken to standardise testing, some confounds may have been 
introduced by differential environmental factors, particularly with differences between 
the groups assessment locations. Auditory and visual distractions as well as 
interruptions could not be fully controlled. The PASAT involves audio recordings, 
played through speakers which may have been affected by ambient noise. Participants 
were also tested at different times of the day, which may have resulted in confounds 
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between participants associated with fatigue and alertness. However, if this was 
standardised, there may be group differences between HC and MS participants as 
fatigue may impact individuals with MS at different times of day to HC (Powell, Liossi, 
Schlotz, & Moss-Morris, 2017).  
 
4.4.4. Cognitive impairment index 
 
There are some limitations of the cognitive impairment index. The standardisation 
sample for BICAMS tests plus PASAT3 (Orchard, Giovannoni & Langdon, 2013) 
utilised a mixed phenotype MS group (76% RR-MS) with some progressive 
phenotypes, which was compared to the present study which only included RR-MS. 
This may have resulted in greater levels of cognitive impairment in the normal data 
associated with progression of the disease (Amato, Zipoli & Portaccio, 2006; Calabrese 
et al., 2009; Planche, Gibelin, Cregut, Pereira, Clavelou, 2016). However, individuals 
with RR-MSc were purposefully selected by the clinical team towards the end of data 
collection, and exclusively selected by the researcher following RR-MSnc saturation. 
Thus, the current study likely has a greater proportion of RR-MSc. This may have 
resulted in greater cognitive impairment in the current group compared to published 
norms. Further research should be carried out to gain normal data on BICAMS for 
different subcategories of RR-MS. Additionally, the WLG utilised Dutch norms. 
Cultural and linguistic factors may reduce the generalisability of these norms to the 
present study. 
  
 129 
4.4.5. Clinical factors introducing variance 
 
4.4.5.1. Speech/dysarthria 
 
It is possible that RR-MSc participants had more dysarthria. Dysarthria and ‘scanning 
speech’ are common in those with cerebellar signs (Poser & Brinar, 2001; 
Schmahmann, 2004; Weier et al., 2015a). Dysarthria may have reduced test scores that 
require rapid oral motor responses (Arnett, Smith, Barwick, Benedict & Ahlstrom, 
2008; Smith & Arnett, 2007). Within the current study these include the WLG, SDMT, 
PASAT3 and CVLT-II. One experimental study compared 50 MS patients with 50 
healthy controls utilising a regression analysis to determine the variance explained by 
a dysarthria, measured on a reliable and valid oral motor speed task (SDMT: 6-10%; 
PASAT 2-4%; naming task 7-11%) (Arnett et al., 2008). This demonstrates a slight, 
but significant contribution of objective articulation speed deficits on cognitive test 
performance. This may result in an overestimate of cognitive impairment within the 
RR-MSc group. Further studies should formally assess dysarthria. However, though 
dysarthria was not formally evaluated in participant selection, no significant dysarthria 
was noted for any participants during the assessment.  
 
4.4.5.2. Visual disorders and processing 
 
Visual symptoms such as acuity disturbances and nystagmus may also add additional 
confounds to results. Visual difficulties are one of the most common symptoms of MS 
(Costa, Genova, DeLuca, & Chiaravalloti, 2016; Qureshi, Beh, Frohman, & Frohman, 
2014). Costa et al. (2016) report that these are easily assessed objectively, however 
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informal and subjective evaluations are commonplace in MS IPS literature, such as 
within the current study. These subjective ratings may have reduced the replicability of 
the present study. One study examined the effects of mild visual acuity disturbances in 
RR-MS who subjectively reported adequate vision (Bruce, Bruce, & Arnett, 2007). 
This study demonstrated that even mild visual acuity disturbances can account for a 
significant amount of the variance (13%) on a battery of visual attention (including the 
SDMT). Nystagmus is a common in MS and is associated with cerebellar dysfunction 
(Iyer et al., 2015; Kutzelnigg et al., 2007; Tornes, Conway, & Sheremata, 2014; Weier 
et al., 2015b). For clarity and acuity of vision, stimuli must be steadily held as retinal 
images (particularly in the fovea) (Stahl, Plant, & Leigh, 2002). This requires corrective 
eye movements and ability to suppress unwanted eye movements, as well as 
compensatory eye movements from a vestibule-ocular reflex responding to head 
movements (Stahl, Plant, & Leigh, 2002). Nystagmus therefore results in acuity 
disturbances, which impairs performance in cognitive tests with visual requirements 
(Bruce, Bruce & Arnett, 2007). Within the present study, this is likely to impact BVMT-
R and SDMT. This is also likely to impact sensorimotor aspects of the peg tests. 
Assuming both peg tests have the same sensorimotor requirements, both tests should 
be equally affected and thus the MPI would remain unaffected.  Further studies should 
formally assess visual function. 
 
Individuals with MS may have reduced visual processing capacity beyond ocular-motor 
disturbances. Recognition of a limitation of temporal processing within the visual 
system has been recognised in a recent study (Lopes Costa et al., 2016). These have 
been shown to impact on cognitive tests including the SDMT (Lopes Costa et al., 2016). 
Within the present study we assume that RR-MSc and RR-MSnc have the same visual 
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processing abilities, however we cannot exclude the possibility that visual processing 
was different between groups. Further research within this area is required.  
 
4.4.5.3. Medication 
 
Within the present study, individuals were excluded if they received steroid treatment 
in the previous two months. No further information was gathered regarding current 
medical treatment or adherence. Some evidence has suggested that DMTs may have 
benefits on cognitive performance (Barak & Achiron, 2002; Fischer et al., 2000; 
Langdon, 2012; Patti et al., 2010; 2012; 2013; Paty & Li, 1993). It is possible that 
differential medical treatments and adherence between participants, could add 
additional confounds.  
 
4.4.5.4. Comorbidities 
 
Within the present study, individuals were excluded if they had any pre-existing 
diagnosed mental health difficulties, epilepsy or substance misuse disorders. However, 
screens for premorbid pathologies such as attention deficit hyperactivity disorder 
(ADHD) and dyslexia were not screened for. These could add confounds into the 
current findings, and these are commonly overlooked within MS research (Costa, 
Genova, DeLuca, & Chiaravalloti, 2016). 
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4.4.5.5. Level of disability 
 
EDSS is the most common method of quantifying disability within MS, but it 
disproportionately reflects locomotion. Within the current study, individuals were 
excluded if they were unable to walk without aid or rest for more than 200 meters (as 
this is the limit for EDSS 5). Higher scores on EDSS (4.5 – 5) are associated with 
restricted ambulation without aid (between 200 meters and 500 meters). Since 
cerebellar damage in MS is associated with physical symptoms which may impair 
ambulation such as ataxia, tremor and loss of coordination (Middleton & Strick, 2000; 
Schmahmann, 2004; Weier et al., 2015a) it is likely that RR-MSc will have higher 
EDSS scores. This was found by de Groot et al. (2009) who demonstrated that 
impairment of the cerebellar tract was associated with an EDSS of more than 4.5. 
Significant differences were found between the RR-MSnc and RR-MSc groups for 
EDSS, however this was not included in the analysis as this was considered descriptive 
of realistic clinical differences between RR-MSnc and RR-MSc. 
 
4.4.6. Cognitive Battery  
 
Some limitations associated with the neuropsychological test battery were recognised. 
The battery was selected due to the sensitivity and specificity to cognitive impairment 
in MS. A relatively brief battery was used as fatigue is common in MS, and to minimise 
inconvenience caused to the participants. Three out of five cognitive tests were those 
from the BICAMS (Langdon et al., 2012). The final two tests (WLG and PASAT) are 
included in the BRB-N (Rao & the Cognitive Function Study Group of the National 
Multiple Sclerosis Society, 1990). The utility of internationally recognised tests of 
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cognition in MS, such as the BICAMS, allows for comparison across studies (Costa, 
Genova, DeLuca, & Chiaravalloti, 2016). 
 
A ceiling effect, was reached on the PASAT3 where three HCs achieved the top score. 
This may have resulted in an underestimation of differences between the HC group and 
MS groups increasing the likelihood of type-II error. Including the PASAT2 would 
have increased the ceiling on this test. However, although all individuals engaged fully 
with the PASAT3, some reported finding it aversive. This fits with published literature 
regarding the testing process (Bosnes, Dahl & Almkvist, 2015; Roman, 1991; Walker 
et al., 2012). Therefore, adding a faster tempo task may not have provided benefits to 
outweigh the ethical costs.   
 
Including further tests of executive function could allow for more clarity in the 
cognitive profile of RR-MSc. Significant research has demonstrated deficits in 
executive functions in MS, however no ‘typical profile’ has been recognised 
(Chiaravalloti & DeLuca, 2008). By considering a heterogeneous definition of MS, 
with considerations of differing phenotypes, a typical profile may emerge. For instance, 
for RR-MSc, Ceresa et al. (2012) implicated frontocerebellar connections in executive 
functions, and grey matter cerebellar higher lesion load has been demonstrated to 
reduce performance on the Stroop (Clausi et al., 2009; Trennery, 1989; van de Pavert 
et al., 2016). Including an array of executive function tasks including Delis-Kaplan 
Executive Function System (D-KEFS) colour/word interference and Tower of London 
Task (Delis, Kaplan, & Kramer, 2001), Brixton spatial anticipation task and Hayling 
Sentence completion task (Burgess & Shallice, 1997) could begin to develop these 
profiles.  
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The battery incorporates both visual and verbal tasks (learning trials for CVLT-II and 
BVMT-R), which are recommended by the BICAMS (Langdon et al., 2012). However, 
the current battery lacks memory presented within context, or with delayed recall. 
Including subtests from the AMIPB (Coughlan & Hollows, 1985) or Weschler Memory 
Scale (Wechsler, 2009) could provide information in these areas. Also, to provide 
clarity over whether memory difficulties are associated with dysexecutive memory 
profiles (recall difficulties) or rapid-forgetting/assimilation difficulties, the battery 
should include a recognition trial. Similarly, to more effectively disentangle IPS and 
attentional processes, specific attention tasks could be incorporated, such as the Test of 
Everyday Attention (TEA; Robertson, Nimmo-Smith, Ward, & Ridgeway, 1994). This 
could provide useful information for rehabilitation.  
 
4.4.7. Statistical power 
 
The present study had a sample of 56 participants, falling below the recommended 
minimum of 63. This was associated with difficulties recognised by clinical teams in 
finding individuals with RR-MSc who had an EDSS score of five or below. The initial 
power calculation was based on group differences for SDMT in Valentino et al. (2009), 
utilising an effect size of !2 = 0.80. Within the current study, the observed effect size 
for SDMT was !2 = 1.06. This means that the actual power within that analysis for 
SDMT was .91 indicating an adequately powered study for this variable. 
 
However, for the non-significant variable within the analysis (WLG), the effect size 
was !2 = 0.92 (still a large effect size). The actual power within the analysis for WLG 
is .77, indicating a marginally underpowered study. It is possible that the study was not 
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adequately powered to detect a significant effect for this cognitive task (type-II error).  
Increasing the sample size may have found significance for this variable. Effect sizes 
are reported in Appendix 25 and are deemed adequate. 
 
A decision was made not to remove statistical outliers from the analysis, as the clinical 
population covers a broad range of disability. Including these outliers in the analysis 
allows for retention of clinically relevant variance, however may still cause statistical 
problems, such as an over-estimation of effect. The groups were not balanced equally 
(21:21:14) meaning that for the RR-MSc group (n = 14), there may have been a greater 
impact of outliers on the data.  
 
A significant number of analyses were carried out to test the three hypotheses. Least 
significant difference tests were utilised as post-hoc adjustments to the p-value can be 
criticised for being overly conservative (Coolican, 2014; Perneger, 1998). With the 
current test battery, which assessed an array of domains, these were considered too 
conservative. Therefore, results should be interpreted with caution due to increased 
likelihood of familywise error (increased risk of type-I error).   
 
4.5. Clinical Implications  
 
The current study demonstrated significant differences, in cognitive domains of RR-
MSc and RR-MSnc which are evident from early in the disease course. This suggests 
that cerebellar symptomology defines a distinct cognitive subtype associated with more 
severe and widespread cognitive impairment.  This provides prognostic information for 
cognition, motor-planning and function for individuals with recognised cerebellar 
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lesions and atrophy. Differential levels of cognitive impairment between RR-MSc and 
RR-MSnc is indicative that RR-MSc will have worse prognosis (Amato et al., 2010). 
This can be useful for a systemic understanding of the likely difficulties that an 
individual may have, or may encounter with disease progression. Thus, appropriate 
treatment planning and life decisions (e.g. employment or driving) can be considered 
at an early stage.  
 
The present study demonstrated that those with RR-MSc have significantly reduced 
IPS compared to RR-MSnc. They also seem to demonstrate further memory 
impairments than are expected within the general population. This finding could 
support neurologists in identifying patients who may benefit from a neuropsychological 
examination and subsequent rehabilitation. For example, one paper suggested that early 
intervention for cognitive impairment in MS may prove effective, through 
strengthening cognitive reserve by engaging patients in regular mentally stimulating 
activities following early identification (Sumowski, 2015). Considering individuals 
diagnosed with MS with cerebellar damage as high-risk for cognitive decline may allow 
for early intervention in cognitive decline.  There is still substantial debate over the 
effectiveness of cognitive rehabilitation in MS (Filippi & Rocca, 2013), though some 
studies have demonstrated benefits of this within MS for memory, executive functions, 
attention, IPS and verbal fluency (Amato et al., 2014; Chiaravalloti, Moore, Nikelshpur, 
& DeLuca, 2013; Mattioli et al., 2010; Pedullà et al., 2016). Adjustments of cognitive 
task difficulty based on performance and impairment was demonstrated to be beneficial 
(Pedullà et al., 2016), and therefore identification of different cognitive profiles in the 
current study would allow for tailored rehabilitation packages based on phenotype.  
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The demonstrated reduction in motor function and planning for those with cerebellar 
symptoms is of significant clinical importance. Individuals with MS have exacerbated 
fluctuations in fatigue and strength (Powell, Liossi, Schlotz, & Moss-Morris, 2017). 
Thus, more cerebellar function is required to incorporate these changes to create 
internal models for effective motor planning. Cerebellar damage therefore can be very 
debilitating for individuals with RR-MS. Within neurorehabilitation teams, 
understandings of the interrelations of these cognitive functions and physical 
rehabilitation techniques would be imperative in designing effective therapeutic 
exercises and goal planning for physical therapy modalities. Examples of difficulties 
that individuals may experience at a macro level include state estimation for 
rehabilitation of ataxic gait or ability to ‘transfer’ from one place to another. At a micro 
level these could include compensatory eye movements to maintain retinal images 
(Frens & Donchin, 2009).   
 
It may be that the GPT is more sensitive to cerebellar symptom presentation and change 
than the 9HPT. Within the current study, the range of the GPT (range = 142.66) which 
was much greater than the 9HPT (range = 21.35). This increased spread of participants 
may increase the sensitivity of the measure to dysfunction. There was no significant 
difference in strength of correlations with NARCOMS, however this may be associated 
with the ranking of scores for non-parametric comparisons, due to only having five 
possible NARCOMS scores.   
 
At present, the clinical usefulness of the MPI is yet to be determined. The initial data is 
promising, however further research must be conducted to establish psychometric 
properties. Figure 1 demonstrates a reasonable overlap of scores and thus it might be 
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difficult to categorise what counts as a motor planning deficit. It may be that age-based 
norms may be required to find clinically meaningful cut-offs, as motor decline occurs 
more rapidly in older populations (Roy et al., 2016). However, a larger sample would 
be required to analyse this.  Further research should be conducted within this area as 
this could provide a quantification of motor planning impairment, from which an 
understanding of potential life restrictions and disability can be derived. This may have 
safety planning implications, for instance when used in conjunction with driving 
assessment batteries, or implications for rehabilitation.  
 
The study has also demonstrated criterion validity for the NARCOMS for individuals 
with more significant cerebellar symptoms than in the previous validation (Marrie & 
Goldman, 2011). This demonstrated moderate to strong associations for 9HPT, GPT 
and MPI. This may be a more efficient way of rating people with cerebellar dysfunction, 
which can be conducted over the telephone or by MS nurses as opposed to face-to-face 
examinations by physicians trained in the EDSS.   
 
The association of cognition and motor planning, indicative of a universal cerebellar 
transform that spans domains of cognition has clinical implications. A day-to-day 
example incorporating both cognition and automation of motor actions is driving. Thus, 
it may be indicated to consider cognitive assessments spanning all domains, as well as 
motor planning in assessments of driving proficiency for those with RR-MSc.  
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4.6. Future Research 
 
A follow up study, or longitudinal study, exploring the differences in cognitive profile 
and motor function and planning may provide a greater understanding into differential 
prognosis in RR-MSnc and RR-MSc. One paper demonstrated sensitivity of the SDMT 
and PASAT to cognitive decline in individuals with RR-MS within one year (López-
Góngora, Querol, & Escartín, 2015). For this reason, a one-year follow up of the present 
study is being conducted within the research department.  
 
It may also be beneficial to assess differences in executive dysfunction in RR-MSc and 
RR-MSnc. Research has demonstrated impacts of MS pathology on executive 
functions, however no typical profiles have been recognised (Chiaravalloti & DeLuca, 
2008). It is possible that by considering further subtypes of MS, including RR-MSc, 
profiles of executive dysfunction may emerge.  
 
Further research with a larger sample may provide a greater understanding of the 
relationship between IPS and MPI. Increased statistical power would facilitate the use 
of regression models.   
 
The current study focused on individuals with RR-MS with relatively low levels of 
disability (EDSS five or less). Consideration of motor planning and function, and the 
interrelation of this to cognition within PPMS, SPMS, or PRMS for those with and 
without cerebellar lesions or atrophy may provide a further understanding of the 
involvement of the cerebellum in MS. It may also be of interest to consider those with 
a CIS with damage located within the MS to examine these phenomena. Considerations 
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of treatment approaches for these recognised subgroups of MS may also warrant 
interesting findings.   
 
Future research could explore similar hypotheses whilst defining RR-MSc with 
neuroimaging techniques. Variables such as lesion load or T2-Weighted MRI based 
cranial volume measurements, would allow for more accurate diagnosis of those with 
cerebellar symptomology, which does not rely on self-report. It would allow for 
correlational analysis, thus considering individuals on a continuum rather than as binary 
groups. This would also provide further information associated with the topographical 
organisation of the cerebellum (e.g. anterior cerebellum and motor control and posterior 
with cognitive processes).  
 
Further research should be conducted to consider the clinical usefulness of the MPI, 
with generation of age matched norms to derive meaningful cut-offs.  
 
4.7. Conclusions  
 
The study aimed to explore the differences in the cognitive profile and motor planning 
and function within MS. The cerebellum is a predilection site for atrophy and therefore 
RR-MSc is common. Previous research has associated RR-MSc with more significantly 
impaired cognitive function and motor function than in RR-MSnc. Within the present 
study, comparisons between RR-MSnc, RR-MSc and HC revealed more significant 
cognitive impairment in RR-MSc than RR-MSnc and HC in IPS, visual memory and 
verbal memory. RR-MSc demonstrated more widespread cognitive impairment than 
those without cerebellar symptoms. Individuals with RR-MSc also performed worse in 
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peg tests examining extremity function. Furthermore, they demonstrated more 
difficulty on a MPI, which aimed to isolate time spent on motor planning from sensory-
motor aspects of peg tests.  
 
To the authors knowledge this is the first empirical study examining motor planning 
within RR-MSc. The study provided early support for the hypothesis that individuals 
with RR-MSc perform worse than RR-MSnc on tests of motor planning. Theoretically 
the reduction in performance in RR-MSc may be associated with reduced cerebellar 
functionality to create subcortical representations/models of motor functions. These 
incorporate a wide range of sensory and cognitive information which can be reproduced 
with minimal cognitive input and allocation of attention. Without this functionality, less 
efficient and more noisy CNS inputs are relied upon for motor actions and planning, 
thus reducing speed and accuracy.   
 
Research outside of MS has suggested that the cerebellum provides similar models for 
cognitive processes, and cerebellar dysfunction can result in global cognitive 
impairment. Within the present study there were moderate to large correlations between 
memory domains, IPS and the MPI. This cross-domain association of motor planning 
and function to cognitive function may be associated with the ‘universal cerebellar 
transform’ suggestive that the cerebellum acts as an ‘oscillation dampener’ to 
coordinate an array of inputs of cognitive and motor functions into consistent, 
coordinated and timely response.  
 
These findings have significant implications for provision of prognosis within a highly 
heterogeneous disorder. It also provides considerations for differential rehabilitation 
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approaches for individuals with RR-MSc, for whom rehabilitation is usually less 
effective. These findings contribute the understanding that the role of the cerebellum 
extends beyond the motor domain. Further research should focus on methodological 
considerations of the present study, broader assessment of cognitive domains, the 
clinical utility of the MPI, as well as differential treatment approaches for RR-MSnc 
and RR-MSc.   
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Information Sheet: 28.04.16 V1.2MS 
  
  
Study Title: Cognition in Multiple Sclerosis  
 
Ethics Committee Reference Number:  
 
We would like to invite you to take part in our research study.  Before you decide we 
would like you to understand why the research is being done and what it would involve.  
A member of the research team will go through the information sheet with you, 
discuss the information and answer any questions you have.  
We‘d suggest this should take about 15-20 minutes.  Please feel free to talk to others 
about the study if you wish. 
 
Part 1 tells you the background/purpose of the study and what will happen to you if you 
take part.  
 
Part 2 gives you more detailed information about the conduct of the study.  
 
Please ask us for more information if anything is unclear. 
 
Research Sites 
1) Participants homes 
2) St. Peter’s Hospital - Guildford Road, Chertsey, Surrey, KT16 0PZ 
 
Questions about the research can be directed to: 
The Principal Investigator: Jonathan Hinchliffe 
Department  of Clinical Psychology, Royal Holloway University of London, Egham, 
Surrey, TW20 0EX 
Tel: 01784 414012 
Email: Cerecog@live.rhul.ac.uk 
Alternatively, feel free to ask any questions to your consultant neurologist (Dr. Khaled 
Abdel-Aziz, Dr. David Barnes or Dr. Jan Coeberghe). 
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Complaints procedure 
If you have any concerns or questions about any aspects of the study, please contact the 
principal investigator (Jonathan Hinchliffe) who will endeavour to answer your 
questions.  
 
If you remain unhappy and wish to make a formal complaint, you can do this by 
contacting Professor Dawn Langdon  
Department of Psychology, Royal Holloway University of London, Egham, Surrey, TW20 
0EX 
Email: d.langdon@rhul.ac.uk  
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Part 1 
 
Background to the project 
Multiple sclerosis (MS) is a chronic degenerative disease of the central nervous system. 
It affects 100,000 people in the UK and individuals are typically diagnosed between 20-
40 years of age.  There are a number of physical symptoms of multiple sclerosis such as 
fatigue, visual problems, muscle weakness, spasm, pain and difficulties with balance. 50-
60% of individuals also experience cognitive impairment (changes in thinking abilities). 
 
Purpose of the research 
The purpose of the study is to compare the cognitive profile (strengths and weaknesses 
in thinking skills) of individuals with MS to those who do not have MS. The study will be 
particularly looking at how certain physical symptoms relate to different profiles of 
thinking skills. This has clinical and theoretical implications, increasing the 
understanding of the effects of multiple sclerosis, as well as creating an ability to 
differentially diagnose individuals. This will then allow professionals to best support 
people to compensate for difficulties they experience and increase the quality of life of 
individuals with multiple sclerosis.   
 
Who can take part? 
You are eligible to take part if you are between 18 and 60 years of age, and you have a 
diagnosis of relapsing remitting multiple sclerosis. To take part, you must have been 
born and educated in England. We will be unable to include you if you have experienced 
a relapse or major medication change in the last two months.  We will also not be able 
to include you if you are currently abusing drugs or alcohol, if you have a significant 
psychiatric condition or have another neurological condition. If you are unsure that any 
of these apply to you, please discuss it with the chief investigator. 
 
Do I have to take part? 
No. Your participation is completely voluntary. Non-participation will not affect clinical 
care. 
 
How do I take part? 
If you agree to take part, someone will go through the information sheet with you and 
you will be asked to sign a consent form.  A member of the research team will then 
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contact you to discuss your participation and arrange a time to meet and complete the 
research.  It can take two hours or more to complete all the tasks.  It is possible that 
these tasks could cause you to become fatigued. Please bear in mind that you are free 
to withdraw at any time, without giving a reason. This would not affect the standard of 
care you receive or your legal rights. 
 
What will I have to do if I take part? 
You will initially be asked to complete a number of questionnaires, and then to 
complete a number of tests. These will measure various areas of cognition including 
verbal fluency, processing speed, attention, working memory, verbal learning, memory, 
premorbid IQ, dexterity and extremity function. Some of these tests may be challenging.  
 
Where will I have to go and for how long? 
The researcher may see some participants in their own homes or at St Peter’s Hospital. 
Participation will take about 2 hours and can usually be completed in one session with 
breaks if you need them. 
 
When will I give consent to take part in the research?  
Following reading through this information sheet, the researcher will provide more 
information and answer any questions that you may have. When you, and the 
researcher, feel fully satisfied that you have all the information you require to make an 
informed decision, consent will be sought. At this point, you will be asked to sign the 
consent form. No assessments will take place before informed consent is gained.  
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Part 2 
 
What are the potential benefits of taking part? 
Whilst there may be no personal benefits to participating, the information you give 
could greatly contribute to improvements in the availability of cognitive testing for 
people with MS. 
 
What are the potential disadvantages of taking part? 
It is possible that you may feel fatigued whilst carrying out the tests. Should this 
happen, please let Jonathan Hinchliffe know, and we can take a break or complete the 
tests on another occasion. 
 
Will my participation be kept confidential? 
We will follow ethical and legal practice to ensure that all information you provide to us, 
and the results from your tests will be kept strictly confidential. Some parts of your 
medical records and data collected will be looked at by the principal investigator, their 
academic supervisor and specific members of the clinical team at Ashford and St Peter’s 
Hospital.  All data will be coded anonymously and stored securely. 
 
We will not let your GP know that you are taking part in the study.  However, if a 
member of the research team feels you would benefit from discussing the study or your 
general well-being with your GP or your neurology team they may advise you to do so. 
 
The overall results of the study will be made public in a completely anonymous form 
ensuring that no participants can be identified. 
 
The only time we would consider breaking confidentiality is if you disclose information 
that makes the researcher concerned for your safety or that of someone else.  We 
would then do our best to discuss options available to you and ourselves in terms of 
informing other people.   
  
What will happen to my results after the study?  
All your information will be stored anonymously.  Analysis of the information obtained 
will be completed on a computer by the principal investigator based at Royal Holloway, 
University of London. The paper copies of the results will be stored in a secure filing 
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cabinet at Royal Holloway University of London for 3 years for audit purposes. At which 
point all data will be disposed of following confidential disposal procedures.   
 
The overall findings of the study will be published in a scientific paper or peer reviewed 
journal. The data will also be incorporated into the doctoral thesis of the principal 
investigator.  Findings may also be distributed through voluntary organisations such as 
the MS Society and presented at appropriate scientific conferences.  
If you would like a summary of the study’s findings please indicate this on the consent 
form.   
 
What will happen if I want to withdraw from the study? 
You can decide you no longer wish to take part at any point. Following your request to 
withdraw from the study, all the data collected from you will be destroyed. This will not 
affect the standard of care you receive or your legal rights. 
 
Should you give consent and later lose capacity to do so we will include your data in the 
study unless you indicate otherwise on the consent form. 
 
Who is organising the research?  
The principal investigator is a Trainee Clinical Psychologist (Jonathan Hinchliffe), who is 
conducting the research as part of his doctorate in clinical psychology. The research will 
be supervised by a Professor of Neuropsychology (Professor Dawn Langdon) and is 
sponsored by Royal Holloway University of London. Three consultant neurologists (Dr. 
Khaled Abdel-Aziz, Dr David Barnes and Dr Jan Coeberghe) are collaborators in the 
study. 
 
A Research Ethics Committee (REC) has approved this study.  RECs are independent 
groups of people who protect your interests by reviewing all research undertaken in the 
NHS. 
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Consent Form 
 
Study Title: Cognition in multiple sclerosis 
Name of principal investigator: Jonathan Hinchliffe 
Participant reference number: 
Ethics Committee Reference Number: 16/SC/0165 
 Please initial 
to confirm 
1. I confirm that I have read and understand the information sheet for the above 
study dated Information Sheet: 28.04.16 V1.2MS 

2. I have had the opportunity to consider the information, ask questions and have 
received adequate answers.  
 
3. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
4. Where it is relevant to my taking part in this research, I understand that 
relevant sections of my medical notes and data collected during the study may 
be looked at by the research team and responsible individuals from the NHS 
Trust.  I give permission for these individuals to have access to my records. 
 
5. I give permission for data already collected to be retained for the purposes of 
the research if I lose capacity to consent to taking part whilst the study is 
ongoing. 
 
6. I would like to receive group feedback about the overall results of the study.  I 
understand this will be sent once the study is complete in late 2017. I give 
permission for my address to be held by the above named researcher until the 
end of the research to facilitate this. 
 
7. I agree to take part in the above research study.  
 
____________________________________________ Date: _________________ 
Name of participant 
_____________________________________________ Date: _________________ 
Name of person taking consent 
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Jonathan Hinchliffe (BSc Hons, MSc, PGDip) 
Department on Clinical Psychology 
Royal Holloway, University of London 
Egham 
Surrey 
TW20 0EX 
Dear Sir/Madam, 
 
This letter provides an outline of a research project that you may wish to take part in: 
‘Cognition in Multiple Sclerosis’. The project aims to look at strengths and weaknesses in 
the thinking skills of individuals with multiple sclerosis, and to compare these with those 
who do not have multiple sclerosis. 
 
Background: Multiple sclerosis (MS) is a chronic degenerative disease of the central 
nervous system. It affects 100,000 people in the UK and individuals are typically 
diagnosed between 20-40 years of age. 50-60% of individuals experience cognitive 
impairment (changes in thinking abilities).  
 
Purpose: To compare the cognitive profile (strengths and weaknesses in thinking skills) 
of individuals with MS to those who do not have MS. The study will be particularly 
looking at how certain physical symptoms relate to different profiles of thinking skills. 
This has clinical and theoretical implications, increasing the understanding of the effects 
of multiple sclerosis, as well as creating an ability to differentially diagnose individuals. 
This will then help professionals to best support people to compensate for difficulties 
they experience and increase the quality of life of individuals with multiple sclerosis.   
 
Who is conducting the research? Jonathan Hinchliffe (Trainee Clinical Psychologist, 
01784 414012) is the principal investigator for the research. This research will be 
submitted as part of his doctoral thesis (Doctor in Clinical Psychology) and is sponsored 
by Royal Holloway University of London. Taking part is entirely voluntary and whether 
you participate, or do not participate, will have no impact on your care at Ashford and 
St. Peter’s Hospitals. Jonathan’s contact details are located on the bottom of this letter.  
 
What is involved? Involvement in the study will take less than two hours. You will be 
invited to meet with Jonathan Hinchliffe, either at your own home or at St. Peter’s 
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Hospital. You will initially be asked to complete a number of questionnaires, and then to 
complete a number of tests. Some of these tests may be challenging, but most people 
find them enjoyable.  
 
What happens next? If you are interested in taking part in the study, please contact 
Jonathan Hinchliffe on the contact details below. A more detailed information sheet can 
be provided on request, and you are welcome to discuss participation in the study with 
the neurology team or with Jonathan.  If you are not interested in taking part then you 
do not need to take any further action. Your details will remain confidential and we will 
not attempt to contact you regarding this research again.  
 
What if I change my mind? You can withdraw from the study at any time, without 
providing a reason for doing so. At this point any existing information that you have 
given will be removed.  
 
 
Thank you very much for taking the time to consider taking part in this research project.  
 
Yours sincerely,  
 
 
 
Jonathan Hinchliffe  
Trainee Clinical Psychologist / Principal Investigator 
Tel: 01784 414012 
Email: Cerecog@live.rhul.ac.uk 
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Jonathan Hinchliffe (BSc Hons, MSc, PGDip) 
Department on Clinical Psychology 
Royal Holloway, University of London 
Egham 
Surrey 
TW20 0EX 
Dear Sir/Madam, 
 
This letter provides an outline of a research project that you may wish to take part in: ‘Cognition in Multiple 
Sclerosis’. The project aims to look at strengths and weaknesses in the thinking skills of individuals with 
multiple sclerosis, and to compare these with those who do not have multiple sclerosis. 
 
Background: Multiple sclerosis (MS) is a chronic degenerative disease of the central nervous system. It 
affects 100,000 people in the UK and individuals are typically diagnosed between 20-40 years of age. 50-
60% of individuals experience cognitive impairment (changes in thinking abilities).  
 
Purpose: To compare the cognitive profile (strengths and weaknesses in thinking skills) of individuals with 
MS to those who do not have MS. This has clinical and theoretical implications, increasing the 
understanding of the effects of multiple sclerosis, as well as creating an ability to differentially diagnose 
individuals. This will then help professionals to best support people to compensate for difficulties they 
experience and increase the quality of life of individuals with multiple sclerosis.   
 
Who is conducting the research? Jonathan Hinchliffe (Trainee Clinical Psychologist) is the principal 
investigator for the research. This research will be submitted as part of his doctoral thesis (Doctor in Clinical 
Psychology) and is sponsored by Royal Holloway University of London. Taking part is entirely voluntary and 
whether you participate, or do not participate, will have no impact on your care at Ashford and St. Peter’s 
Hospitals. Jonathan’s contact details are located on the bottom of this letter.  
 
What is involved? Involvement in the study will take less than two hours. You will be invited to meet with 
Jonathan Hinchliffe, either at Royal Holloway University of London or other appropriate venues. You will 
initially be asked to complete a number of questionnaires, and then to complete a number of tests. Some 
of these tests may be challenging, but most people find them enjoyable.  
 
What happens next? If you are interested in taking part in the study, please contact Jonathan Hinchliffe on 
the contact details below. A more detailed information sheet can be provided on request, and you are 
welcome to discuss participation in the study with the neurology team or with Jonathan.  If you are not 
interested in taking part then you do not need to take any further action. Your details will remain 
confidential and we will not attempt to contact you regarding this research again.  
 
What if I change my mind? You can withdraw from the study at any time, without providing a reason for 
doing so. At this point any existing information that you have given will be removed.  
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Thank you very much for taking the time to consider taking part in this research project.  
 
Yours sincerely,  
 
 
 
Jonathan Hinchliffe  
Trainee Clinical Psychologist / Principal Investigator 
Tel: 01784 414012 
Email: Cerecog@live.rhul.ac.uk 
 
 
 
 226 
 Appendix 9: HC Participant Information Sheet
  
                                                                                                                                                                                                                           
            
Information Sheet: 28.04.16 V1.2HC 
  
  
Study Title: Cognition in Multiple Sclerosis  
 
Ethics Committee Reference Number:  
 
We would like to invite you to take part in our research study.  Before you decide we would like you to 
understand why the research is being done and what it would involve.  A member of the research 
team will go through the information sheet with you, discuss the information and answer any 
questions you have.  
We‘d suggest this should take about 15-20 minutes.  Please feel free to talk to others about the study 
if you wish.  
 
Part 1 tells you the background/purpose of the study and what will happen to you if you take part.  
Part 2 gives you more detailed information about the conduct of the study.  
 
Please ask us for more information if anything is unclear. 
 
Research Sites 
1) St Peter’s Hospital 
2) Royal Holloway University of London - Department of Clinical Psychology, Royal Holloway 
University of London, Egham, Surrey, TW20 0EX 
 
Questions about the research can be directed to: 
The Principal Investigator: Jonathan Hinchliffe 
Department  of Clinical Psychology, Royal Holloway University of London, Egham, Surrey, TW20 0EX 
Tel: 01784 414012 
Email: Cerecog@live.rhul.ac.uk 
 
Complaints procedure 
 
If you have any concerns or questions about any aspects of the study, please contact the principal 
investigator (Jonathan Hinchliffe) who will endeavour to answer your questions.  
 
If you remain unhappy and wish to make a formal complaint, you can do this by contacting  
 
Professor Dawn Langdon  
Department of Psychology, Royal Holloway University of London, Egham, Surrey, TW20 0EX 
Email: d.langdon@rhul.ac.uk  
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Part 1  
 
Background to the project 
Multiple sclerosis (MS) is a chronic degenerative disease of the central nervous system. It affects 
100,000 people in the UK and individuals are typically diagnosed between 20-40 years of age. Cognitive 
impairment (changes in thinking abilities) is recognised in 50-60% of individuals. In order to understand 
the pattern of difficulties people with MS have in thinking we must compare them to healthy 
individuals.   
 
Purpose of the research 
The purpose of the study is to compare the cognitive profile (strengths and weaknesses in thinking 
skills) of individuals with MS to those who do not have MS. This has clinical and theoretical 
implications, increasing the understanding of the effects of multiple sclerosis, as well as creating an 
ability to differentially diagnose individuals. This will then allow professionals to best support people to 
compensate for difficulties they experience and increase the quality of life of individuals with multiple 
sclerosis.   
 
Who can take part? 
You are eligible to take part if you are between 18 and 60 years of age. To take part, you must have 
been born and educated in England.  We will not be able to include you if you are currently abusing 
drugs or alcohol, if you have a significant psychiatric condition or have a neurological condition that 
may affect your thinking skills. If you are unsure that any of these apply to you, please discuss it with 
the chief investigator. 
 
Do I have to take part? 
No. Your participation is completely voluntary. 
 
How do I take part? 
If you agree to take part, someone will go through the information sheet with you and you will be 
asked to sign a consent form.  A member of the research team will then contact you to discuss your 
participation and arrange a time to meet and complete the research. It can take two hours or more to 
complete all the tasks.  It is possible that these tasks could cause you to become fatigued.  Please bear 
in mind that you are free to withdraw at any time, without giving a reason.  
 
What will I have to do if I take part? 
You will initially be asked to complete a number of questionnaires, and then to complete a number of 
tests. These will measure various areas of cognition including verbal fluency, processing speed, 
attention, working memory, verbal learning, memory, premorbid IQ, dexterity and extremity function. 
Some of these tests may be challenging, but most people find them enjoyable.  
 
Where will I have to go and for how long? 
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The researcher may participants at St Peter’s Hospital or at Royal Holloway University of London. 
Participation will take about 2 hours and can usually be completed in one session with breaks if you 
need them. 
 
When will I give consent to take part in the research?  
Following reading through this information sheet, the researcher will provide more information and 
answer any questions that you may have. When you, and the researcher, feel fully satisfied that you 
have all the information you require to make an informed decision, consent will be sought. At this 
point, you will be asked to sign the consent form. No assessments will take place before informed 
consent is gained.  
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Part 2 
 
What are the potential benefits of taking part? 
Whilst there may be no personal benefits to participating, the information you give could greatly 
contribute to improvements in the availability of cognitive testing for people with MS. 
 
What are the potential disadvantages of taking part? 
It is possible that you may feel fatigued whilst carrying out the tests. Should this happen, please let 
Jonathan Hinchliffe know, and we can take a break or complete the tests on another occasion. 
 
Will my participation be kept confidential? 
We will follow ethical and legal practice to ensure that all information you provide to us, and the 
results from your tests will be kept strictly confidential. All data will be coded anonymously and stored 
securely. 
 
The overall results of the study will be made public in a completely anonymous form ensuring that no 
participants can be identified. 
  
What will happen to my results after the study?  
All your information will be stored anonymously.  Analysis of the information obtained will be 
completed on a computer by the principal investigator based at Royal Holloway, University of London. 
The paper copies of the results will be stored in a secure filing cabinet at Royal Holloway University of 
London for 5 years for audit purposes. At which point all data will be disposed of following confidential 
disposal procedures.   
 
The overall findings of the study will be published in a scientific paper or peer reviewed journal. The 
data will also be incorporated into the doctoral thesis of the principal investigator.  Findings may also 
be distributed through voluntary organisations such as the MS Society and presented at appropriate 
scientific conferences.  
 
If you would like a summary of the study’s findings please indicate this on the consent form.   
 
What will happen if I want to withdraw from the study? 
You can decide you no longer wish to take part at any point. Following your request to withdraw from 
the study, all the data collected from you will be destroyed.  
 
Should you give consent and later lose capacity to do so we will include your data in the study unless 
you indicate otherwise on the consent form. 
 
Who is organising the research?  
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The principal investigator is a Trainee Clinical Psychologist (Jonathan Hinchliffe), who is conducting the 
research as part of his doctorate in clinical psychology. The research will be supervised by a Professor 
of Neuropsychology (Professor Dawn Langdon) and is sponsored by Royal Holloway University of 
London. Three consultant neurologists (Dr. Khaled Abdel-Aziz, Dr David Barnes and Dr Jan Coeberghe) 
are collaborators in the study. 
 
A Research Ethics Committee (REC) has approved this study.  RECs are independent groups of people 
who protect your interests by reviewing all research undertaken in the NHS. 
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Consent Form 
 
Study Title: Cognition in multiple s§clerosis 
Name of principal investigator: Jonathan Hinchliffe 
Participant reference number: 
Ethics Committee Reference Number: 16/SC/0165 
 Please 
initial to 
confirm 
1. I confirm that I have read and understand the information sheet for the above 
study dated Information Sheet: 28.04.16 V1.2HC. 

2. I have had the opportunity to consider the information, ask questions and have 
received adequate answers.  
 
3. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
4. I give permission for data already collected to be retained for the purposes of 
the research if I lose capacity to consent to taking part whilst the study is 
ongoing. 
 
5. I would like to receive group feedback about the overall results of the study.  I 
understand this will be sent once the study is complete in late 2017. I give 
permission for my address to be held by the above named researcher until the 
end of the research to facilitate this. 
 
6. I agree to take part in the above research study.  
 
____________________________________________ Date: _________________ 
Name of participant 
_____________________________________________ Date: _________________ 
Name of person taking consent 
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[Removed from online version] 
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[Removed from online version] 
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[Removed from online version] 
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Appendix 12: Word List Generation – Version A (WLG) 
 
[Removed from online version] 
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Appendix 13: Paced Auditory Serial Addition Test (PASAT)  
 
[Removed from online version] 
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Appendix 14: California Verbal Learning Task II (CVLT-II) 
 
[Removed from online version] 
 239 
Appendix 15: Brief Visual Memory Test – Revised (BVMT-R) 
 
[Removed from online version] 
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Appendix 16: Test of Premorbid Functioning (TOPF) 
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Appendix 17: Hospital Anxiety and Depression Scale (HADS)  
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Appendix 18: Fatigue Severity Scale (FSS) 
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Appendix 19: NARCOMS: Tremor and coordination Scale (TACS) 
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Appendix 20: EDSS Telephone Version – Reproduced with permission from 
Professor Ludvig Kappos (Senior Author) 
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Appendix 21: EDSS Functional System Convertor 
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Appendix 22: Nine-hole peg test instructions (9HPT) 
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Appendix 23: Grooved pegboard test instructions (GPT) 
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Appendix 24: Skewness and Kurtosis Calculations and Transformations 
 
(Page 1) 
Variable HC RR-MSnc RR-MSc 
 Skewness Kurtosis Skewness Kurtosis Skewness Kurtosis 
FSS 1.80 -0.50 -1.24 -0.67 -0.80 -1.07 
HADS-D 2.16 0.22 0.91 -0.79 0.06 -0.73 
HADS-A 1.33 1.07 0.57 -1.07 1.56 0.83 
9HPT -0.08 -0.64 2.73* 1.48 0.65 -1.00 
SDMT 3.09* 1.71 -0.80 1.43 -0.29 -0.68 
Premorbid IQ -3.81* 2.10 -0.84 0.45 1.11 1.13 
CVLT-II -0.40 -1.02 0.67 -0.87 -0.03 0.21 
BVMT-R -2.12 0.71 -1.59 -0.72 0.00 -1.30 
Scores <±2.58 meet criteria for normal distribution (p < .01) 
* Scores >±2.58 (must be transformed) 
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(Page 2) 
Variable HC RR-MSnc RR-MSc 
 Skewness Kurtosis Skewness Kurtosis Skewness Kurtosis 
GPT 0.82 -0.83 2.17 0.59 3.34* 1.89 
MPI 0.64 -0.83 2.79* 1.26 3.38* 1.92 
WLG 2.20 1.30 0.05 -1.05 -0.72 -0.78 
PASAT -0.69 -0.73 -1.63 0.26 0.10 -0.90 
Age 2.06 -0.81 -0.11 -1.02 0.14 -0.98 
Years since diagnosis N/A N/A 2.35 0.79 0.29 -1.01 
Scores <±2.58 meet criteria for normal distribution (p < .01) 
* Scores >±2.58 (must be transformed) 
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Skew and Kurtosis z-scores for Transformed Variables 
* Scores >±2.58  
 
 Transformation HC RR-MSnc RR-MSc 
  Skewness Kurtosis Skewness Kurtosis Skewness Kurtosis 
9HPT Square Root -0.29 -0.67 2.29 1.21 0.49 -1.01 
SDMT Square Root 2.64* 1.46 -2.00 1.81 -0.78 -0.52 
GPT Log 10 0.62 -0.94 1.41 -0.48 2.30 1.24 
MPI Log 10 0.26 -0.83 1.66 0.41 2.09 1.09 
TOPF X4 -2.62* 1.41 0.65 -0.90 2.52 1.78 
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Appendix 25: Effect Sizes 
 
 Effect size f Effect size d 
SDMT 1.06 3.19 
 
CVLT-II 0.86 
 
2.59 
 
BVMT-R 0.97 
 
2.90 
 
WLG 0.92 
 
2.76 
 
PASAT 0.96 
 
2.89 
 
9HPT 0.97 
 
2.91 
 
GPT 0.98 
 
2.94 
 
MPI 0.98 
 
2.94 
 
 
 
 
 
 
